EDAP TMS (EDAP) 20-F 7 Apr 23 2022 FY Annual report (foreign) Financial data

Document And Entity Information

Document And Entity Information	12 Months Ended
	Dec. 31, 2022 shares
Document Information [Line Items]
Document Type	20-F
Document Registration Statement	false
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Document Transition Report	false
Document Shell Company Report	false
Entity File Number	000-29374
Entity Registrant Name	EDAP TMS SA
Entity Incorporation, State or Country Code	I0
Entity Address, Address Line One	Parc d’Activites la Poudrette-Lamartine
Entity Address, Address Line Two	4/6, rue du Dauphiné
Entity Address, Postal Zip Code	69120
Entity Address, City or Town	Vaulx-en-Velin
Entity Address, Country	FR
Title of 12(b) Security	American Depositary Shares
Entity Central Index Key	0001041934
Trading Symbol	EDAP
Security Exchange Name	NASDAQ
ICFR Auditor Attestation Flag	true
Entity Common Stock, Shares Outstanding (in shares)	36,910,925
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Emerging Growth Company	false
Document Accounting Standard	U.S. GAAP
Entity Shell Company	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Amendment Flag	false
Auditor Name	KPMG S.A.
Auditor Firm ID	1253
Auditor Location	Lyon, France
Business Contact
Document Information [Line Items]
Entity Address, Address Line One	Parc d’Activites la Poudrette-Lamartine
Entity Address, Address Line Two	4/6, rue du Dauphiné
Entity Address, Postal Zip Code	69120
Entity Address, City or Town	Vaulx-en-Velin
Entity Address, Country	FR
Contact Personnel Name	Ms. Blandine Confort
City Area Code	33
Local Phone Number	4 72 15 31 50
Contact Personnel Email Address	bconfort@edap-tms.com

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	€ 63,136	€ 47,183
Current portion of net trade accounts and notes receivable	13,421	10,864
Other receivables	1,522	1,255
Inventories	11,780	7,499
Other assets, current portion	660	581
Total current assets	90,518	67,382
Non-current assets
Property and equipment, net	4,200	3,617
Operating lease right-of-use assets	1,784	1,555
Intangible assets, net	725	728
Goodwill	2,412	2,412
Deposits and other non-current assets	656	634
Deferred tax assets	829	898
Total assets	101,123	77,226
Current liabilities
Trade accounts and notes payable	6,647	5,512
Deferred revenues, current portion	4,050	3,408
Social security and other payroll withholdings taxes	1,550	1,314
Employee absences compensation	798	704
Income taxes payable	219	501
Other accrued liabilities	3,873	2,755
Short-term borrowings	1,846	1,914
Current obligations under finance leases	224	340
Current portion of operating lease obligations	901	673
Current portion of long-term debt	1,601	830
Total current liabilities	21,708	17,951
Non-current liabilities
Deferred revenues, non-current	264	440
Obligations under finance leases	324	430
Operating lease obligations, non-current	899	888
Total long-term portion	3,587	4,930
Other long-term liabilities	2,710	2,534
Total liabilities	29,492	27,172
Shareholders' equity
Common stock, 0.13 par value; 37,197,731 shares issued and 36,910,925 shares outstanding at December 31, 2022 0.13 par value 33,758,564 shares issued and 33,466,136 shares outstanding at December 31, 2021	4,776	4,389
Additional paid-in capital	113,952	89,621
Retained earnings	(42,372)	(39,438)
Cumulative other comprehensive loss	(3,829)	(3,589)
Treasury stock, at cost 286,806 shares at December 31, 2022 and 292,428 shares at December 31, 2021	(897)	(928)
Total shareholders' equity	71,632	50,054
Total liabilities and shareholders' equity	€ 101,123	€ 77,226

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - € / shares	Dec. 31, 2022	Dec. 31, 2021
CONSOLIDATED BALANCE SHEETS
Common stock, par value	€ 0.13	€ 0.13
Common stock, shares issued	37,197,731	33,758,564
Commons stock, shares outstanding	36,910,925	33,466,136
Treasury stock	286,806	292,428

CONSOLIDATED STATEMENTS OF INCO

CONSOLIDATED STATEMENTS OF INCOME (LOSS) - EUR (€)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenues	€ 55,108,000	€ 44,065,000	€ 41,662,000
Cost of sales	(30,916,000)	(25,643,000)	(23,283,000)
Gross profit	24,193,000	18,422,000	18,379,000
Research and development expenses	(4,920,000)	(3,402,000)	(4,496,000)
Selling and marketing expenses	(16,379,000)	(10,732,000)	(9,279,000)
General and administrative expenses	(7,152,000)	(5,900,000)	(4,335,000)
Income (loss) from operations	(4,257,000)	(1,612,000)	269,000
Financial (expense) income, net	236,000	145,000	(98,000)
Foreign currency exchange gain (loss), net	1,925,000	2,360,000	(1,359,000)
Income (loss) before taxes	(2,096,000)	893,000	(1,188,000)
Income tax (expense) benefit	(837,000)	(193,000)	(516,000)
Net income (loss)	€ (2,933,058)	€ 699,890	€ (1,703,668)
Basic income (loss) per share (in EUR per share)	€ (0.09)	€ 0.02	€ (0.06)
Diluted income (loss) per share (in EUR per share)	€ (0.09)	€ 0.02	€ (0.06)
Basic Weighted average shares outstanding (in shares)	34,392,598	32,129,047	29,148,108
Diluted Weighted average shares outstanding (in shares)	34,392,598	32,422,871	29,148,108
Product
Revenues	€ 55,108,000	€ 44,060,000	€ 41,649,000
Goods
Revenues	38,462,000	29,040,000	27,523,000
Cost of sales	(20,528,000)	(16,181,000)	(14,951,000)
RPP's and leases
Revenues	5,617,000	4,968,000	4,745,000
Cost of sales	(3,387,000)	(3,108,000)	(2,601,000)
Spare parts and services
Revenues	11,030,000	10,052,000	9,382,000
Cost of sales	€ (7,000,000)	(6,354,000)	(5,732,000)
Other revenues
Revenues		€ 6,000	€ 12,000

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - EUR (€)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
Net income (loss)	€ (2,933,058)	€ 699,890	€ (1,703,668)
Foreign currency translation adjustments	(596,000)	(554,000)	410,000
Provision for retirement indemnities	282,000	77,000	(38,000)
Deferred tax for retirement indemnities	73,000	(48,000)
Comprehensive income (loss), net of tax	€ (3,173,000)	€ 175,000	€ (1,332,000)

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY - EUR (€)	Common stock	Additional paid-in capital.	Retained Earnings / (Loss)	Other comprehensive income (loss)	Treasury stock	Total
Balance at Dec. 31, 2019	€ 3,826,000	€ 66,331,000	€ (38,435,000)	€ (3,436,000)	€ (928,000)	€ 27,359,000
Balance (in shares) at Dec. 31, 2019	29,141,566
Net (loss) / income			(1,704,000)			(1,703,668)
Translation adjustment				410,000		410,000
Stock-based compensation		160,000				160,000
Capital increase	€ 3,000	57,000				60,000
Capital increase (in shares)	23,750
Provision for retirement indemnities				(38,000)		(38,000)
Balance (in shares) at Dec. 31, 2020	29,165,316
Balance at Dec. 31, 2020	€ 3,830,000	66,548,000	(40,139,000)	(3,064,000)	(928,000)	26,248,000
Net (loss) / income			700,000			699,890
Translation adjustment				(554,000)		(554,000)
Stock-based compensation		1,900,000				1,900,000
Capital increase	€ 559,000	21,173,000				21,732,000
Capital increase (in shares)	4,300,820
Provision for retirement indemnities				77,000		77,000
Deferred tax for retirement indemnities				(48,000)		(48,000)
Balance (in shares) at Dec. 31, 2021	33,466,136
Balance at Dec. 31, 2021	€ 4,389,000	89,621,000	(39,439,000)	(3,589,000)	(928,000)	50,054,000
Net (loss) / income			(2,933,000)			(2,933,058)
Translation adjustment				(596,000)		(596,000)
Stock-based compensation		2,103,000				2,103,000
Capital increase	€ 388,000	22,228,000				22,616,000
Capital increase (in shares)	3,444,789
Treasury stock disposition					31,000	31,000
Provision for retirement indemnities				282,000		282,000
Deferred tax for retirement indemnities				73,000		73,000
Balance (in shares) at Dec. 31, 2022	36,910,925
Balance at Dec. 31, 2022	€ 4,776,000	€ 113,952,000	€ (42,372,000)	€ (3,829,000)	€ (897,000)	€ 71,632,000

CONSOLIDATED STATEMENTS OF ST_2

CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (Parenthetical) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY
Issuance costs	€ 1,954	€ 1,961

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - EUR (€)		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Net income (loss)		€ (2,933,058)	€ 699,890	€ (1,703,668)
Adjustments to reconcile net income (loss) to net cash generated by (used in) operating activities:
Depreciation and amortization		1,605,000	1,920,000	2,105,000
Share based compensation		2,103,000	1,900,000	160,000
US Paycheck Protection Program loan Forgiveness			(187,000)
Change in allowances for doubtful accounts & slow-moving inventories		124,000	363,000	734,000
Change in long-term provisions		79,000	(350,000)	455,000
Net capital loss on disposals of assets		266,000	142,000	291,000
Deferred tax expense (benefit)		48,000	(563,000)	45,000
Operating cash flow before changes in working capital		1,292,000	3,925,000	2,087,000
Increase/Decrease in operating assets and liabilities:
Decrease (Increase) in trade accounts and notes and other receivables		(1,974,000)	(103,000)	1,137,000
Decrease (Increase) in inventories		(4,482,000)	166,000	(554,000)
Decrease (Increase) in other assets		(82,000)	(210,000)	69,000
(Decrease) Increase in trade accounts and notes payable		1,143,000	(38,000)	(422,000)
(Decrease) Increase in accrued expenses, other current liabilities		1,079,000	706,000	(339,000)
Net change in operating assets and liabilities		(4,316,000)	520,000	(110,000)
Net cash generated by (used in) operating activities		(3,024,000)	4,445,000	1,977,000
Cash flows from investing activities:
Additions to capitalized assets produced by the Company		(1,570,000)	(1,161,000)	(1,339,000)
Acquisitions of property and equipment		(613,000)	(393,000)	(531,000)
Acquisitions of intangible assets		(137,000)	(92,000)	(103,000)
Decrease (Increase) of other financial assets			13,000	(2,000)
Increase in deposits and guarantees		(58,000)	(6,000)	(36,000)
Net cash generated by (used in) investing activities		(2,378,000)	(1,638,000)	(2,011,000)
Cash flow from financing activities:
Proceeds from capital increase	[1]	21,960,000	21,289,000
Proceeds from stock-option exercise		688,000	442,000	60,000
Proceeds from long term borrowings, net of financing costs		286,000	1,058,000	4,848,000
Repayment of long term borrowings		(803,000)	(1,401,000)	(519,000)
Repayment of obligations under financing leases		(350,000)	(406,000)	(321,000)
Increase (decrease) in bank overdrafts and short-term borrowings		(38,000)	(717,000)	(867,000)
Net cash generated by (used in) financing activities		21,741,000	20,266,000	3,201,000
Net effect of exchange rate changes on cash and cash equivalents		(388,000)	(585,000)	642,000
Net increase (decrease) in cash and cash equivalents		15,952,000	22,488,000	3,810,000
Cash and cash equivalents at beginning of year		47,183,000	24,696,000	20,886,000
Cash and cash equivalents at end of year		€ 63,136,000	€ 47,183,000	€ 24,696,000
[1] The net proceeds from capital increase of €21,960 thousand relate to the Company’s successful common stock offering in September 2022 and of €21,289 thousand relate to the Company’s successful common stock offering in April 2021 – refer to Note 17-1.

CONSOLIDATED STATEMENTS OF CA_2

CONSOLIDATED STATEMENTS OF CASH FLOW (Parenthetical) - EUR (€) € in Thousands	1 Months Ended		12 Months Ended
	Sep. 30, 2022	Apr. 30, 2021	Dec. 31, 2022		Dec. 31, 2021
CONSOLIDATED STATEMENTS OF CASH FLOWS
Proceeds from capital increase	€ 21,960	€ 21,289	€ 21,960	[1]	€ 21,289	[1]
[1] The net proceeds from capital increase of €21,960 thousand relate to the Company’s successful common stock offering in September 2022 and of €21,289 thousand relate to the Company’s successful common stock offering in April 2021 – refer to Note 17-1.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2022
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	1— SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES 1-1 Nature of operations EDAP TMS S.A. and its subsidiaries (‘‘the Company’’) are engaged in the development, production, marketing, distribution and maintenance of a portfolio of minimally-invasive medical devices for the treatment of urological diseases. The Company currently produces innovative robotic devices for treating stones of the urinary tract and localized prostate cancer. We also derive revenues from the distribution of urodynamics products and urology lasers. Net sales consist primarily of direct sales to hospitals and clinics in France and Europe, export sales to third-party distributors and agents, and export sales through subsidiaries based in Germany, Italy, the United States and Asia. The Company purchases the majority of the components used in its products from a number of suppliers but for some components, relies on a single source. Delay would be caused if the supply of these components or other components was interrupted and these delays could be extended in certain situations where a component substitution may require regulatory approval. Failure to obtain adequate supplies of these components in a timely manner could have a material adverse effect on the Company’s business, financial position and results of operations. 1-2 Basis of preparation These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). 1-3 Management estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles (‘‘U.S. GAAP’’) requires management to make estimates and assumptions, such as business plans, stock price volatility, duration of standard warranty per market, duration and interest rate of operating leases, price of maintenance contracts used to determine the amount of revenue to be deferred and life duration of our range of products. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. 1-4 Consolidation The accompanying consolidated financial statements include the accounts of EDAP TMS S.A. and all its domestic and foreign owned subsidiaries after elimination of intercompany balances and transactions. We do not have any significant interests in any variable interest entities. 1-5 Revenue recognition The Company’s revenue consists of: - Sales of goods (devices and consumables), where invoicing generally takes place upon delivery. Consumables revenues included in sales contracts are deferred until delivery. - Revenue-per-Procedures (“RPP”) and leases: they comprise (i) revenues on a per treatment basis which are invoiced after each treatment, or in advance, or on a periodic basis, (ii) leases of devices, which are generally invoiced on a monthly or quarterly basis, and (iii) immaterial lease components arising from multiple-element arrangements, where specific sales terms are negotiated in accordance with each customer’s individual requirements and which are generally invoiced based on contract terms, - Sales of spare parts and services (maintenance, upgrades, mobility and others). Spare parts are invoiced when delivered. Regarding services, invoicing is performed either on a subscription basis (in advance or at the end of the period) or when performed. Sales of our medical devices and sales of disposables, sales of RPPs and leases, and sales of spare parts and services, are all net of commissions. The Company invoices its customers based on the billing schedules in its sales arrangements. Payments are generally due between one to three months from date of invoice. The Company accounts for a contract with a customer when there is a legally enforceable contract between the Company and its customer, the rights of the goods or services and their payment terms can be identified, the contract has commercial substance, collectability of the contract consideration is probable, it is approved and the parties are committed to their obligations. Our sale arrangements may contain multiple elements, including device(s), consumables and services. For these multiple-element arrangements, the Company accounts for individual goods and services as separate performance obligations: (i) if a customer can benefit from the good or service on its own or with other resources that are readily available to the customer, and (ii) if they are a distinct good or service that is separately identifiable from other items in the multiple-element arrangement. The Company’s sale arrangements may include a combination of the following performance obligations: device(s), consumables, leases and services (such as, but not limited to, warranty extension). For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the goods or services. If a standalone selling price is not directly observable, then the Company estimates the standalone selling price considering market conditions and entity-specific factors including, but not limited to, features and functionality of the goods and services, geographies, and type of customer. The Company regularly reviews standalone selling prices and updates these estimates as necessary. The Company recognizes revenue when the performance obligations are satisfied by transferring control over the goods or service to a customer. The Company’s revenue consists of the following: Sales of goods: Sales of goods are and have historically been comprised of sales net of commission of medical devices (ESWL lithotripters and HIFU devices) and net sales of disposables (mostly Focalpaks and Ablapaks in the HIFU division and electrodes in the ESWL division). Sales of goods also includes products such as micro-ultrasound devices, urology lasers and urodynamics devices distributed through our agents and third-party distributors. For devices and disposables, revenue is recognized when the Company transfers control to the customer (i.e. when the customer has the ability to direct the use of, and obtain substantially all of the remaining benefit from, the device or disposables), which is generally at the point of delivery or installation, depending on the terms of the arrangement (i.e. when the customer can use the goods to provide services or sell or exchange the good), and based on contractual incoterms. Such installation-related costs are immaterial in the context of the contract with the customer and do not constitute a distinct performance obligation. The Company’s sales arrangements do not provide a right of return. The goods are generally covered by a period of one Sales of RPPs and leases: Sales of RPP and leases include the revenues from the sale of treatment procedures and from the leasing of machines. For RPP, we provide machines to clinics and hospitals for free for a limited period, rather than selling the devices. These hospitals and clinics perform treatments using the devices and usually pay us based on the number of individual treatments provided. Revenues from leasing of machine are considered as immaterial. Revenues related to the sale of treatments invoiced on a ‘‘Revenue-Per-Procedure’’ (‘‘RPP’’) basis are recognized when the treatment procedure has been completed. Revenues from devices leased to customers under operating leases are recognized on a straight-line basis. Regarding multiple-element arrangements with a lease component, a portion of the contract is allocated to the lease component on the basis of observable market prices applied by the Company for similar devices under operating leases. The lease component is recognized on a straight line basis over the contractual period. Other immaterial components under the contract are recognized in accordance with their nature. Sales of spare parts and services: Revenues related to spare parts are recognized when spare parts are delivered to distributors who perform their own maintenance services. Spare parts used in the performance of EDAP’s own maintenance and repair services are generally not recognized separately, unless a type of spare part is specifically excluded from the maintenance contract terms. Revenues related to Services mainly consist of maintenance contracts which rarely exceed one year and are recognized on a straight line basis over the term of the service period as the customer benefits from the service equally throughout the service contract period. For services rendered when no maintenance contract is in place or for services not included in the scope of a maintenance contract, revenues are recorded when services are performed. The Company recognizes revenue for extended warranties included in the multiple-element arrangements as a separate performance obligation in Sales of services on a straight-line basis over the extended warranty period. In the majority of countries in which the Company operates, the statutory warranty period is one to two years and the extended warranty covers periods beyond this statutory period. Standard warranties do not constitute a separate performance obligation. The Company accrues for the warranty costs at the time of sale of the device through the multiple-element arrangement. Distributors: As part of its sale process in countries other than continental France, when the Company does not have a local subsidiary, sales of goods to end-customers are performed through agents and distributors. Such agents and distributors are primarily responsible for the sales’ process, bear the inventory risk, and are free to determine the sale prices. Sales of goods to agents and distributors are recognized when the control is transferred to the related agent or distributor which generally occurs based on contractual incoterms. Deferred revenue: Deferred revenue for the periods presented primarily relates to service contracts where the service fees are billed up-front, generally quarterly or annually, prior to those services having been performed, and consists primarily of billing or cash receipts in advance of services due under maintenance contracts or extended warranty contracts. The associated deferred revenue is generally recognized ratably over the service period. Disaggregation of revenue: Disaggregation by primary geographical market, and timing of revenue recognition is reported in Note 18. Contract Balances: Details on contract liabilities are reported on Note 11. The Company applies the practical expedient in paragraph 606-10-50-14 and does not disclose information about remaining performance obligations that have original expected durations of one year or less. This relates mainly to maintenance services. 1-6 Costs of sales Costs of sales include all direct product costs, costs related to shipping, handling, duties and importation fees, as well as certain indirect costs such as service and supply chain departments expenses. Indirect costs are allocated by type of sales (goods, RPP and leases, spare parts and services) using an allocation method determined by management by type of costs and segment activities and reviewed on an annual basis. 1-7 Shipping and handling costs Shipping and handling costs are not considered as performance obligations. Shipping and handling costs are recorded as a component of cost of sales. 1-8 Cash equivalents and short term investments Cash equivalents are cash investments which are highly liquid and have initial maturities of 90 days or less. Cash investments with a maturity higher than 90 days are considered as short-term investments. There is no short-term investment at December 31, 2022. 1-9 Accounts Receivable The Company maintains an allowance for doubtful accounts for estimated losses inherent in its accounts receivable portfolio. In establishing the required allowance, management considers historical losses adjusted to take into account current market conditions and the Company’s customers’ financial condition, the amount of receivables in dispute, and the current receivables aging and current payment patterns. The Company reviews its allowance for doubtful accounts quarterly. Past due balances over 90 days and over a specified amount are reviewed individually for collectability. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. Write-offs for 2022 and 2021 approximated €640 thousand and €0 thousand, respectively. The Company does not have any off-balance-sheet credit exposure related to its customers. 1-10 Inventories Inventories are valued at the lower of cost and net realizable value. Cost is either the manufacturing cost, which is principally comprised of components and labor costs for our own manufactured products, or purchase price for urology products we distribute. Cost is determined on a first-in, first-out basis for components and spare parts and by specific identification for finished goods (medical devices). The Company establishes reserves for inventory estimated to be obsolete, unmarketable or slow moving, first based on a detailed comparison between quantity in inventory and historical consumption and then based on case-by-case analysis of the difference between the cost of inventory and the related estimated market value. 1-11 Property and equipment Property and equipment is stated at historical cost, net of accumulated depreciation and impairment. Depreciation of property and equipment is calculated using the straight-line method over the estimated useful life of the related assets, as follows: ​ ​ ​ ​ ​ ​ ​ ​ Leasehold improvements (in years) ​ ​ 10 or lease term if shorter ​ ​ Equipment (in years) 3 — 10 Furniture, fixtures, fittings and other (in years) 2 ​ — 10 ​ Equipment includes industrial equipment and research equipment that has alternative future uses. Equipment also includes devices that are manufactured by the Company and leased to customers through operating leases related to Revenue-Per-Procedure transactions and devices subject to sale and leaseback transactions. This equipment is depreciated over a period of seven years. 1-12 Long-lived assets The Company reviews the carrying value of its long-lived assets, including fixed assets and intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be fully recoverable. Recoverability of long-lived assets is assessed by a comparison of the carrying amount of the assets (or the Group of assets, including the asset in question, that represents the lowest level of separately-identifiable cash flows) to the total estimated undiscounted cash flows expected to be generated by the asset or group of assets. If the future net undiscounted cash flows is less than the carrying amount of the asset or group of assets, the asset or group of assets is considered impaired and an expense is recognized equal to the amount required to reduce the carrying amount of the asset or group of assets to its then fair value. Fair value is determined by discounting the cash flows expected to be generated by the assets, when the quoted market prices are not available for the long-lived assets. Estimated future cash flows are based on assumptions and are subject to risk and uncertainty. 1-13 Goodwill and intangible assets Goodwill represents the excess of purchase price over the fair value of identifiable net assets of businesses acquired. Goodwill is not amortized but instead tested annually for impairment or more frequently when events or change in circumstances indicate that the assets might be impaired. When impairment indicators are identified, the impairment test is performed by comparing the fair value of a reporting unit with its carrying amount, including goodwill. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. For the purpose of any impairment test, the Company relies upon projections of future undiscounted cash flows and takes into account assumptions regarding the evolution of the market and its ability to successfully develop and commercialize its products. Changes in market conditions could have a major impact on the valuation of these assets and could result in additional impairment losses. Intangible assets consist primarily of purchased patents relating to lithotripters, purchased licenses, a purchased trade name and a purchased trademark. The basis for valuation of these assets is their historical acquisition cost. Amortization of intangible assets is calculated by the straight-line method over the shorter of the contractual or estimated useful life of the assets, as follows: ​ ​ ​ ​ Patents (in years) 5 SAP Licenses (in years) 10 Other licenses (in years) 5 Trade name and trademark (in years) 7 ​ 1-14 Treasury Stocks Treasury stock purchases are accounted for at cost. The sale of treasury stocks is accounted for using the first in first out method. Gains on the sale or retirement of treasury stocks are accounted for as additional paid-in capital whereas losses on the sale or retirement of treasury stock are recorded as additional paid-in capital to the extent that previous net gains from sale or retirement of treasury stocks are included therein; otherwise the losses shall be recorded to accumulated benefit (deficit) account. Gains or losses from the sale or retirement of treasury stock do not affect reported results of operations. Treasury stocks held by a Company cannot exceed 10% of the total number of shares issued. 1-15 Warranty expenses The Company provides customers with a warranty for each product sold and accrues warranty expense at time of sale based upon historical claims experience. Standard warranty period may vary from 1 year to 2 years depending on the market. The warranty expense is incurred at time of accrual and not when paid. Warranty expense amounted to €112 thousand, €110 thousand and €266 thousand for the years ended December 31, 2022, 2021 and 2020, respectively. 1-16 Income taxes The Company accounts for income taxes in accordance with ASC 740, ‘‘Accounting for Income Taxes’’ Under ASC 740, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured by applying enacted tax rates and laws to taxable years in which such differences are expected to reverse. A valuation allowance is established if, based on the weight of available evidence, it is more likely than not that some portion, or all of the deferred tax assets, will not be realized. In accordance with ASC740, no provision has been made for income or withholding taxes on undistributed earnings of foreign subsidiaries, such undistributed earnings being permanently reinvested. Under ASC740, the measurement of a tax position that meets the more-likely-that-not recognition threshold must take into consideration the amounts and probabilities of the outcomes that could be realized upon ultimate settlement using the facts, circumstances and information available at the reporting date. 1-17 Research and development costs Research and development costs are recorded as an expense in the period in which they are incurred. The French government provides tax credits to companies for innovative research and development. This tax credit is calculated based on a percentage of eligible research and development costs and it can be refundable in cash and is not contingent on future taxable income. As such, the Company considers the research tax credits as a grant, offsetting research and development expenses. 1-18 Advertising costs Advertising costs are recorded as an expense in the period in which they are incurred and are included in selling and administrative expenses in the accompanying consolidated statements of income (loss). Advertising costs amounted to €929 thousand, €490 thousand and €291 thousand for the years ended December 31, 2022, 2021 and 2020, respectively. 1-19 Foreign currency translation and transactions Translation of the financial statements of consolidated companies The reporting currency of EDAP TMS S.A. for all years presented is the euro (€). The functional currency of each subsidiary is its local currency. In accordance with ASC 830, all accounts in the financial statements are translated into euro from the functional currency at the following exchange rates: ● assets and liabilities are translated at year-end exchange rates; ● shareholders’ equity is translated at historical exchange rates (as of the date of contribution); ● statement of income (loss) items are translated at average exchange rates for the year; and ● translation gains and losses are recorded in a separate component of shareholders’ equity. Foreign currencies transactions Transactions involving foreign currencies are translated into the functional currency using the exchange rate prevailing at the time of the transactions. Receivables and payables denominated in foreign currencies are translated at year-end exchange rates. The resulting unrealized exchange gains and losses are recorded in the statement of income (loss). Presentation in the Statement of Income (loss) Aggregate foreign currency transactions gains and losses are disclosed in a single caption in the Statement of Income (loss) under section “Foreign currency exchange gain (loss), net”. 1-20 Earnings per share Basic earnings per share is computed by dividing income available to common shareholders by the weighted average number of shares of common stock outstanding for the period. Diluted earnings per share reflects potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the Company. The dilutive effects of the Company’s common stock options and warrants is determined using the treasury stock method to measure the number of shares that are assumed to have been repurchased using the average market price during the period, which is converted from U.S. dollars at the average exchange rate for the period. 1-21 Derivative instruments ASC 815 requires the Company to recognize all of its derivative instruments as either assets or liabilities in the statement of financial position at fair value. The accounting for changes in the fair value (i.e., gains or losses) of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and further, on the type of hedging relationship. For those derivative instruments that are designated and qualify as hedging instruments, the Company must classify the hedging instrument, based upon the exposure being hedged, as fair value hedge, cash flow hedge or a hedge of a net investment in a foreign operation. Gains and losses from derivative instruments are recorded in the Statement of Income (loss). As of December 31, 2022, there are no derivative instruments. 1-22 Employee stock option and free shares plan The accounting for stock-based awards is based on the fair value of the award measured at the grant date. Accordingly, stock-based compensation cost is recognized in the consolidated statements of income (loss) and comprehensive income (loss) as an operating expense over the requisite service period. The fair value of stock options is determined using the Black-Scholes option- pricing model. The Company determines the fair value of stock option awards on the date of grant using assumptions regarding expected term, share price volatility over the expected term of the awards, risk-free interest rate, and dividend rate. The fair value of free shares is measured using the fair value of the Company's shares as if the free shares were vested and issued on the grant date. Forfeited stock-options and free shares are recognized as they occur, in accordance with ASU 2016-09. The Company recognizes compensation cost for employee awards with only service conditions that have a graded vesting schedule on a straight-line basis over the requisite service period for each separately vesting portion of the award as if the award was, in-substance, multiple awards. At December 31, 2022, the Company had four stock-based employee compensation plans and two free shares plans. 1-23 Warrants There are no warrants outstanding at December 31, 2022. 1-24 Leases Leases as a Lessee In accordance with ASC 842, Leases, and as from January 1, 2019, the Company classifies all leases at the inception of a contract and assess whether the contract is, or contains, a lease. The assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the company controls the use of the identified asset (e.g. whether the company has the right to obtain substantially all of the economic benefits from the use of the asset throughout the period, and whether the company has the right to direct the use of the asset). Leases are classified as either finance leases or operating leases. Substantially all our operating leases are comprised of office space leases, and substantially all our finance leases are comprised of office furniture and technology equipment. The Company recognizes a right-of-use (“ROU”) asset and a lease liability at the lease commencement date. The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial direct costs incurred, plus prepaid lease payments, less any lease incentives received. All ROU assets are reviewed for impairment. For operating leases, the lease liability is initially measured at the present value of the unpaid lease payments at lease commencement date, discounted using the incremental borrowing rate for assets of same duration or characteristics. For finance leases the lease liability is initially measured in the same manner and date as for operating leases and is subsequently measured at amortized cost using the effective interest method For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term. For finance leases, the ROU asset is subsequently amortized using the straight-line method from the lease commencement date to the earlier of the end of its useful life or the end of the lease term unless the lease transfers ownership of the underlying asset to the Company or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the ROU asset is amortized over the useful life of the underlying asset. Amortization of the ROU asset is recognized and presented separately from interest expense on the lease liability. Lease payments included in the measurement of the lease liability comprise the following: the fixed payments, including in-substance fixed payments over the lease term (which includes termination penalties the Company would owe if the lease term assumes the Company’s exercise of a termination option), variable lease payments that depend on an index or rate payments for optional renewal periods where it is reasonably certain the renewal period will be exercised, the exercise price of an option to purchase the underlying asset if the company is reasonably certain to exercise the option, and amounts expected to be payable under a Company provided residual value guarantee. The company assesses the discount rate by requesting credit simulation from certain banks. Variable lease payments associated with the Company’s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented as operating expenses in the Company’s consolidated statements of income (loss) in the same line item as expenses arising from fixed lease payments (operating leases) or amortization of the ROU asset (finance leases). Our real estate leases generally include non-lease maintenance services. The consideration in the contract is allocated to the lease and non-lease components based on standalone selling prices. Some of our real estate leases contain variable lease payments, including payments based on an index or rate. Variable lease payments based on an index or rate are initially measured using the index or rate in effect at lease commencement, and changes to index and rate-based variable lease payments are recognized in profit or loss in the period of the change. Variable payments that do not depend on an index or rate, such as rental payments based on the use of the underlying asset or property taxes and insurance reimbursement, are recorded as operating expenses when incurred. Lease modifications result in remeasurement of the lease payments when that modification is not accounted for as a separate contract. Lease expense for operating leases consists of the lease payments plus any initial direct costs, primarily brokerage commissions, and is recognized on a straight-line basis over the lease term. Included in lease expense are any variable lease payments incurred in the period that were not included in the initial lease liability. Lease expense for finance leases consists of the amortization of the right-of-use asset on a straight-line basis over the lease term and interest expense determined on an amortized cost basis. The lease payments are allocated between a reduction of the lease liability and interest expense. The lease term for all of the Company’s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor . We have elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a term of 12 months or less. The effect of short-term leases on our right-of-use asset and lease liability was not material. We have elected not to review the classification for expired or existing leases, prior to January 1, 2019. Leases as a Lessor: A lessor shall classify a lease as a sales-type lease when the lease meets any of the following criteria at lease commencement: ● The lease transfers ownership of the underlying asset to the lessee by the end of the lease term. ● The lease grants the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise. ● The lease term is for the major part of the remaining economic life of the underlying asset. However, if the commencement date falls at or near the end of the economic life of the underlying asset, this criterion shall not be used for purposes of classifying the lease. ● The present value of the sum of the lease payments and any residual value guaranteed by the lessee that is not already reflected in the lease payments in accordance with paragraph 842-10-30-5(f) equals or exceeds substantially all of the fair value of the underlying asset. ● The underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term. When none of the criteria are met: A lessor shall classify the lease as either a direct financing lease or an operating lease. A lessor shall classify the lease as an operating lease unless both of the following criteria are met, in which case the lessor shall classify the lease as a direct financing lease: ● The present value of the sum of the lease payments and any residual value guaranteed by the lessee that is not already reflected in the lease payments in accordance with paragraph 842-10-30-5(f) and/or any other third party unrelated to the lessor equals or exceeds substantially all of the fair value of the underlying asset; ● It is probable that the lessor will collect the lease payments plus any amount necessary to satisfy a residual value guarantee. 1-25 Recent accounting pronouncements Recently Adopted Accou

CASH EQUIVALENTS

CASH EQUIVALENTS	12 Months Ended
	Dec. 31, 2022
CASH EQUIVALENTS
CASH EQUIVALENTS	2— CASH EQUIVALENTS Cash equivalents at December 31, 2022 and 2021 only comprise cash investments which are highly liquid and have initial maturities of 90 days or less. ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Total cash and cash equivalents 63,136 47,183 Short term investment ​ — ​ — Total cash and cash equivalents 63,136 47,183 ​

TRADE ACCOUNTS AND NOTES RECEIV

TRADE ACCOUNTS AND NOTES RECEIVABLE, NET	12 Months Ended
	Dec. 31, 2022
TRADE ACCOUNTS AND NOTES RECEIVABLE, NET
TRADE ACCOUNTS AND NOTES RECEIVABLE, NET	3— TRADE ACCOUNTS AND NOTES RECEIVABLE, NET Trade accounts and notes receivable consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Trade accounts receivable 12,965 10,992 Notes receivable 617 615 Less: allowance for doubtful accounts (161) (742) Total 13,421 10,864 Less current portion (13,421) (10,864) Total long-term portion — — ​ Notes receivable usually represent commercial bills of exchange (drafts) with initial maturities of 90 days or less. Bad debt expenses amount to a net cost of €32 thousand, a net cost of €2 thousand and €87 thousand, respectively for the years ended December 31, 2022, 2021 and 2020.

OTHER RECEIVABLES

OTHER RECEIVABLES	12 Months Ended
	Dec. 31, 2022
OTHER RECEIVABLES.
OTHER RECEIVABLES.	4— OTHER RECEIVABLES Other receivables consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Research and development tax credit receivable from the French State ​ 581 617 Value-added taxes receivable ​ 894 574 Other receivables from Government and public authorities ​ — — Others ​ 46 64 Total ​ 1,522 1,255 ​

INVENTORIES

INVENTORIES	12 Months Ended
	Dec. 31, 2022
INVENTORIES.
INVENTORIES	5— INVENTORIES ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Components, spare parts ​ 7,543 4,955 Work-in-progress ​ 283 250 Finished goods – own manufactured products ​ 1,514 1,166 Finished goods – distribution products ​ 3,702 2,598 Total gross inventories ​ 13,042 8,968 Less: allowance for slow-moving inventory and net realizable value ​ (1,262) (1,470) Total ​ 11,780 7,499 ​ The provision for slow moving inventory relates to components and spare parts. The increase in the allowance for slow moving inventory (excluding exchange rate impact), which are classified within cost of sales, amounted to €93 thousand for the year ended December 31, 2022, €371 thousand for the year ended December 31, 2021, and €651 thousand for the year ended December 31, 2020.

OTHER ASSETS

OTHER ASSETS	12 Months Ended
	Dec. 31, 2022
OTHER ASSETS
OTHER ASSETS	6— OTHER ASSETS Other assets consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Prepaid expenses, current portion ​ 660 581 Total ​ 660 581 ​ Prepaid expenses mainly consist of rental and future congresses and conferences expenses. ​

PROPERTY AND EQUIPMENT, NET

PROPERTY AND EQUIPMENT, NET	12 Months Ended
	Dec. 31, 2022
PROPERTY AND EQUIPMENT, NET
PROPERTY AND EQUIPMENT, NET	7— PROPERTY AND EQUIPMENT, NET Property and equipment consist of Property and equipment purchased or capitalized by the Company and finance leases for 2022 and 2021. 7-1 Property and Equipment, net Property and equipment consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Equipment ​ 9,553 ​ 8,894 Furniture, fixture, and fittings and other 3,108 2,678 Total gross value 12,661 11,572 Less: accumulated depreciation and amortization (8,916) (8,594) Total 3,745 2,978 ​ Depreciation expense related to property and equipment (inclusive of depreciation expense on equipment leased to customers) amounted to €1,194 thousand, €1,521 thousand and €1,695 thousand for the years ended December 31, 2022, 2021 and 2020, respectively. Assets leased to customers: Capitalized costs on equipment leased to customers of €753 thousand and €423 thousand are included in property and equipment at December 31, 2022 and 2021, respectively. Accumulated amortization of these assets leased to third parties was €264 thousand and €108 thousand, at December 31, 2022 and 2021, respectively. Depreciation expense on equipment leased to customers amounted to €37 thousand, €40 thousand and €240 thousand, for the years ended December 31, 2022, 2021 and 2020, respectively. 7-2 Finance leases Finance lease right-of-use assets ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Facilities ​ 269 ​ 290 Equipment 220 220 Vehicles and IT equipment 780 1,497 Total gross value 1,269 2,007 Less: accumulated depreciation and amortization 813 1,368 Total 455 639 ​ Depreciation expense related to finance lease right-of-use assets amounted to €303 thousand, €275 thousand and €401 for the years ended December 31, 2022, 2021, 2020, respectively. ​

OPERATING LEASE RIGHT-OF-USE AS

OPERATING LEASE RIGHT-OF-USE ASSETS	12 Months Ended
	Dec. 31, 2022
OPERATING LEASE RIGHT-OF-USE ASSETS.
OPERATING LEASE RIGHT-OF-USE ASSETS	8— OPERATING LEASE RIGHT-OF-USE ASSETS Operating lease right-of-use assets consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Facilities 1,536 1,290 Equipment 57 158 Furniture, fixture, and fittings and other 191 107 Total net operating lease right of use 1,784 1,555 ​ Operating lease cost amounted to €910 thousand and €917 thousand for the years ended December 31, 2022 and 2021, respectively. Variable lease costs related to above contracts amounted to €152 thousand and €123 thousand for the years ended December 31, 2022 and 2021, respectively. Non-recognized lease liabilities for short term leases amounted to €74 thousand and €70 thousand for the years ended December 31, 2022 and 2021, respectively.

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS	12 Months Ended
	Dec. 31, 2022
GOODWILL AND INTANGIBLE ASSETS
GOODWILL AND INTANGIBLE ASSETS	9— GOODWILL AND INTANGIBLE ASSETS As discussed in Note 1-13, ASC 350 requires that goodwill not be amortized but instead be tested at least annually for impairment, or more frequently when events or change in circumstances indicate that the asset might be impaired, by comparing the carrying value to the fair value of the reporting unit to which they are assigned. The Company considers its ASC 280 operating segments — High Intensity Focused Ultrasound (HIFU), Lithotripsy (ESWL) and Distribution services (DIST) — to be its reporting units for purposes of testing for impairment. Goodwill amounts to €496 thousand for the ESWL division, 1,271 thousand for the DIST division and to €645 thousand for the HIFU division, at December 31, 2022. The Company completed the required annual impairment test in the fourth quarter of 2022. To determine the fair value of the Company’s reporting units, the Company used the discounted cash flow approach for each of the three reportable units. In all three cases, the fair value of the reporting unit was in excess of the reporting unit’s book value, which resulted in no goodwill impairment. Intangible assets consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Licenses 1,585 1,448 Trade name and trademark 370 400 Patents 412 412 Organization costs 225 225 Total gross value 2,592 2,484 Accumulated amortization for licenses (863) (723) Accumulated amortization for trade name and trademark (368) (397) Accumulated amortization for patents (412) (412) Accumulated amortization for organization costs (225) (225) Less: Total accumulated amortization (1,868) (1,756) Total 725 728 ​ Amortization expenses related to intangible assets amounted to €141 thousand, €125 thousand and €113 thousand, for the years ended December 31, 2022, 2021 and 2020, respectively. ​ ​ For the five coming years, the annual estimated amortization expense will consist of the following: ​ ​ ​ ​ ​ December 31, ​ 2022 2023 143 2024 135 2025 125 2026 122 2027 107 2028 and thereafter ​ 76 Total 706 ​

TRADE ACCOUNTS AND NOTES PAYABL

TRADE ACCOUNTS AND NOTES PAYABLE	12 Months Ended
	Dec. 31, 2022
TRADE ACCOUNTS AND NOTES PAYABLE
TRADE ACCOUNTS AND NOTES PAYABLE	10— TRADE ACCOUNTS AND NOTES PAYABLE Trade accounts and notes payable consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Trade accounts payable 6,640 5,511 Notes payable 7 1 Total 6,647 5,512 ​ Trade accounts payable usually represent invoices with a due date of 90 days or less and invoices to be received. Notes payable represent commercial bills of exchange (drafts) with initial maturities of 90 days or less.

DEFERRED REVENUES

DEFERRED REVENUES	12 Months Ended
	Dec. 31, 2022
DEFERRED REVENUES
DEFERRED REVENUES	11— DEFERRED REVENUES Deferred revenues consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Deferred revenues on maintenance contracts ​ 1,803 ​ 1,624 Deferred revenue on RPP ​ 517 ​ 315 Deferred revenue on sale of devices ​ 83 ​ 114 Deferred revenue on extension of warranty, included in sales contracts ​ 535 ​ 740 Deferred revenue on treatment probe lease and other ​ 1,376 ​ 1,055 Total ​ 4,314 ​ 3,848 Less long term portion ​ (264) ​ (440) Current portion ​ 4,050 ​ 3,408 ​ Deferred revenue on extension of warranty will be recognized over the following periods: ​ ​ ​ ​ ​ December 31, ​ 2022 2023 302 2024 145 2025 84 2026 5 2027 — 2028 and thereafter ​ — Total 535 ​ ​ ​ Changes in deferred revenue on extension of warranty are as follows: ​ ​ ​ ​ ​ Total Balance as of December 31, 2020 782 New extension of warranty 256 Recognition of revenue (298) Balance as of December 31, 2021 740 New extension of warranty 162 Recognition of revenue (367) Balance as of December 31, 2022 535 ​

OTHER ACCRUED LIABILITIES

OTHER ACCRUED LIABILITIES	12 Months Ended
	Dec. 31, 2022
OTHER ACCRUED LIABILITIES.
OTHER ACCRUED LIABILITIES	12— OTHER ACCRUED LIABILITIES Other accrued liabilities consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Retirement indemnities 2,153 2,382 Provision for warranty costs 162 252 Accruals for payroll and associated taxes 1,848 944 Conditional government advances 463 463 Value added tax payable 531 463 Advances received from customers 861 225 Provision for Asset Retirement Obligation (Japan) 101 109 Provision for employee termination indemnities (Korea) 122 97 Others 340 353 Total 6,583 5,289 Less non-current portion (2,710) (2,534) Current portion 3,873 2,755 ​ We received government conditional advances and grants for advanced research program HECAM which are provided for and managed by French state-owned entity “Banque Publique d’Investissement” (“Bpifrance”). This arrangement consists of both grants and conditional advances which are paid in fixed instalments at predetermined contractual dates, subject generally to milestones based on progress of the research and documentation. Grants received are non-refundable. Conditional advances received are subject to a fixed 1.44% interest rate. Despite a first mono-centric study successfully implemented with Lyon’s Centre Leon Bérard cancer center, we decided not to pursue the development of HIFU for liver cancer as a per-operative approach. The multi-centric Phase II study, which was to be initiated following the mono-centric study, will not be implemented. We considered that the per-operative approach initially targeted will not offer the breakthrough innovation expected by the market and will lead to comparative lengthy clinical studies with existing therapeutic solutions to fulfill the requirement of the new European MDR regulations which became effective in May 2021. In 2020, the Company decided to reorient the efforts, knowledge and assets resulting from the HECAM project in two directions. The first, with a technology and approach very similar to the one developed for liver cancer, will focus on pancreatic cancer for patients with few or even no alternatives. The second will still target liver cancer application but through an extracorporeal solution to offer to patients affected by primary or metastatic liver cancer an undisputable benefit compared to the existing alternatives. In 2021, after agreeing with Bpifrance, the Company decided not to pursue the HECAM project under the initial parameters and based on results obtained as part of the HECAM program, and we had to reimburse €0.6 million, with the balance of €0.4 million reclassified as a non-refundable grant. In 2021, we also received conditional advances for €0.4 million from Banque Publique d’Investissement for business development programs in China and Africa. Grants that relate to expenses we incur for this research program are recognized in the line item “Research and Development Expenses” in the period in which the expenses subject to the grants have been incurred (see Note 21). Conditional advances as of December 31, 2022, mature as follows: ​ ​ ​ ​ 2023 18 2024 93 2025 93 2026 93 2027 86 2028 and thereafter ​ 81 Total 463 ​ Changes in the provision for warranty costs are as follows: ​ ​ ​ ​ ​ ​ ​ 2022 2021 Beginning of year 252 368 Amount used during the year (202) (225) New warranty expenses 112 110 End of year 162 252 Less current portion (100) (206) Long term portion 62 46 ​

LEASE OBLIGATIONS

LEASE OBLIGATIONS	12 Months Ended
	Dec. 31, 2022
LEASE OBLIGATIONS
LEASE OBLIGATIONS	13— LEASE OBLIGATIONS 13-1 Financing leases The Company leases certain of its equipment under finance leases. At December 31, 2022, the corresponding liability associated with this lease equipment amounts to €55 thousand for medical devices and to €494 thousand for vehicles and other IT equipment. Maturities of finance leases liabilities for the years ended December 31, 2022 and 2021 are as follows: ​ ​ ​ ​ ​ December 31, ​ 2022 2023 234 2024 149 2025 102 2026 63 2027 12 2028 and thereafter ​ 6 Total undiscounted minimum lease payments 566 Less: amount representing interest (17) Present value of minimum lease payments 548 Less: current portion (224) Long-term portion 324 ​ ​ ​ ​ ​ December 31, ​ 2021 2022 358 2023 215 2024 124 2025 75 2026 46 2027 and thereafter ​ 7 Total undiscounted minimum lease payments 825 Less: amount representing interest (55) Present value of minimum lease payments 770 Less: current portion (340) Long-term portion 430 ​ Interest paid under finance lease obligations was €12 thousand, €55 thousand and €29 thousand the years ended December 31, 2022, 2021 and 2020 respectively. The weighted average remaining lease term and the weighted average discount rate for finance leases at December 31, 2022 was 1.02 years and 1.32% and at December 31, 2021 was 2.11 years and 2.93%. 13-2 Operating leases Maturities of operating lease liabilities consist of the following amounts: ​ ​ ​ ​ ​ December 31, ​ 2022 2023 ​ 901 2024 636 2025 238 2026 24 2027 — 2028 and thereafter ​ — Total undiscounted minimum lease payments 1,799 Less: current portion (901) Long-term portion 899 ​ ​ ​ ​ ​ December 31, ​ 2021 2022 673 2023 523 2024 277 2025 69 2026 18 2027 and thereafter ​ 2 Total undiscounted minimum lease payments 1,562 Less: current portion ​ (673) Long-term portion ​ 888 ​ The weighted average remaining lease term and the weighted average discount rate for operating leases at December 31, 2022 was 2.18 years and 2.29% and at December 31, 2021 was 2.62 Total rent expenses under operating leases amounted to €912 thousand, €953 thousand and €941 thousand, for the years ended December 31, 2022, 2021 and 2020, respectively. These total rent expenses are related to office rentals, office equipment and car rentals.

SHORT-TERM BORROWINGS

SHORT-TERM BORROWINGS	12 Months Ended
	Dec. 31, 2022
SHORT-TERM BORROWINGS.
SHORT-TERM BORROWINGS	14— SHORT-TERM BORROWINGS As of December 31, 2022 and 2021, short-term borrowings consist mainly of €1,846 thousand and €1,914 thousand of factored account receivables and for which the Company maintains the effective control, respectively. ​

LONG TERM DEBT

LONG TERM DEBT	12 Months Ended
	Dec. 31, 2022
LONG TERM DEBT
LONG TERM DEBT	15— LONG TERM DEBT 15-1 Long-term debt: ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 France term loan 4,593 4,848 Japanese term loan 558 786 Germany term loan 28 111 USA term loan — — Korea term loan ​ 8 ​ 11 Malaysia term loan — 3 Total long term debt 5,188 5,759 Less current portion (1,601) (830) Total long-term portion 3,587 4,930 ​ As of December 31, 2022 and 2021, long-term debt in Japan consists of two loans in denominated in Yen and subscribed with the following conditions: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP Technomed Co. Ltd 80,000,000 ​ August 2, 2026 1.98 % Monthly installment EDAP Technomed Co. Ltd 50,000,000 ​ April 2, 2025 1.8 % Monthly installment ​ As of December 31, 2022 and 2021, long-term debt in Germany consists of one loan in Euro with the following terms : ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP TMS GMBH 400,000 ​ April 30, 2023 2.40 % Monthly installment ​ This loan was pledged against an HIFU equipment with a purchase value of €438 thousand. As of December 31, 2022, long-term debt in France consists of three loans in Euro subscribed in 2020 which terms and maturity were amended and a new loan in Euro subscribed in 2021 with the following terms: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Drown ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP TMS FRANCE 1,066,081 ​ July 1, 2025 0.99 % Monthly installment ​ This loan is pledged against the Company’s cash in USD for an amount equal to the countervalue of the loan in USD. This loan constitutes a complete financial package of €1,530,000, of which €1,066,081 were drawn at the end of December 2022 to finance HIFU treatment probes. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP TMS FRANCE 2,000,000 ​ July 30, 2026 0.73 % Monthly installment ​ This loan is a COVID-related loan guaranteed by the French government entered into in 2020 with an initial one-year repayment term subsequently extended to six years. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP TMS FRANCE 2,000,000 ​ August 4, 2026 0.73 % Monthly installment ​ ​ This loan, in Euro, is a COVID-related loan guaranteed by the French government in 2020 with an initial one year repayment term subsequently extended to six years. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP TMS FRANCE 72,222 ​ July 5, 2024 0.45 % Monthly installment ​ This loan is related to the acquisition of computer servers. ​ As of December 31, 2021, long-term debt in France consists of a loan in Euro to finance the ERP project and three loans in Euro subscribed in 2020 with the following terms: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Drown ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP TMS FRANCE 780,457 ​ April 1, 2025 0.99 % Monthly installment ​ ​ This loan is pledged against the Company’s cash in USD for an amount equal to the countervalue of the loan in USD. This loan constitutes a complete financial package of €1,530,000, of which €780,457 was drawn at the end of December to finance HIFU treatment probes. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP TMS FRANCE 2,000,000 ​ July 30, 2026 0.73 % Monthly installment ​ This loan is a COVID-related loan guaranteed by the French government in 2020 with an initial one year repayment term subsequently extended to six years ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP TMS FRANCE 2,000,000 ​ August 4, 2026 0.73 % Monthly installment ​ This loan is a COVID-related loan guaranteed by the French government in 2020 with an initial one year repayment term. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP TMS FRANCE 72,222 ​ July 5, 2024 0.45 % Monthly instalment ​ This loan is related to the acquisition of computer servers. ​ As of December 31, 2021, long-term debt in Malaysia consisted of a loan in Ringgit with the following conditions: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP TECHNOMED SDN BHD 90,000 ​ July 31, 2022 4.64 % Monthly installment ​ A long-term debt in the USA which consisted of a loan denominated in USD with the following terms and related to the U.S. Paycheck Protection Program was forgiven in 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP TECHNOMED INC 221,217 ​ May 14, 2022 1 % Monthly installment ​ 15-2 Financial instruments carried at fair value: As of December 31, 2022, there are no warrants outstanding. Refer to Note 26 for more details on the fair value of other Financial Instruments. 15-3 Long-term debt maturity: Long-term debt carried at amortized cost at December 31, 2022 matures as follows: ​ ​ ​ ​ 2023 1,601 2024 1,570 2025 1,335 2026 682 2027 — 2028 and thereafter ​ — Total 5,188 ​

OTHER LONG-TERM LIABILITIES

OTHER LONG-TERM LIABILITIES	12 Months Ended
	Dec. 31, 2022
OTHER LONG-TERM LIABILITIES.
OTHER LONG-TERM LIABILITIES	16— OTHER LONG-TERM LIABILITIES Other long-term liabilities consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Provision for retirement indemnities (Japan & France), less current portion 1,962 2,281 Provision for employee termination indemnities (Korea) less current portion 122 97 Provision for Asset Retirement Obligation (Japan) less current portion 101 109 Provision for warranty costs, less current portion 62 46 Conditional government advances, less current portion 463 — Accrued interest less current portion — — Total 2,710 2,534 ​ Provision for asset retirement obligation in Japan is related to subsidiary’s offices and warehouses. Pension, post-retirement and post-employment benefits for most of the Company’s employees are sponsored by European governments. In addition to government-sponsored plans, subsidiaries in Japan and France have defined benefit retirement plans in place. The provision for retirement indemnities at December 31, 2022 represents an accrual for lump-sum retirement benefit payments to be paid at the time an employee retires if he or she is still present at the Company at the date of retirement. This provision has been calculated taking into account the estimated payment at retirement (discounted to the current date), turnover and salary increases. The provision is management’s best estimate based on the following assumptions as of year-end: ​ ​ ​ ​ ​ ​ ​ ​ Pension benefits France ​ ​ 2022 ​ 2021 Discount rate 3.80% ​ 1.05% ​ Salary increase 3.00% ​ 2.50% ​ Retirement age 65 65 ​ Average retirement remaining service period 24 24 ​ ​ ​ ​ ​ ​ ​ ​ ​ Pension benefits Japan ​ ​ 2022 ​ 2021 Discount rate 1.30% ​ 0.60% ​ Salary increase 2.50% ​ 2.50% ​ Retirement age 60 60 ​ Average retirement remaining service period 14 14 ​ ​ The discount rate retained is determined by reference to the high quality rates for AA- rated corporate bonds for a duration equivalent to that of the obligations. At December 31, 2022, the provision which represents the projected benefit obligation in accordance with ASC 718 consists of: ​ ​ ​ ​ ​ ​ ​ France Japan Non-current liabilities ​ 845 ​ 1,117 Current liabilities 89 102 Total projected benefit obligation 934 1,219 ​ At December 31, 2021, the provision which represents the projected benefit obligation in accordance with ASC 718 consists of: ​ ​ ​ ​ ​ ​ ​ France Japan Non-current liabilities ​ 1,080 ​ 1,200 Current liabilities — 102 Total projected benefit obligation 1,080 1,302 ​ The Company does not have a funded benefit plan. A detailed reconciliation of pension cost components (in thousands of euros) during fiscal year for each of the three years ending December 31, 2022 is as follows: ​ ​ ​ ​ ​ ​ ​ ​ France 2022 2021 2020 Change in benefit obligations: Projected Benefit obligations at beginning of year 1,080 1,111 969 Service cost 84 90 88 Interest cost 11 6 9 Net loss or (gain) — — — Actuarial (gain) or loss (241) (72) 46 Amortization of net prior service cost — — 1 Benefits paid — (56) — Projected Benefit obligations at end of year (1) 934 1,080 1,111 Unrecognized actuarial (gain) loss (2) (219) 22 94 Unrecognized prior service cost (2) 14 16 17 (1) The accumulated benefit obligation was €701 thousand and €780 thousand at December 31, 2022 and 2021 respectively. (2) The amount in accumulated other comprehensive income (loss) to be recognized as components of net periodic benefit costs in 2022 is 205 thousand. ​ ​ ​ ​ ​ ​ ​ ​ Japan 2022 2021 2020 Change in benefit obligations: Projected Benefit obligations at beginning of year 1,302 1,310 1,230 Service cost 112 120 123 Interest cost 7 7 7 Amortization of net loss — — 1 Actuarial (gain) / loss (30) — (1) Benefits paid (75) (97) (5) Exchange rate impact (95) (39) (44) Projected Benefit obligations at end of year (1) 1,219 1,302 1,310 Unrecognized actuarial (gain) loss (2) 86 126 130 Unrecognized prior service cost (2) — — — (1) The accumulated benefit obligation was €1,027 thousand and €1,123 thousand at December 31, 2022 and 2021, respectively. (2) The amount in accumulated other comprehensive income (loss) to be recognized as components of net periodic benefit costs in 2022 is €86 thousand. The benefits expected to be paid in each of the next five fiscal years, and in the aggregate for the five fiscal years thereafter, are detailed in the table below: ​ ​ ​ ​ ​ ​ ​ France Japan 2023 91 103 2024 — 75 2025 — 156 2026 129 157 2027 85 72 2028-2032 408 682 ​ 713 1,246 ​

SHAREHOLDERS' EQUITY

SHAREHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2022
SHAREHOLDERS' EQUITY.
SHAREHOLDERS' EQUITY	17— SHAREHOLDERS’ EQUITY 17-1 Common stock As of December 31, 2022, EDAP TMS S.A.’s common stock consisted of 37,197,731 issued shares fully paid and with a par value of €0.13 each. 36,910,925 of the shares were outstanding. In April 2021, the Company completed a successful common stock offering and issued 4,150,000 new common shares in the form of ADS for $6.75 per share which resulted in gross proceeds of €23,255 thousand. In connection with this offering, the Company incurred issuance costs amounting to €1,961 thousand. In September 2022, the Company completed a successful common stock offering and issued 3,066,667 new common shares in the form of ADS for $7.50 per share which resulted in gross proceeds of €23,913 thousand. In connection with this offering, the Company incurred issuance costs amounting to €1,954 thousand. ​ 17-2 Pre-emptive subscription rights Shareholders have preemptive rights to subscribe on a pro rata 17-3 Dividend rights Dividends may be distributed from the statutory retained earnings, subject to the requirements of French law and the Company’s by-laws. The Company has not distributed any dividends since its inception as the result of an accumulated statutory deficit of 14,329 thousand. Dividend distributions, if any, will be made in euros. The Company has no plans to distribute dividends in the foreseeable future. 17-4 Treasury stock As of December 31, 2022, all 286,806 shares held as treasury stock consisted of (i) , 106,516 shares acquired between August and December 1998 and (ii) 180,290 shares acquired in June and July 2001 for a total of €697 thousand. All treasury stocks have been acquired to cover stock purchase options (see Note 17-5). 17-5 Stock-option and free share plans As of December 31, 2022, EDAP TMS S.A. sponsored four stock purchase and subscription option plans open to employees of EDAP TMS group: On December 19, 2012, the shareholders authorized the Board of Directors to grant up to 500,000 options to subscribe 500,000 new shares at a fixed price to be set by the Board of Directors. Conforming to this stock option plan, the Board of Directors granted 500,000 options to subscribe to new shares to certain employees of EDAP TMS on January 18, 2013. The exercise price was fixed at €1.91 per share. Options were to begin vesting one year four years ten years 48 months On February 18, 2016, the shareholders authorized the Board of Directors to grant up to 1,000,000 options to subscribe to 1,000,000 new shares at a fixed price to be set by the Board of Directors. Conforming to this stock option plan, the Board of Directors granted 575,000 options to subscribe to new shares to certain employees of EDAP TMS on April 26, 2016. The exercise price was fixed at €3.22 per share. Options were to begin vesting one year four years ten years 48 months Conforming to this February 18, 2016 stock option plan, the Board of Directors granted 260,000 options to subscribe to new shares to certain employees of EDAP TMS on April 25, 2017. The exercise price was fixed at €2.39 per share. Options were to begin vesting one year four years ten years 48 months Conforming to this February 18, 2016 stock option plan, the Board of Directors granted 165,000 options to subscribe to new shares to certain employees of EDAP TMS on August 29, 2018. The exercise price was fixed at €2.65 per share. Options were to begin vesting one year four years ten years 48 months Conforming to this February 18, 2016 stock option plan, the Board of Directors granted 155,000 options to subscribe to new shares to certain employees of EDAP TMS on April 4, 2019. Forfeited options corresponding to employees’ departures were re-allocated. The exercise price was fixed at €3.90 per share. Options were to begin vesting one year four years ten years The impact of this February 18, 2016 Plan on operating income, in accordance with ASC 718, was €160 thousand, €65 thousand and €25 thousand in 2020, 2021 and 2022, respectively. Under this 2016 plan, 696,080 options are outstanding, 668,580 options are exercisable at December 31, 2022. On June 28, 2019, the shareholders authorized the Board of Directors to grant up to a maximum of 358,528 options to purchase pre-existing shares and to grant 1,000,000 options to subscribe to 1,000,000 new shares at a fixed price to be set by the Board of Directors. Conforming to this June 28, 2019 stock option plan, the Board of Directors granted 292,428 options to purchase pre-existing shares and 1,000,000 options to subscribe to new shares to certain employees of EDAP TMS on June 11, 2021. The exercise price was fixed at €5.59 per share. Options were to begin vesting six months after the date of grant and all options will be fully vested as of June 11, 2024 (i.e., three years ten years 36 months The impact of this June 28, 2019 Plan on operating income, in accordance with ASC 718, was €1,484 thousand and €1,104 thousand in 2021 and 2022, respectively. Under this 2019 plan, 1,266,806 options are outstanding, 633,403 options are exercisable at December 31, 2022. On June 30, 2021, the shareholders authorized the Board of Directors to grant up to a maximum of 2,000,000 options to subscribe to 2,000,000 new shares at a fixed price to be set by the Board of Directors. Conforming to this June 30, 2021 stock-option plan, the Board of Directors granted: (i) 100,000 options to subscribe to new shares to certain employees of EDAP TMS on November 17, 2021. The exercise price was fixed at € 5.18 per share. Options were to begin vesting six months after the date of grant and all options will be fully vested as of November 17, 2024 (i.e., three years after the date of grant). The options will expire on November 17, 2031 (i.e., ten years after the date of grant) or when employment with the Company ceases, whichever occurs earlier. The total fair value of the options granted on November 17, 2021 under this plan was € 229 thousand. This non-cash compensation expense was recognized in the Company’s operating expenses over a period of 36 months (using the graded vesting method). (ii) 144,000 options to subscribe to new shares to certain employees of EDAP TMS on May 17, 2022. The exercise price was fixed at € 6.41 per share. Options were to begin vesting six months after the date of grant and all options will be fully vested as of May 17, 2025 (i.e., three years after the date of grant). The options will expire on May 17, 2032 (i.e., ten years after the date of grant) or when employment with the Company ceases, whichever occurs earlier. The total fair value of the options granted on May 17, 2022 under this plan was € 450 thousand. This non-cash compensation expense was recognized in the Company’s operating expenses over a period of 36 months (using the graded vesting method). (iii) 32,000 options to subscribe to new shares to certain employees of EDAP TMS on November 8, 2022. The exercise price was fixed at € 10.32 per share. Options were to begin vesting six months after the date of grant and all options will be fully vested as of November 8, 2025 (i.e., three years after the date of grant). The options will expire on November 8, 2032 (i.e., ten years after the date of grant) or when employment with the Company ceases, whichever occurs earlier. The total fair value of the options granted on November 8, 2022 under this plan was € 161 thousand. This non-cash compensation expense was recognized in the Company’s operating expenses over a period of 36 months (using the graded vesting method). (iv) 395,000 options to subscribe to new shares to certain employees of EDAP TMS on December 15, 2022. The exercise price was fixed at € 9.94 per share. Options were to begin vesting six months after the date of grant and all options will be fully vested as of December 15, 2025 (i.e., three years after the date of grant). The options will expire on December 15, 2032 (i.e., ten years after the date of grant) or when employment with the Company ceases, whichever occurs earlier. The total fair value of the options granted on December 15, 2022 under this plan was € 1,858 thousand. This non-cash compensation expense was recognized in the Company’s operating expenses over a period of 36 months (using the graded vesting method). The impact of this June 30, 2021 Plan on operating income, in accordance with ASC 718, was €25 thousand and €442 thousand in 2021 and 2022, respectively. Under this 2021 plan, 651,000 options are outstanding at December 31, 2022. Forfeited stock-options are recognized as they occur, in accordance with ASU 2016-09. The fair value of each stock option granted during the year is estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 2022 November 2022 May 2022 November 2021 June 2021 Weighted-average expected life (years) 5.79 5.79 5.79 5.79 5.79 Expected volatility rates (1) 45.41 % 45.38 % 44.96 % 45.08 % 46.34 Expected dividend yield 0 % 0 % 0 % 0 % 0 Risk-free interest rate 3.62 % 4.32 % 3.00 % 1.32 % 0.63 Weighted-average exercise price (€) 9.94 10.32 6.41 5.18 5.59 Weighted-average fair value of options granted during the year (€) 4.70 5.05 3.13 2.29 2.37 (1) Historical volatility calculated over the weighted-average expected life. ​ (2) There was no new plan for the year 2020. ​ As of December 31, 2022, a summary of stock option activity to purchase or to subscribe to Shares under these plans is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 2021 ​ 2020 ​ ​ Options Weighted ​ Options Weighted ​ Options Weighted ​ ​ ​ average ​ ​ average ​ ​ average ​ ​ ​ exercice ​ ​ exercice ​ ​ exercice ​ ​ price (€) ​ price (€) ​ price (€) Outstanding on January 1, 2,408,508 4.38 1,186,900 2.81 1,273,900 2.78 Granted 571,000 9.07 1,392,428 5.56 — — Exercised (320,622) 2.14 (150,820) 2.93 (23,750) 2.54 Forfeited (45,000) 5.34 (20,000) 4.01 (21,250) 2.55 Expired — — — — (42,000) 2 Outstanding on December 31, 2,613,886 5.66 2,408,508 4.38 1,186,900 2.81 Exercisable on December 31, 1,362,205 4.35 1,149,401 3.25 970,650 2.73 Share purchase options available for grant on December 31, 20,000 ​ 5,000 ​ 292,428 ​ As of December 31, 2022, 1,329,000 options to subscribe to new shares are available for future grants. ​ The following table summarizes information about options to purchase existing Shares held by the Company, or to subscribe to new Shares, at December 31, 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Outstanding options ​ Fully vested options (1) ​ ​ ​ ​ Weighted ​ Weighted ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ average ​ average ​ Aggregate ​ ​ ​ average ​ Aggregate ​ ​ ​ ​ remaining ​ exercise ​ Intrinsic ​ ​ ​ exercise ​ Intrinsic ​ ​ ​ ​ contractual ​ price ​ Value ​ ​ ​ price ​ Value Exercise price (€) Options life (€) (2) Options (€) (2) 10.32 ​ 32,000 ​ 9.8 ​ 10.32 ​ 330,240 ​ — ​ — ​ — 9.94 ​ 395,000 ​ 10.0 ​ 9.94 ​ 3,926,300 ​ — ​ — ​ — 6.41 ​ 124,000 ​ 9.3 ​ 6.41 ​ 794,840 ​ 24,111 ​ 6.41 ​ 154,552 5.59 ​ 1,266,806 ​ 8.4 ​ 5.59 ​ 7,081,446 ​ 633,403 ​ 5.59 ​ 3,540,723 5.18 ​ 100,000 ​ 8.8 ​ 5.18 ​ 518,000 ​ 36,111 ​ 5.18 ​ 187,055.56 3.90 107,500 6.8 3.90 419,250 80,000 ​ 3.90 ​ 312,000 3.22 365,000 3.3 3.22 1,175,300 365,000 ​ 3.22 ​ 1,175,300 2.65 87,500 5.7 2.65 231,875 87,500 ​ 2.65 ​ 231,875 2.39 136,080 4.3 2.39 325,231 136,080 ​ 2.39 ​ 325,231 2.39 to 10.32 2,613,886 7.4 5.66 14,802,482 1,362,205 4.35 5,926,737 (1) Fully vested options are all exercisable options. On March 29, 2023, the Board of Directors unanimously decided to appoint Ryan Rhodes as the new Chief Executive Officer of the Company, which will become effective on May 1, 2023. Marc Oczachowski will continue to serve as Chairman of the Board of the Company. In this context, the Board decided to accelerate the vesting of all unvested options granted to Mr. Oczachowski under the 2019 option plans such that these options fully vested and became exercisable on March 29, 2023. (Ref. Note 33. Subsequent Events.) (2) The aggregate intrinsic value represents the total pre-tax intrinsic value, based on the Company’s closing stock price of $10.66 at December 31, 2022, which would have been received by the option holders had all in-the-money option holders exercised their options as of that date. A summary of the status of the non-vested options to purchase shares or to subscribe to new shares as of December 31, 2022, and changes during the three years ended December 31, 2022, is presented below: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average ​ ​ ​ ​ Grant-Date Fair ​ Options Value (€) Non-vested at January 1, 2020 ​ 455,000 1.58 Granted ​ — — Vested ​ (235,000) 1.58 Forfeited ​ (3,750) 1.54 Non-vested at December 31, 2020 ​ 216,250 1.59 Granted ​ 1,392,428 2.37 Vested ​ (329,571) 2.06 Forfeited ​ (20,000) 1.89 Non-vested at December 31, 2021 ​ 1,259,107 2.32 Granted ​ 571,000 ​ 4.33 Vested (543,426) 2.32 Forfeited (35,000) 2.80 Non-vested at December 31, 2022 1,251,681 3.22 ​ As of December 31, 2022, there were €2,612 thousand of total unrecognized compensation expenses related to non-vested stock-options, over a period of 2,9 On June 30, 2021, the shareholders authorized the Board of Directors to grant up to a maximum of 200,000 free shares to certain employees. Conforming to this June 30, 2021 authorization, the Board of Directors granted: (i) 61,500 free shares to certain employees of EDAP TMS on September 28, 2021. Free shares shall be definitively acquired by the relevant beneficiaries at the end of the vesting period (minimum one year period starting on the allocation date and ending on the acquisition date, i.e. two years starting on the allocation date). On September 28, 2022, 57,500 free shares were definitely acquired by French resident beneficiaries. The total fair value of the free shares granted on September 28, 2021 under this plan was €340 thousand. This non-cash compensation expense was recognized in the Company’s operating expenses upon allocation. (ii) 40,000 free shares to the CEO of EDAP TMS on March 30, 2022. Free shares shall be definitively acquired by the relevant beneficiaries at the end of the vesting period (minimum one year period starting on the allocation date and ending on the acquisition date, i.e. two years starting on the allocation date). The total fair value of the free shares granted on March 30, 2022 under this plan was €259 thousand. This non-cash compensation expense was recognized in the Company’s operating expenses upon allocation. Under this 2021 plan, 44,000 free shares are outstanding at December 31, 2022. On June 30, 2022, the shareholders authorized the Board of Directors to grant up to 600,000 free shares. This new resolution superseded the June 30, 2021 resolution, cancelling the unused portion of the 2021 resolution. Conforming to this June 30, 2022 authorization, the Board of Directors granted 291,500 free shares to certain employees of EDAP TMS on November 8, 2022. Free shares shall be definitively acquired by the relevant beneficiaries at the end of the vesting period, which begins six months after the date of grant and all shares will be fully vested as of November 8, 2025 (i.e. three years after the date of the grant). The total fair value of the free shares granted on November 8, 2022 under this plan was €2,963 thousand. This non-cash compensation expense is recognized in the Company’s operating expenses over a period of 36 months ​ 17-6 Accumulated other comprehensive income (loss) The components of accumulated other comprehensive income (loss) net of tax, for the years ended December 31, 2022, and 2021, are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, 2022 ​ ​ Foreign currency ​ Provision for ​ ​ ​ ​ translation ​ retirement indemnities ​ ​ ​ ​ adjustment ​ (net of tax) ​ Total Beginning balance (3,377) (212) (3,589) Other comprehensive income (loss) before reclassifications — — — Reclassified from accumulated other comprehensive loss — — — Net current-period other comprehensive income (loss) (596) 355 (240) Ending balance (3,973) 144 (3,829) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, 2021 ​ ​ Foreign currency ​ Provision for ​ ​ ​ ​ translation ​ retirement indemnities ​ ​ ​ ​ adjustment ​ (net of tax) ​ Total Beginning balance (2,824) (241) (3,064) Other comprehensive income (loss) before reclassifications — — — Reclassified from accumulated other comprehensive loss — — — Net current-period other comprehensive income (loss) (554) 29 (525) Ending balance (3,377) (212) (3,589) ​

TOTAL SALES

TOTAL SALES	12 Months Ended
	Dec. 31, 2022
TOTAL SALES
TOTAL SALES	18— TOTAL SALES Amount of net sales derived from our operations in Asia, France, the United States. and other geographical areas, are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, Primary geographical markets (€) 2022 2021 2020 Asia 17,936 16,009 15,872 France 10,637 12,251 10,021 United States 15,036 5,524 5,611 Others geographical areas 11,500 10,276 10,146 Total Net Sales 55,108 44,060 41,649 ​ The amount of net sales is recognized following the timing above: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, Timing of revenue recognition 2022 2021 2020 Products transferred at a point in time 44,173 34,552 32,862 Products and services transferred over time 10,935 9,508 8,787 Total Net Sales 55,108 44,060 41,649 ​

OTHER REVENUES

OTHER REVENUES	12 Months Ended
	Dec. 31, 2022
OTHER REVENUES
OTHER REVENUES	19— OTHER REVENUES Other revenues consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 2020 Licenses and others — 6 12 Total — 6 12 ​ In 2021 and 2020, other revenues mainly consist of sales of a license to Theraclion and training to customers.

COSTS OF SALES

COSTS OF SALES	12 Months Ended
	Dec. 31, 2022
COSTS OF SALES
COSTS OF SALES	20— COSTS OF SALES Costs of sales consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 2020 Direct costs of sales (19,814) (16,199) (14,058) Indirect costs of sales (11,102) (9,443) (9,225) Total costs of sales (30,916) (25,643) (23,283) ​

RESEARCH AND DEVELOPMENT EXPENS

RESEARCH AND DEVELOPMENT EXPENSES	12 Months Ended
	Dec. 31, 2022
RESEARCH AND DEVELOPMENT EXPENSES
RESEARCH AND DEVELOPMENT EXPENSES	21— RESEARCH AND DEVELOPMENT EXPENSES Research and development expenses consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 2020 Gross research and development expenses (5,751) (4,757) (5,173) Research Tax Credit 581 617 492 Grants 250 739 184 Net Research and development expenses (4,920) (3,402) (4,496) ​ In 2022, grants consisted mainly of national grants for the assessment and optimization of the focal treatments of prostate cancer (Perfuse development project). In 2021, grants consisted mainly of national grants for the assessment and optimization of the focal treatments of prostate cancer (Perfuse development project) and of a financial impact for the development of innovative imaging solutions for the focal treatment of liver cancer (HECAM Development project). Ref. Note 12. In 2020, grants consisted mainly of national grants for the assessment and optimization of the focal treatments of prostate cancer (Perfuse development project). Research and development costs are expensed as incurred and include amortization of assets, costs of prototypes, salaries, benefits and other headcount related costs, contract and other outside service fees, and facilities and overhead costs.

FINANCIAL INCOME, NET

FINANCIAL INCOME, NET	12 Months Ended
	Dec. 31, 2022
FINANCIAL INCOME, NET
FINANCIAL INCOME, NET	22— FINANCIAL INCOME, NET Interest (expense) income, net consists of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 2020 Interest income ​ 404 ​ 10 ​ 10 Interest expense (168) (52) (108) Paycheck Protection Program loan forgiveness — 187 — Total 236 145 (98) ​

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2022
INCOME TAXES
INCOME TAXES	23— INCOME TAXES 23-1 Income / (Loss) before income taxes Income / (loss) before income taxes is comprised of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 2020 France ​ (418) ​ 869 ​ (2,042) Other countries (1,678) 24 854 Total (2,096) 893 (1,188) ​ 23-2 Income tax (expense)/ benefit Income tax (expense)/benefit consists of the following : ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 2020 Current income tax expense: ​ ​ ​ France (485) (320) (158) Other countries (251) (436) (312) Sub-total current income tax expense (736) (756) (471) Deferred income tax (expense) benefit: France (8) 8 8 Other countries (93) 556 (53) Sub-total deferred income tax (expense) benefit (101) 563 (45) Total (837) (193) (516) ​ 23-3 Deferred income taxes: Deferred income taxes reflect the impact of temporary differences between the amounts of assets and liabilities reported for financial reporting purposes and such amounts as measured in accordance with tax laws. The tax effects of temporary differences which give rise to significant deferred tax assets (liabilities) are as follows by nature : ​ ​ ​ ​ ​ ​ ​ 2022 2021 Net operating loss carry forwards ​ 13,793 ​ 13,611 Elimination of intercompany profit in inventory 480 182 Elimination of intercompany profit in fixed assets 256 278 Provisions for retirement indemnities 658 642 Capital leases treated as operating leases for tax 26 40 Other items 360 487 Total deferred tax assets 15,573 15,239 Total deferred tax liabilities — — Net deferred tax assets 15,573 15,239 Valuation allowance for deferred tax assets (14,744) (14,341) Deferred tax assets (liabilities), net of allowance 829 898 ​ Net operating loss carryforwards available amount to €59,632 thousand as of December 31, 2022, of which €29,791 thousand relates to EDAP TMS SA, €29,022 thousand relates to Edap Technomed Inc., €776 thousand relates to Edap Technomed Co Ltd Japan, —and €43 thousand relates to Edap TMS Gmbh. These net operating losses generate deferred tax assets of €13,793 thousand as at December 31, 2022. Realization of these tax assets is contingent on future taxable earnings in the applicable tax jurisdictions. As of December 31, 2022, €58,856 thousand out of these €59,632 thousand net operating loss carry-forwards have no expiration date but the amount of the net operating loss carry-forward, which can be used each year to offset taxable earnings, is limited in all jurisdictions. The remaining tax loss carry-forwards expire from years 2022 through 2032. In accordance with ASC 740, a valuation allowance is established if, based on the weight of available evidence, it is more-likely-than-not that some portion or all of the deferred tax asset will not be realized. The 2017 U.S. Tax Act was enacted on December 22, 2017. The 2017 U.S. Tax Act includes a number of changes in existing tax law which impacted our business in the U.S. Starting with tax year 2018, the U.S. corporate tax rates changed from a graduated system ranging from 15% to 39% to a flat 21% of taxable net income. For taxable net income of $100 thousand and greater for years 2018 and following, EDAP’s U.S. subsidiary would pay significantly lower taxes than with the previous tax law. Starting from tax year 2020, the French corporate tax rates of taxable net income gradually decreased from 28% to 25% in 2022. 23-4 Effective tax income (expense) A reconciliation of differences between the statutory French income tax rate and the Company’s effective tax income (loss) is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 2021 2020 Theoretical income tax (expense) benefit at French statutory tax rate ​ 524 ​ (237) ​ 333 Income of foreign subsidiaries taxed at different tax rates (174) (95) 9 Effect of net operating loss carry-forwards and valuation allowances (1) (643) 626 (749) Non-taxable debt fair value variation — — — Permanent differences (99) (258) (159) Effect of cancellation of intra-group positions (366) (130) 152 French business tax included in income tax (CVAE) (99) (85) (156) Other (1) 20 (15) 55 Effective income tax (expense) benefit (837) (193) (516) (1) Certain immaterial amounts in prior years have been reclassified to conform to the current year presentation (deferred income taxes on certain temporary differences impacted by a full valuation allowance reclassified from “other” to “Effect of net operating loss carry-forwards and valuation allowances”). 23-5 Uncertainty in Income Taxes According to ASC 740, the Company reviewed the tax positions of each subsidiary. On December 31, 2022 the Company believes that there is no significant uncertainty in the Company’s tax positions. The Company remains subject to examination by major tax jurisdictions. Interest and penalties on income taxes are classified as a component of the provision for income taxes. There were no interest or penalties in 2022, 2021 and 2020.

EARNINGS (LOSS) PER SHARE

EARNINGS (LOSS) PER SHARE	12 Months Ended
	Dec. 31, 2022
EARNINGS (LOSS) PER SHARE
EARNINGS (LOSS) PER SHARE	24— EARNINGS (LOSS) PER SHARE ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 2020 Income (loss) available to common shareholders (in Euros) ​ € (2,933,058) ​ € 699,890 ​ € (1,703,668) Weighted average number of shares for the computation of basic EPS ​ 34,392,598 ​ 32,129,047 ​ 29,148,108 Basic EPS (in Euros) ​ € (0.09) ​ € 0.02 ​ € (0.06) Effect of dilutive securities ​ 2,502,171 ​ 293,824 ​ 622,723 Weighted average number of shares for the computation of diluted EPS ​ 34,392,598 ​ 32,422,871 ​ 29,148,108 Diluted EPS income / (loss) (in Euros) ​ € (0.09) ​ € 0.02 ​ € (0.06) ​ Diluted EPS income / (loss) available to common shareholders is computed including all dilutive securities that are in the money. The effects of dilutive securities for the year ended December 31, 2022 and 2020 were excluded from the calculation of diluted earnings per share as a net loss was reported in this period.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2022
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES	25— COMMITMENTS AND CONTINGENCIES 25-1 Commitments The Company currently has commitments regarding its operating leases as described in Note 13-2. 25-2 Contingencies The Company currently has contingencies relating to standard warranties provided to customers for products as described in Note 1-15 and Note 12.

FAIR VALUE OF FINANCIAL INSTRUM

FAIR VALUE OF FINANCIAL INSTRUMENTS	12 Months Ended
	Dec. 31, 2022
FAIR VALUE OF FINANCIAL INSTRUMENTS
FAIR VALUE OF FINANCIAL INSTRUMENTS	26— FAIR VALUE OF FINANCIAL INSTRUMENTS The following disclosure of the estimated fair value of financial instruments was made in accordance with the requirements of ASC 820 ‘‘Disclosure about fair value of financial instruments’’ and indicates the fair value hierarchy of the valuation techniques utilized to determine such fair value. ASC 820 defines three levels of inputs that may be used to measure fair value and requires that the assets or liabilities carried at fair value be disclosed by the input level under which they were valued. The input levels are defined as follows: Level 1: Quoted (unadjusted) prices in active markets for identical assets and liabilities that the reporting entity can access at the measurement date. Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3: Unobservable inputs for the asset or liability. ​ The recorded amount of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities and short-term borrowings are a reasonable estimate of their fair value due to the short-term maturities of these instruments. As of December 31, 2022 and December 31, 2021, the Company did not have any other asset or liability measured at fair value. As of December 31, 2022 and December 31, 2021, the fair value of the Company’s long-term debt was not materially different from the carrying value. ​

CONCENTRATION OF CREDIT RISK

CONCENTRATION OF CREDIT RISK	12 Months Ended
	Dec. 31, 2022
CONCENTRATION OF CREDIT RISK
CONCENTRATION OF CREDIT RISK	27— CONCENTRATION OF CREDIT RISK Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents and trade accounts and notes receivable from customers, primarily located in France, Japan and the United States. The Company maintains cash deposits with major banks. Management periodically assesses the financial condition of these institutions and believes that credit risk is limited. The Company has implemented procedures to monitor the creditworthiness of its customers. The Company obtains bank guarantees for first time or infrequent unknown customers, and in certain cases obtains insurance against the risk of a payment default by the customer. The Company reviewed individual customer balances considering current and historical loss experience and general economic conditions in determining the allowance for doubtful accounts receivable of €0.2 million and €0.7 million, for the years ended December 31, 2022 and 2021, respectively. Actual losses may vary from the current estimates, and any adjustments are reported in earnings in the periods in which they become known. In 2022, 2021 and 2020, the Company did not generate more than 10% revenue with a single customer.

FOREIGN CURRENCY TRANSACTIONS

FOREIGN CURRENCY TRANSACTIONS	12 Months Ended
	Dec. 31, 2022
FOREIGN CURRENCY TRANSACTIONS
FOREIGN CURRENCY TRANSACTIONS	28— FOREIGN CURRENCY TRANSACTIONS The Company generates a significant percentage of its revenues, and of its operating expenses, in currencies other than the euro. The Company’s operating profitability could be materially adversely affected by large fluctuations in the rate of exchange between the euro and such other currencies. The Company may engage in foreign exchange hedging activities when deemed necessary, but there can be no assurance that hedging activities will be offset by the impact of movements in exchange rates on the Company’s results of operations. As of December 31, 2022, there were no outstanding hedging instruments. ​

SEGMENT INFORMATION

SEGMENT INFORMATION	12 Months Ended
	Dec. 31, 2022
SEGMENT INFORMATION
SEGMENT INFORMATION	29— SEGMENT INFORMATION Our activity is organized into three divisions: HIFU, ESWL (including lithotripsy activities) and Distribution. Through these three divisions, we develop, produce, market and distribute minimally invasive medical devices, mainly for urological diseases. HIFU division includes sales of Focal One, Ablatherm and related consumables and services, ESWL division includes revenues generated by the existing Sonolith range of lithotripters and, Distribution division includes the sale of complimentary products such as lasers, micro-ultrasound systems and other products from third parties. The organization of our activities into three divisions better clarified our vision and enhanced our financial reporting of our three businesses HIFU, ESWL and Distribution. This new structure also allows for an improved measurement of our business progress. The business in which the Company operates is the development, production and distribution of minimally invasive medical devices, primarily for the treatment of urological diseases. Substantially all revenues result from the sale of medical devices and their related license and royalty payments from third parties. The segments derive their revenues from this activity. The following tables set forth the key Statement of income (loss) figures, by segment for fiscal years 2022, 2021 and 2020 and the key balance sheet figures, by segment, for fiscal years 2022, 2021 and 2020. Segment operating profit or loss and segment assets are determined in accordance with the same policies as those described in the summary of significant accounting policies and they are reviewed by the CODM, who is the CEO. Interest income and expense, current and deferred income taxes are not allocated to individual segments. A reconciliation of segment operating profit or loss to consolidated net loss is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 2020 Segment operating income (loss) (4,257) (1,612) 269 Financial income (expense), net 236 145 (98) Foreign Currency exchange (losses) gains, net 1,925 2,360 (1,359) Income tax (expense) benefit (837) (193) (516) Consolidated net income (loss) (2,933) 700 (1,704) ​ A summary of the Company’s operations by segment is presented below for years ended December 31, 2022, 2021 and 2020: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ HIFU ESWL DISTRIB Reconciling Total 2022 ​ Division ​ Division ​ Division ​ Items ​ consolidated Sales of goods 9,437 4,880 24,145 ​ — 38,462 Sales of RPPs & leases 4,287 1,058 272 ​ — 5,617 Sales of spare parts and services 1,909 5,630 3,491 ​ — 11,030 Total sales 15,634 11,568 27,907 ​ — 55,108 External other revenues — — — ​ — — Total revenues 15,634 11,568 27,907 ​ — 55,108 Total COS (6,788) (6,732) (17,396) ​ — (30,916) Gross profit 8,846 4,836 10,511 ​ — 24,193 R&D expenses (3,525) (950) (444) ​ — (4,920) Selling and marketing expenses (8,083) (1,887) (6,409) ​ — (16,379) G&A expenses (2,131) (1,077) (1,690) (2,254) (7,152) Total expenses (13,739) (3,914) (8,543) (2,254) (28,450) Operating income (loss) from operations (4,894) 922 1,968 (2,254) (4,257) Total Assets 16,293 ​ 12,997 ​ 26,407 ​ 45,426 101,123 Capital expenditures 1,715 ​ 307 ​ 356 ​ — 2,378 Non-current assets 4,269 ​ 2,149 ​ 4,187 ​ — 10,605 Goodwill 645 ​ 496 ​ 1,271 ​ — 2,412 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ HIFU ESWL DISTRIB Reconciling Total 2021 ​ Division ​ Division ​ Division ​ Items ​ consolidated Sales of goods 4,515 4,236 20,289 — 29,040 Sales of RPPs & leases 3,679 1,022 267 — 4,968 Sales of spare parts and services 1,715 5,758 2,578 — 10,052 Total sales 9,910 11,016 23,134 — 44,060 External other revenues 6 — — — 6 Total revenues 9,915 11,016 23,134 — 44,065 Total COS (5,311) (6,080) (14,252) — (25,643) Gross profit 4,604 4,936 8,882 — 18,422 R&D expenses (2,238) (835) (329) — (3,402) Selling and marketing expenses (3,910) (2,048) (4,774) — (10,732) G&A expenses (1,481) (1,161) (1,355) (1,904) (5,900) Total expenses (7,630) (4,043) (6,458) (1,904) (20,034) Operating income (loss) from operations (3,025) 893 2,424 (1,904) (1,612) Total Assets 13,597 ​ 13,596 ​ 25,344 ​ 24,690 77,226 Capital expenditures 1,234 ​ 141 ​ 261 ​ — 1,636 Non-current assets 3,689 ​ 2,185 ​ 3,971 ​ — 9,845 Goodwill 645 ​ 496 ​ 1,271 ​ — 2,412 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ HIFU ESWL DISTRIB Reconciling Total 2020 ​ Division ​ Division ​ Division ​ Items ​ consolidated Sales of goods 6,000 6,248 15,274 — 27,523 Sales of RPPs & leases 3,594 927 224 — 4,745 Sales of spare parts and services 1,831 5,707 1,844 — 9,382 Total sales 11,425 12,882 17,342 — 41,649 External other revenues 12 — — — 12 Total revenues 11,438 12,882 17,342 — 41,662 Total COS (5,144) (7,232) (10,906) — (23,283) Gross profit 6,293 5,649 6,436 — 18,379 R&D expenses (2,583) (1,555) (358) — (4,496) Selling and marketing expenses (3,151) (2,052) (4,076) 0 (9,279) G&A expenses (1,005) (964) (900) (1,465) (4,335) Total expenses (6,738) (4,572) (5,335) (1,465) (18,110) Operating income (loss) from operations (445) 1,078 1,102 (1,465) 269 Total Assets 16,279 15,567 20,795 2,551 55,193 Capital expenditures 1,144 309 557 — 2,010 Non-current assets 3,706 2,466 3,628 — 9,801 Goodwill 645 496 1,271 — 2,412 ​

VALUATION ACCOUNTS

VALUATION ACCOUNTS	12 Months Ended
	Dec. 31, 2022
VALUATION ACCOUNTS
VALUATION ACCOUNTS	​ 30— VALUATION ACCOUNTS ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Allowance Allowance ​ ​ ​ ​ for deferred ​ for doubtful ​ Slow-moving ​ Warranty ​ ​ tax assets ​ accounts ​ inventory ​ reserve Balance as of December 31, 2019 14,977 ​ 1,489 ​ 1,084 ​ 371 Charges to costs and expenses 596 ​ 90 ​ 651 ​ 266 Deductions: write-off and others (65) ​ (858) ​ (172) ​ (268) Balance as of December 31, 2020 15,508 ​ 721 ​ 1,563 ​ 369 Charges to costs and expenses 346 ​ 2 ​ 371 ​ 110 Deductions: write-off and others (1,513) ​ 19 ​ (464) ​ (227) Balance as of December 31, 2021 14,341 ​ 742 ​ 1,470 ​ 252 Charges to costs and expenses 1,538 ​ 32 ​ 93 ​ 112 Deductions: write-off and others (1,135) ​ (613) ​ (300) ​ (202) Balance as of December 31, 2022 14,744 ​ 161 ​ 1,262 ​ 162 ​

SUPPLEMENTAL DISCLOSURES OF CAS

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION	12 Months Ended
	Dec. 31, 2022
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION	​ 31— SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION Interest and income taxes paid are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 2020 Income taxes paid (refunds received) 410 307 377 Interest paid 168 114 124 Interest received 403 10 10 ​ Non-cash transactions: ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 2020 Financing lease obligations incurred 162 233 192 Operating lease obligations incurred 1,162 674 317 ​ ​ Cash paid for amounts included in the measurement of lease liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 2020 Operating cash flow used in operating leases 900 916 ​ 941 Operating cash flow used in finance leases 12 18 ​ 18 Financing cash flow used in finance leases 350 406 ​ 321 ​

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2022
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS	32— RELATED PARTY TRANSACTIONS On August 19, 2019, EDAP Technomed Co. Ltd. (Japan) contracted a loan amounting to JPY 80,000,000. As a current practice in Japan, this loan required a personal warranty from the representative director, president and CEO of the subsidiary Mr. Jean-François Bachelard. EDAP TMS S.A., as the parent company, counter-warranted this personal loan and agreed to indemnify Mr. Bachelard, in an indemnification letter dated September 12, 2019 expiring upon loan maturity date of August 26, 2026. On April 22, 2020, EDAP Technomed Co. Ltd (Japan) contracted another loan amounting to JPY 50,000,000 requiring a personal warranty from the representative director, president and CEO of the subsidiary Mr. Jean-François Bachelard. EDAP TMS S.A., as the parent company, counter-warranted this personal loan and agreed to indemnify Mr. Bachelard, in an indemnification letter dated June 2, 2020, expiring upon loan maturity date of April 2, 2025. On April 27, 2021, EDAP Technomed Sdn Bdh (Malaysia) contracted with Maybank to issue a Performance Guarantee amounting to MYR 8,000.00, expiring on June 30, 2023. As a current practice in Malaysia, any bank guarantee requires a personal warranty from the representative director, president and CEO of the subsidiary Mr. Hervé de Soultrait. Consequently, Mr. de Soultrait personally counter-guaranteed this Performance Guarantee by making a fixed deposit of MYR 8,000.00 to Maybank, valid until June 30, 2023. ​

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2022
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS	33— SUBSEQUENT EVENTS In line with EDAP’s global group strategy, and its focus on expansion in the United States and rest of world markets, and upon recommendation of the Compensation Committee and the Nomination Committee, on March 29, 2023, the Board of Directors unanimously decided to appoint Ryan Rhodes as the new Chief Executive Officer of the Company for an indefinite term, which will become effective on May 1, 2023. Marc Oczachowski will continue to serve as Chairman of the Board of the Company. In this context, the Board decided to accelerate the vesting of all unvested options granted to Mr. Oczachowski under the 2019 option plans such that these options fully vested and became exercisable on March 29, 2023, and, with respect to the previously granted free shares and as permitted under the plans, waived certain conditions to vesting. The Company is currently evaluating the costs associated with the severance package and the acceleration of vesting of share-based plans, which will be recorded in financial year 2023. ​ ​ .

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2022
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Nature of operations	1-1 Nature of operations EDAP TMS S.A. and its subsidiaries (‘‘the Company’’) are engaged in the development, production, marketing, distribution and maintenance of a portfolio of minimally-invasive medical devices for the treatment of urological diseases. The Company currently produces innovative robotic devices for treating stones of the urinary tract and localized prostate cancer. We also derive revenues from the distribution of urodynamics products and urology lasers. Net sales consist primarily of direct sales to hospitals and clinics in France and Europe, export sales to third-party distributors and agents, and export sales through subsidiaries based in Germany, Italy, the United States and Asia. The Company purchases the majority of the components used in its products from a number of suppliers but for some components, relies on a single source. Delay would be caused if the supply of these components or other components was interrupted and these delays could be extended in certain situations where a component substitution may require regulatory approval. Failure to obtain adequate supplies of these components in a timely manner could have a material adverse effect on the Company’s business, financial position and results of operations.
Basis of preparation	1-2 Basis of preparation These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP).
Management estimates	1-3 Management estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles (‘‘U.S. GAAP’’) requires management to make estimates and assumptions, such as business plans, stock price volatility, duration of standard warranty per market, duration and interest rate of operating leases, price of maintenance contracts used to determine the amount of revenue to be deferred and life duration of our range of products. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.
Consolidation	1-4 Consolidation The accompanying consolidated financial statements include the accounts of EDAP TMS S.A. and all its domestic and foreign owned subsidiaries after elimination of intercompany balances and transactions. We do not have any significant interests in any variable interest entities.
Revenue recognition	1-5 Revenue recognition The Company’s revenue consists of: - Sales of goods (devices and consumables), where invoicing generally takes place upon delivery. Consumables revenues included in sales contracts are deferred until delivery. - Revenue-per-Procedures (“RPP”) and leases: they comprise (i) revenues on a per treatment basis which are invoiced after each treatment, or in advance, or on a periodic basis, (ii) leases of devices, which are generally invoiced on a monthly or quarterly basis, and (iii) immaterial lease components arising from multiple-element arrangements, where specific sales terms are negotiated in accordance with each customer’s individual requirements and which are generally invoiced based on contract terms, - Sales of spare parts and services (maintenance, upgrades, mobility and others). Spare parts are invoiced when delivered. Regarding services, invoicing is performed either on a subscription basis (in advance or at the end of the period) or when performed. Sales of our medical devices and sales of disposables, sales of RPPs and leases, and sales of spare parts and services, are all net of commissions. The Company invoices its customers based on the billing schedules in its sales arrangements. Payments are generally due between one to three months from date of invoice. The Company accounts for a contract with a customer when there is a legally enforceable contract between the Company and its customer, the rights of the goods or services and their payment terms can be identified, the contract has commercial substance, collectability of the contract consideration is probable, it is approved and the parties are committed to their obligations. Our sale arrangements may contain multiple elements, including device(s), consumables and services. For these multiple-element arrangements, the Company accounts for individual goods and services as separate performance obligations: (i) if a customer can benefit from the good or service on its own or with other resources that are readily available to the customer, and (ii) if they are a distinct good or service that is separately identifiable from other items in the multiple-element arrangement. The Company’s sale arrangements may include a combination of the following performance obligations: device(s), consumables, leases and services (such as, but not limited to, warranty extension). For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the goods or services. If a standalone selling price is not directly observable, then the Company estimates the standalone selling price considering market conditions and entity-specific factors including, but not limited to, features and functionality of the goods and services, geographies, and type of customer. The Company regularly reviews standalone selling prices and updates these estimates as necessary. The Company recognizes revenue when the performance obligations are satisfied by transferring control over the goods or service to a customer. The Company’s revenue consists of the following: Sales of goods: Sales of goods are and have historically been comprised of sales net of commission of medical devices (ESWL lithotripters and HIFU devices) and net sales of disposables (mostly Focalpaks and Ablapaks in the HIFU division and electrodes in the ESWL division). Sales of goods also includes products such as micro-ultrasound devices, urology lasers and urodynamics devices distributed through our agents and third-party distributors. For devices and disposables, revenue is recognized when the Company transfers control to the customer (i.e. when the customer has the ability to direct the use of, and obtain substantially all of the remaining benefit from, the device or disposables), which is generally at the point of delivery or installation, depending on the terms of the arrangement (i.e. when the customer can use the goods to provide services or sell or exchange the good), and based on contractual incoterms. Such installation-related costs are immaterial in the context of the contract with the customer and do not constitute a distinct performance obligation. The Company’s sales arrangements do not provide a right of return. The goods are generally covered by a period of one Sales of RPPs and leases: Sales of RPP and leases include the revenues from the sale of treatment procedures and from the leasing of machines. For RPP, we provide machines to clinics and hospitals for free for a limited period, rather than selling the devices. These hospitals and clinics perform treatments using the devices and usually pay us based on the number of individual treatments provided. Revenues from leasing of machine are considered as immaterial. Revenues related to the sale of treatments invoiced on a ‘‘Revenue-Per-Procedure’’ (‘‘RPP’’) basis are recognized when the treatment procedure has been completed. Revenues from devices leased to customers under operating leases are recognized on a straight-line basis. Regarding multiple-element arrangements with a lease component, a portion of the contract is allocated to the lease component on the basis of observable market prices applied by the Company for similar devices under operating leases. The lease component is recognized on a straight line basis over the contractual period. Other immaterial components under the contract are recognized in accordance with their nature. Sales of spare parts and services: Revenues related to spare parts are recognized when spare parts are delivered to distributors who perform their own maintenance services. Spare parts used in the performance of EDAP’s own maintenance and repair services are generally not recognized separately, unless a type of spare part is specifically excluded from the maintenance contract terms. Revenues related to Services mainly consist of maintenance contracts which rarely exceed one year and are recognized on a straight line basis over the term of the service period as the customer benefits from the service equally throughout the service contract period. For services rendered when no maintenance contract is in place or for services not included in the scope of a maintenance contract, revenues are recorded when services are performed. The Company recognizes revenue for extended warranties included in the multiple-element arrangements as a separate performance obligation in Sales of services on a straight-line basis over the extended warranty period. In the majority of countries in which the Company operates, the statutory warranty period is one to two years and the extended warranty covers periods beyond this statutory period. Standard warranties do not constitute a separate performance obligation. The Company accrues for the warranty costs at the time of sale of the device through the multiple-element arrangement. Distributors: As part of its sale process in countries other than continental France, when the Company does not have a local subsidiary, sales of goods to end-customers are performed through agents and distributors. Such agents and distributors are primarily responsible for the sales’ process, bear the inventory risk, and are free to determine the sale prices. Sales of goods to agents and distributors are recognized when the control is transferred to the related agent or distributor which generally occurs based on contractual incoterms. Deferred revenue: Deferred revenue for the periods presented primarily relates to service contracts where the service fees are billed up-front, generally quarterly or annually, prior to those services having been performed, and consists primarily of billing or cash receipts in advance of services due under maintenance contracts or extended warranty contracts. The associated deferred revenue is generally recognized ratably over the service period. Disaggregation of revenue: Disaggregation by primary geographical market, and timing of revenue recognition is reported in Note 18. Contract Balances: Details on contract liabilities are reported on Note 11. The Company applies the practical expedient in paragraph 606-10-50-14 and does not disclose information about remaining performance obligations that have original expected durations of one year or less. This relates mainly to maintenance services.
Costs of sales	1-6 Costs of sales Costs of sales include all direct product costs, costs related to shipping, handling, duties and importation fees, as well as certain indirect costs such as service and supply chain departments expenses. Indirect costs are allocated by type of sales (goods, RPP and leases, spare parts and services) using an allocation method determined by management by type of costs and segment activities and reviewed on an annual basis.
Shipping and handling costs	1-7 Shipping and handling costs Shipping and handling costs are not considered as performance obligations. Shipping and handling costs are recorded as a component of cost of sales.
Cash equivalents and short term investments	1-8 Cash equivalents and short term investments Cash equivalents are cash investments which are highly liquid and have initial maturities of 90 days or less. Cash investments with a maturity higher than 90 days are considered as short-term investments. There is no short-term investment at December 31, 2022.
Accounts Receivable	1-9 Accounts Receivable The Company maintains an allowance for doubtful accounts for estimated losses inherent in its accounts receivable portfolio. In establishing the required allowance, management considers historical losses adjusted to take into account current market conditions and the Company’s customers’ financial condition, the amount of receivables in dispute, and the current receivables aging and current payment patterns. The Company reviews its allowance for doubtful accounts quarterly. Past due balances over 90 days and over a specified amount are reviewed individually for collectability. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. Write-offs for 2022 and 2021 approximated €640 thousand and €0 thousand, respectively. The Company does not have any off-balance-sheet credit exposure related to its customers.
Inventories	1-10 Inventories Inventories are valued at the lower of cost and net realizable value. Cost is either the manufacturing cost, which is principally comprised of components and labor costs for our own manufactured products, or purchase price for urology products we distribute. Cost is determined on a first-in, first-out basis for components and spare parts and by specific identification for finished goods (medical devices). The Company establishes reserves for inventory estimated to be obsolete, unmarketable or slow moving, first based on a detailed comparison between quantity in inventory and historical consumption and then based on case-by-case analysis of the difference between the cost of inventory and the related estimated market value.
Property and equipment	1-11 Property and equipment Property and equipment is stated at historical cost, net of accumulated depreciation and impairment. Depreciation of property and equipment is calculated using the straight-line method over the estimated useful life of the related assets, as follows: ​ ​ ​ ​ ​ ​ ​ ​ Leasehold improvements (in years) ​ ​ 10 or lease term if shorter ​ ​ Equipment (in years) 3 — 10 Furniture, fixtures, fittings and other (in years) 2 ​ — 10 ​ Equipment includes industrial equipment and research equipment that has alternative future uses. Equipment also includes devices that are manufactured by the Company and leased to customers through operating leases related to Revenue-Per-Procedure transactions and devices subject to sale and leaseback transactions. This equipment is depreciated over a period of seven years.
Long-lived assets	1-12 Long-lived assets The Company reviews the carrying value of its long-lived assets, including fixed assets and intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be fully recoverable. Recoverability of long-lived assets is assessed by a comparison of the carrying amount of the assets (or the Group of assets, including the asset in question, that represents the lowest level of separately-identifiable cash flows) to the total estimated undiscounted cash flows expected to be generated by the asset or group of assets. If the future net undiscounted cash flows is less than the carrying amount of the asset or group of assets, the asset or group of assets is considered impaired and an expense is recognized equal to the amount required to reduce the carrying amount of the asset or group of assets to its then fair value. Fair value is determined by discounting the cash flows expected to be generated by the assets, when the quoted market prices are not available for the long-lived assets. Estimated future cash flows are based on assumptions and are subject to risk and uncertainty.
Goodwill and intangible assets	1-13 Goodwill and intangible assets Goodwill represents the excess of purchase price over the fair value of identifiable net assets of businesses acquired. Goodwill is not amortized but instead tested annually for impairment or more frequently when events or change in circumstances indicate that the assets might be impaired. When impairment indicators are identified, the impairment test is performed by comparing the fair value of a reporting unit with its carrying amount, including goodwill. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. For the purpose of any impairment test, the Company relies upon projections of future undiscounted cash flows and takes into account assumptions regarding the evolution of the market and its ability to successfully develop and commercialize its products. Changes in market conditions could have a major impact on the valuation of these assets and could result in additional impairment losses. Intangible assets consist primarily of purchased patents relating to lithotripters, purchased licenses, a purchased trade name and a purchased trademark. The basis for valuation of these assets is their historical acquisition cost. Amortization of intangible assets is calculated by the straight-line method over the shorter of the contractual or estimated useful life of the assets, as follows: ​ ​ ​ ​ Patents (in years) 5 SAP Licenses (in years) 10 Other licenses (in years) 5 Trade name and trademark (in years) 7 ​
Treasury Stocks	1-14 Treasury Stocks Treasury stock purchases are accounted for at cost. The sale of treasury stocks is accounted for using the first in first out method. Gains on the sale or retirement of treasury stocks are accounted for as additional paid-in capital whereas losses on the sale or retirement of treasury stock are recorded as additional paid-in capital to the extent that previous net gains from sale or retirement of treasury stocks are included therein; otherwise the losses shall be recorded to accumulated benefit (deficit) account. Gains or losses from the sale or retirement of treasury stock do not affect reported results of operations. Treasury stocks held by a Company cannot exceed 10% of the total number of shares issued.
Warranty expenses	1-15 Warranty expenses The Company provides customers with a warranty for each product sold and accrues warranty expense at time of sale based upon historical claims experience. Standard warranty period may vary from 1 year to 2 years depending on the market. The warranty expense is incurred at time of accrual and not when paid. Warranty expense amounted to €112 thousand, €110 thousand and €266 thousand for the years ended December 31, 2022, 2021 and 2020, respectively.
Income taxes	1-16 Income taxes The Company accounts for income taxes in accordance with ASC 740, ‘‘Accounting for Income Taxes’’ Under ASC 740, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured by applying enacted tax rates and laws to taxable years in which such differences are expected to reverse. A valuation allowance is established if, based on the weight of available evidence, it is more likely than not that some portion, or all of the deferred tax assets, will not be realized. In accordance with ASC740, no provision has been made for income or withholding taxes on undistributed earnings of foreign subsidiaries, such undistributed earnings being permanently reinvested. Under ASC740, the measurement of a tax position that meets the more-likely-that-not recognition threshold must take into consideration the amounts and probabilities of the outcomes that could be realized upon ultimate settlement using the facts, circumstances and information available at the reporting date.
Research and development costs	1-17 Research and development costs Research and development costs are recorded as an expense in the period in which they are incurred. The French government provides tax credits to companies for innovative research and development. This tax credit is calculated based on a percentage of eligible research and development costs and it can be refundable in cash and is not contingent on future taxable income. As such, the Company considers the research tax credits as a grant, offsetting research and development expenses.
Advertising costs	1-18 Advertising costs Advertising costs are recorded as an expense in the period in which they are incurred and are included in selling and administrative expenses in the accompanying consolidated statements of income (loss). Advertising costs amounted to €929 thousand, €490 thousand and €291 thousand for the years ended December 31, 2022, 2021 and 2020, respectively.
Foreign currency translation and transactions	1-19 Foreign currency translation and transactions Translation of the financial statements of consolidated companies The reporting currency of EDAP TMS S.A. for all years presented is the euro (€). The functional currency of each subsidiary is its local currency. In accordance with ASC 830, all accounts in the financial statements are translated into euro from the functional currency at the following exchange rates: ● assets and liabilities are translated at year-end exchange rates; ● shareholders’ equity is translated at historical exchange rates (as of the date of contribution); ● statement of income (loss) items are translated at average exchange rates for the year; and ● translation gains and losses are recorded in a separate component of shareholders’ equity. Foreign currencies transactions Transactions involving foreign currencies are translated into the functional currency using the exchange rate prevailing at the time of the transactions. Receivables and payables denominated in foreign currencies are translated at year-end exchange rates. The resulting unrealized exchange gains and losses are recorded in the statement of income (loss). Presentation in the Statement of Income (loss) Aggregate foreign currency transactions gains and losses are disclosed in a single caption in the Statement of Income (loss) under section “Foreign currency exchange gain (loss), net”.
Earnings per share	1-20 Earnings per share Basic earnings per share is computed by dividing income available to common shareholders by the weighted average number of shares of common stock outstanding for the period. Diluted earnings per share reflects potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the Company. The dilutive effects of the Company’s common stock options and warrants is determined using the treasury stock method to measure the number of shares that are assumed to have been repurchased using the average market price during the period, which is converted from U.S. dollars at the average exchange rate for the period.
Derivative instruments	1-21 Derivative instruments ASC 815 requires the Company to recognize all of its derivative instruments as either assets or liabilities in the statement of financial position at fair value. The accounting for changes in the fair value (i.e., gains or losses) of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and further, on the type of hedging relationship. For those derivative instruments that are designated and qualify as hedging instruments, the Company must classify the hedging instrument, based upon the exposure being hedged, as fair value hedge, cash flow hedge or a hedge of a net investment in a foreign operation. Gains and losses from derivative instruments are recorded in the Statement of Income (loss). As of December 31, 2022, there are no derivative instruments.
Employee stock option and free shares plan	1-22 Employee stock option and free shares plan The accounting for stock-based awards is based on the fair value of the award measured at the grant date. Accordingly, stock-based compensation cost is recognized in the consolidated statements of income (loss) and comprehensive income (loss) as an operating expense over the requisite service period. The fair value of stock options is determined using the Black-Scholes option- pricing model. The Company determines the fair value of stock option awards on the date of grant using assumptions regarding expected term, share price volatility over the expected term of the awards, risk-free interest rate, and dividend rate. The fair value of free shares is measured using the fair value of the Company's shares as if the free shares were vested and issued on the grant date. Forfeited stock-options and free shares are recognized as they occur, in accordance with ASU 2016-09. The Company recognizes compensation cost for employee awards with only service conditions that have a graded vesting schedule on a straight-line basis over the requisite service period for each separately vesting portion of the award as if the award was, in-substance, multiple awards. At December 31, 2022, the Company had four stock-based employee compensation plans and two free shares plans.
Warrants	1-23 Warrants There are no warrants outstanding at December 31, 2022.
Leases	1-24 Leases Leases as a Lessee In accordance with ASC 842, Leases, and as from January 1, 2019, the Company classifies all leases at the inception of a contract and assess whether the contract is, or contains, a lease. The assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the company controls the use of the identified asset (e.g. whether the company has the right to obtain substantially all of the economic benefits from the use of the asset throughout the period, and whether the company has the right to direct the use of the asset). Leases are classified as either finance leases or operating leases. Substantially all our operating leases are comprised of office space leases, and substantially all our finance leases are comprised of office furniture and technology equipment. The Company recognizes a right-of-use (“ROU”) asset and a lease liability at the lease commencement date. The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial direct costs incurred, plus prepaid lease payments, less any lease incentives received. All ROU assets are reviewed for impairment. For operating leases, the lease liability is initially measured at the present value of the unpaid lease payments at lease commencement date, discounted using the incremental borrowing rate for assets of same duration or characteristics. For finance leases the lease liability is initially measured in the same manner and date as for operating leases and is subsequently measured at amortized cost using the effective interest method For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term. For finance leases, the ROU asset is subsequently amortized using the straight-line method from the lease commencement date to the earlier of the end of its useful life or the end of the lease term unless the lease transfers ownership of the underlying asset to the Company or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the ROU asset is amortized over the useful life of the underlying asset. Amortization of the ROU asset is recognized and presented separately from interest expense on the lease liability. Lease payments included in the measurement of the lease liability comprise the following: the fixed payments, including in-substance fixed payments over the lease term (which includes termination penalties the Company would owe if the lease term assumes the Company’s exercise of a termination option), variable lease payments that depend on an index or rate payments for optional renewal periods where it is reasonably certain the renewal period will be exercised, the exercise price of an option to purchase the underlying asset if the company is reasonably certain to exercise the option, and amounts expected to be payable under a Company provided residual value guarantee. The company assesses the discount rate by requesting credit simulation from certain banks. Variable lease payments associated with the Company’s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented as operating expenses in the Company’s consolidated statements of income (loss) in the same line item as expenses arising from fixed lease payments (operating leases) or amortization of the ROU asset (finance leases). Our real estate leases generally include non-lease maintenance services. The consideration in the contract is allocated to the lease and non-lease components based on standalone selling prices. Some of our real estate leases contain variable lease payments, including payments based on an index or rate. Variable lease payments based on an index or rate are initially measured using the index or rate in effect at lease commencement, and changes to index and rate-based variable lease payments are recognized in profit or loss in the period of the change. Variable payments that do not depend on an index or rate, such as rental payments based on the use of the underlying asset or property taxes and insurance reimbursement, are recorded as operating expenses when incurred. Lease modifications result in remeasurement of the lease payments when that modification is not accounted for as a separate contract. Lease expense for operating leases consists of the lease payments plus any initial direct costs, primarily brokerage commissions, and is recognized on a straight-line basis over the lease term. Included in lease expense are any variable lease payments incurred in the period that were not included in the initial lease liability. Lease expense for finance leases consists of the amortization of the right-of-use asset on a straight-line basis over the lease term and interest expense determined on an amortized cost basis. The lease payments are allocated between a reduction of the lease liability and interest expense. The lease term for all of the Company’s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor . We have elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a term of 12 months or less. The effect of short-term leases on our right-of-use asset and lease liability was not material. We have elected not to review the classification for expired or existing leases, prior to January 1, 2019. Leases as a Lessor: A lessor shall classify a lease as a sales-type lease when the lease meets any of the following criteria at lease commencement: ● The lease transfers ownership of the underlying asset to the lessee by the end of the lease term. ● The lease grants the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise. ● The lease term is for the major part of the remaining economic life of the underlying asset. However, if the commencement date falls at or near the end of the economic life of the underlying asset, this criterion shall not be used for purposes of classifying the lease. ● The present value of the sum of the lease payments and any residual value guaranteed by the lessee that is not already reflected in the lease payments in accordance with paragraph 842-10-30-5(f) equals or exceeds substantially all of the fair value of the underlying asset. ● The underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term. When none of the criteria are met: A lessor shall classify the lease as either a direct financing lease or an operating lease. A lessor shall classify the lease as an operating lease unless both of the following criteria are met, in which case the lessor shall classify the lease as a direct financing lease: ● The present value of the sum of the lease payments and any residual value guaranteed by the lessee that is not already reflected in the lease payments in accordance with paragraph 842-10-30-5(f) and/or any other third party unrelated to the lessor equals or exceeds substantially all of the fair value of the underlying asset; ● It is probable that the lessor will collect the lease payments plus any amount necessary to satisfy a residual value guarantee.
Recent accounting pronouncements	1-25 Recent accounting pronouncements Recently Adopted Accounting Pronouncements Effective January 1, 2022, the Company adopted ASU 2021-05 (Lessors—Certain leases with variable lease payments) which requires lessors to classify as operating leases those leases with variable lease payments that do not depend on an index or rate if another classification (i.e. sales-type or direct financing) would result in a commencement date (‘day 1’) selling loss. The adoption of ASU 2021-05 did not have a material impact on the Company’s financial position or results of operations. None of the recent accounting pronouncements not yet adopted by the Company are expected to have a material impact on the Company’s financial statements.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2022
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Schedule of depreciation of property and equipment is estimated useful life of the related assets	​ ​ ​ ​ ​ ​ ​ ​ Leasehold improvements (in years) ​ ​ 10 or lease term if shorter ​ ​ Equipment (in years) 3 — 10 Furniture, fixtures, fittings and other (in years) 2 ​ — 10 ​
Schedule of amortization of intangible assets is contractual or estimated useful life of the assets	​ ​ ​ ​ Patents (in years) 5 SAP Licenses (in years) 10 Other licenses (in years) 5 Trade name and trademark (in years) 7 ​

CASH EQUIVALENTS (Tables)

CASH EQUIVALENTS (Tables)	12 Months Ended
	Dec. 31, 2022
CASH EQUIVALENTS
Schedule of Cash and Cash Equivalents [Table Text Block]	​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Total cash and cash equivalents 63,136 47,183 Short term investment ​ — ​ — Total cash and cash equivalents 63,136 47,183

TRADE ACCOUNTS AND NOTES RECE_2

TRADE ACCOUNTS AND NOTES RECEIVABLE, NET (Tables)	12 Months Ended
	Dec. 31, 2022
TRADE ACCOUNTS AND NOTES RECEIVABLE, NET
Schedule of trade accounts and notes receivable	​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Trade accounts receivable 12,965 10,992 Notes receivable 617 615 Less: allowance for doubtful accounts (161) (742) Total 13,421 10,864 Less current portion (13,421) (10,864) Total long-term portion — — ​

OTHER RECEIVABLES (Tables)

OTHER RECEIVABLES (Tables)	12 Months Ended
	Dec. 31, 2022
OTHER RECEIVABLES.
Schedule of other receivables	​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Research and development tax credit receivable from the French State ​ 581 617 Value-added taxes receivable ​ 894 574 Other receivables from Government and public authorities ​ — — Others ​ 46 64 Total ​ 1,522 1,255

INVENTORIES (Tables)

INVENTORIES (Tables)	12 Months Ended
	Dec. 31, 2022
INVENTORIES.
Schedule of Inventory, Current	​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Components, spare parts ​ 7,543 4,955 Work-in-progress ​ 283 250 Finished goods – own manufactured products ​ 1,514 1,166 Finished goods – distribution products ​ 3,702 2,598 Total gross inventories ​ 13,042 8,968 Less: allowance for slow-moving inventory and net realizable value ​ (1,262) (1,470) Total ​ 11,780 7,499 ​

OTHER ASSETS (Tables)

OTHER ASSETS (Tables)	12 Months Ended
	Dec. 31, 2022
OTHER ASSETS
Schedule of other assets	​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Prepaid expenses, current portion ​ 660 581 Total ​ 660 581

PROPERTY AND EQUIPMENT, NET (Ta

PROPERTY AND EQUIPMENT, NET (Tables)	12 Months Ended
	Dec. 31, 2022
PROPERTY AND EQUIPMENT, NET
Schedule of Property and equipment	​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Equipment ​ 9,553 ​ 8,894 Furniture, fixture, and fittings and other 3,108 2,678 Total gross value 12,661 11,572 Less: accumulated depreciation and amortization (8,916) (8,594) Total 3,745 2,978 ​
Schedule of Finance lease right-of-use assets	​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Facilities ​ 269 ​ 290 Equipment 220 220 Vehicles and IT equipment 780 1,497 Total gross value 1,269 2,007 Less: accumulated depreciation and amortization 813 1,368 Total 455 639 ​

OPERATING LEASE RIGHT-OF-USE _2

OPERATING LEASE RIGHT-OF-USE ASSETS (Tables)	12 Months Ended
	Dec. 31, 2022
OPERATING LEASE RIGHT-OF-USE ASSETS.
Schedule of Operating lease right-of-use assets	​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Facilities 1,536 1,290 Equipment 57 158 Furniture, fixture, and fittings and other 191 107 Total net operating lease right of use 1,784 1,555 ​

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS (Tables)	12 Months Ended
	Dec. 31, 2022
GOODWILL AND INTANGIBLE ASSETS
Schedule of Intangible assets	​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Licenses 1,585 1,448 Trade name and trademark 370 400 Patents 412 412 Organization costs 225 225 Total gross value 2,592 2,484 Accumulated amortization for licenses (863) (723) Accumulated amortization for trade name and trademark (368) (397) Accumulated amortization for patents (412) (412) Accumulated amortization for organization costs (225) (225) Less: Total accumulated amortization (1,868) (1,756) Total 725 728 ​
Schedule of Intangible assets, annual estimated amortization expense	​ ​ ​ ​ ​ December 31, ​ 2022 2023 143 2024 135 2025 125 2026 122 2027 107 2028 and thereafter ​ 76 Total 706

TRADE ACCOUNTS AND NOTES PAYA_2

TRADE ACCOUNTS AND NOTES PAYABLE (Tables)	12 Months Ended
	Dec. 31, 2022
TRADE ACCOUNTS AND NOTES PAYABLE
Schedule of trade accounts and notes payable	​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Trade accounts payable 6,640 5,511 Notes payable 7 1 Total 6,647 5,512 ​

DEFERRED REVENUES (Tables)

DEFERRED REVENUES (Tables)	12 Months Ended
	Dec. 31, 2022
DEFERRED REVENUES
Schedule of Deferred revenues	​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Deferred revenues on maintenance contracts ​ 1,803 ​ 1,624 Deferred revenue on RPP ​ 517 ​ 315 Deferred revenue on sale of devices ​ 83 ​ 114 Deferred revenue on extension of warranty, included in sales contracts ​ 535 ​ 740 Deferred revenue on treatment probe lease and other ​ 1,376 ​ 1,055 Total ​ 4,314 ​ 3,848 Less long term portion ​ (264) ​ (440) Current portion ​ 4,050 ​ 3,408 ​
Schedule of Deferred revenue on extension of warranty	​ ​ ​ ​ ​ December 31, ​ 2022 2023 302 2024 145 2025 84 2026 5 2027 — 2028 and thereafter ​ — Total 535 ​
Changes in deferred revenue on extension of warranty	​ ​ ​ ​ ​ Total Balance as of December 31, 2020 782 New extension of warranty 256 Recognition of revenue (298) Balance as of December 31, 2021 740 New extension of warranty 162 Recognition of revenue (367) Balance as of December 31, 2022 535

OTHER ACCRUED LIABILITIES (Tabl

OTHER ACCRUED LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2022
OTHER ACCRUED LIABILITIES.
Schedule of other accrued liabilities	​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Retirement indemnities 2,153 2,382 Provision for warranty costs 162 252 Accruals for payroll and associated taxes 1,848 944 Conditional government advances 463 463 Value added tax payable 531 463 Advances received from customers 861 225 Provision for Asset Retirement Obligation (Japan) 101 109 Provision for employee termination indemnities (Korea) 122 97 Others 340 353 Total 6,583 5,289 Less non-current portion (2,710) (2,534) Current portion 3,873 2,755 ​
Schedule of Conditional advances	​ ​ ​ ​ 2023 18 2024 93 2025 93 2026 93 2027 86 2028 and thereafter ​ 81 Total 463 ​
Schedule of Changes in the provision for warranty costs	​ ​ ​ ​ ​ ​ ​ 2022 2021 Beginning of year 252 368 Amount used during the year (202) (225) New warranty expenses 112 110 End of year 162 252 Less current portion (100) (206) Long term portion 62 46

LEASE OBLIGATIONS (Tables)

LEASE OBLIGATIONS (Tables)	12 Months Ended
	Dec. 31, 2022
LEASE OBLIGATIONS
Schedule of Maturities of finance leases liabilities	​ ​ ​ ​ ​ December 31, ​ 2022 2023 234 2024 149 2025 102 2026 63 2027 12 2028 and thereafter ​ 6 Total undiscounted minimum lease payments 566 Less: amount representing interest (17) Present value of minimum lease payments 548 Less: current portion (224) Long-term portion 324 ​ ​ ​ ​ ​ December 31, ​ 2021 2022 358 2023 215 2024 124 2025 75 2026 46 2027 and thereafter ​ 7 Total undiscounted minimum lease payments 825 Less: amount representing interest (55) Present value of minimum lease payments 770 Less: current portion (340) Long-term portion 430 ​
Schedule of Maturities of operating leases liabilities	​ ​ ​ ​ ​ December 31, ​ 2022 2023 ​ 901 2024 636 2025 238 2026 24 2027 — 2028 and thereafter ​ — Total undiscounted minimum lease payments 1,799 Less: current portion (901) Long-term portion 899 ​ ​ ​ ​ ​ December 31, ​ 2021 2022 673 2023 523 2024 277 2025 69 2026 18 2027 and thereafter ​ 2 Total undiscounted minimum lease payments 1,562 Less: current portion ​ (673) Long-term portion ​ 888 ​

LONG TERM DEBT (Tables)

LONG TERM DEBT (Tables)	12 Months Ended
	Dec. 31, 2022
LONG TERM DEBT
Schedule of Long-term Debt	​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 France term loan 4,593 4,848 Japanese term loan 558 786 Germany term loan 28 111 USA term loan — — Korea term loan ​ 8 ​ 11 Malaysia term loan — 3 Total long term debt 5,188 5,759 Less current portion (1,601) (830) Total long-term portion 3,587 4,930 ​
Schedule of Long-term Debt Instruments	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP Technomed Co. Ltd 80,000,000 ​ August 2, 2026 1.98 % Monthly installment EDAP Technomed Co. Ltd 50,000,000 ​ April 2, 2025 1.8 % Monthly installment ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP TMS GMBH 400,000 ​ April 30, 2023 2.40 % Monthly installment ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Drown ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP TMS FRANCE 1,066,081 ​ July 1, 2025 0.99 % Monthly installment ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP TMS FRANCE 2,000,000 ​ July 30, 2026 0.73 % Monthly installment ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP TMS FRANCE 2,000,000 ​ August 4, 2026 0.73 % Monthly installment ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP TMS FRANCE 72,222 ​ July 5, 2024 0.45 % Monthly installment ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Drown ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP TMS FRANCE 780,457 ​ April 1, 2025 0.99 % Monthly installment ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP TMS FRANCE 2,000,000 ​ July 30, 2026 0.73 % Monthly installment ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP TMS FRANCE 2,000,000 ​ August 4, 2026 0.73 % Monthly installment ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP TMS FRANCE 72,222 ​ July 5, 2024 0.45 % Monthly instalment ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP TECHNOMED SDN BHD 90,000 ​ July 31, 2022 4.64 % Monthly installment ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP TECHNOMED INC 221,217 ​ May 14, 2022 1 % Monthly installment ​
Schedule of Long-term Debt and Financial Instrument Maturities	​ ​ ​ ​ 2023 1,601 2024 1,570 2025 1,335 2026 682 2027 — 2028 and thereafter ​ — Total 5,188

OTHER LONG-TERM LIABILITIES (Ta

OTHER LONG-TERM LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2022
OTHER LONG-TERM LIABILITIES.
Schedule of Other Long-term Liabilities	​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Provision for retirement indemnities (Japan & France), less current portion 1,962 2,281 Provision for employee termination indemnities (Korea) less current portion 122 97 Provision for Asset Retirement Obligation (Japan) less current portion 101 109 Provision for warranty costs, less current portion 62 46 Conditional government advances, less current portion 463 — Accrued interest less current portion — — Total 2,710 2,534 ​
Defined Benefit Plan, Assumptions	​ ​ ​ ​ ​ ​ ​ ​ Pension benefits France ​ ​ 2022 ​ 2021 Discount rate 3.80% ​ 1.05% ​ Salary increase 3.00% ​ 2.50% ​ Retirement age 65 65 ​ Average retirement remaining service period 24 24 ​ ​ ​ ​ ​ ​ ​ ​ ​ Pension benefits Japan ​ ​ 2022 ​ 2021 Discount rate 1.30% ​ 0.60% ​ Salary increase 2.50% ​ 2.50% ​ Retirement age 60 60 ​ Average retirement remaining service period 14 14 ​ ​
Schedule of Amounts Recognized in Balance Sheet	At December 31, 2022, the provision which represents the projected benefit obligation in accordance with ASC 718 consists of: ​ ​ ​ ​ ​ ​ ​ France Japan Non-current liabilities ​ 845 ​ 1,117 Current liabilities 89 102 Total projected benefit obligation 934 1,219 ​ At December 31, 2021, the provision which represents the projected benefit obligation in accordance with ASC 718 consists of: ​ ​ ​ ​ ​ ​ ​ France Japan Non-current liabilities ​ 1,080 ​ 1,200 Current liabilities — 102 Total projected benefit obligation 1,080 1,302 ​
Schedule of Defined Benefit Plans Disclosures	​ ​ ​ ​ ​ ​ ​ ​ France 2022 2021 2020 Change in benefit obligations: Projected Benefit obligations at beginning of year 1,080 1,111 969 Service cost 84 90 88 Interest cost 11 6 9 Net loss or (gain) — — — Actuarial (gain) or loss (241) (72) 46 Amortization of net prior service cost — — 1 Benefits paid — (56) — Projected Benefit obligations at end of year (1) 934 1,080 1,111 Unrecognized actuarial (gain) loss (2) (219) 22 94 Unrecognized prior service cost (2) 14 16 17 (1) The accumulated benefit obligation was €701 thousand and €780 thousand at December 31, 2022 and 2021 respectively. (2) The amount in accumulated other comprehensive income (loss) to be recognized as components of net periodic benefit costs in 2022 is 205 thousand. ​ ​ ​ ​ ​ ​ ​ ​ Japan 2022 2021 2020 Change in benefit obligations: Projected Benefit obligations at beginning of year 1,302 1,310 1,230 Service cost 112 120 123 Interest cost 7 7 7 Amortization of net loss — — 1 Actuarial (gain) / loss (30) — (1) Benefits paid (75) (97) (5) Exchange rate impact (95) (39) (44) Projected Benefit obligations at end of year (1) 1,219 1,302 1,310 Unrecognized actuarial (gain) loss (2) 86 126 130 Unrecognized prior service cost (2) — — — (1) The accumulated benefit obligation was €1,027 thousand and €1,123 thousand at December 31, 2022 and 2021, respectively. (2) The amount in accumulated other comprehensive income (loss) to be recognized as components of net periodic benefit costs in 2022 is €86 thousand.
Schedule of Expected Benefit Payments	​ ​ ​ ​ ​ ​ ​ France Japan 2023 91 103 2024 — 75 2025 — 156 2026 129 157 2027 85 72 2028-2032 408 682 ​ 713 1,246

SHAREHOLDERS' EQUITY (Tables)

SHAREHOLDERS' EQUITY (Tables)	12 Months Ended
	Dec. 31, 2022
SHAREHOLDERS' EQUITY.
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 2022 November 2022 May 2022 November 2021 June 2021 Weighted-average expected life (years) 5.79 5.79 5.79 5.79 5.79 Expected volatility rates (1) 45.41 % 45.38 % 44.96 % 45.08 % 46.34 Expected dividend yield 0 % 0 % 0 % 0 % 0 Risk-free interest rate 3.62 % 4.32 % 3.00 % 1.32 % 0.63 Weighted-average exercise price (€) 9.94 10.32 6.41 5.18 5.59 Weighted-average fair value of options granted during the year (€) 4.70 5.05 3.13 2.29 2.37 (1) Historical volatility calculated over the weighted-average expected life. ​ (2) There was no new plan for the year 2020. ​
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 2021 ​ 2020 ​ ​ Options Weighted ​ Options Weighted ​ Options Weighted ​ ​ ​ average ​ ​ average ​ ​ average ​ ​ ​ exercice ​ ​ exercice ​ ​ exercice ​ ​ price (€) ​ price (€) ​ price (€) Outstanding on January 1, 2,408,508 4.38 1,186,900 2.81 1,273,900 2.78 Granted 571,000 9.07 1,392,428 5.56 — — Exercised (320,622) 2.14 (150,820) 2.93 (23,750) 2.54 Forfeited (45,000) 5.34 (20,000) 4.01 (21,250) 2.55 Expired — — — — (42,000) 2 Outstanding on December 31, 2,613,886 5.66 2,408,508 4.38 1,186,900 2.81 Exercisable on December 31, 1,362,205 4.35 1,149,401 3.25 970,650 2.73 Share purchase options available for grant on December 31, 20,000 ​ 5,000 ​ 292,428 ​ As of December 31, 2022, 1,329,000 options to subscribe to new shares are available for future grants. ​
Share-based Payment Arrangement, Option, Exercise Price Range	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Outstanding options ​ Fully vested options (1) ​ ​ ​ ​ Weighted ​ Weighted ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ average ​ average ​ Aggregate ​ ​ ​ average ​ Aggregate ​ ​ ​ ​ remaining ​ exercise ​ Intrinsic ​ ​ ​ exercise ​ Intrinsic ​ ​ ​ ​ contractual ​ price ​ Value ​ ​ ​ price ​ Value Exercise price (€) Options life (€) (2) Options (€) (2) 10.32 ​ 32,000 ​ 9.8 ​ 10.32 ​ 330,240 ​ — ​ — ​ — 9.94 ​ 395,000 ​ 10.0 ​ 9.94 ​ 3,926,300 ​ — ​ — ​ — 6.41 ​ 124,000 ​ 9.3 ​ 6.41 ​ 794,840 ​ 24,111 ​ 6.41 ​ 154,552 5.59 ​ 1,266,806 ​ 8.4 ​ 5.59 ​ 7,081,446 ​ 633,403 ​ 5.59 ​ 3,540,723 5.18 ​ 100,000 ​ 8.8 ​ 5.18 ​ 518,000 ​ 36,111 ​ 5.18 ​ 187,055.56 3.90 107,500 6.8 3.90 419,250 80,000 ​ 3.90 ​ 312,000 3.22 365,000 3.3 3.22 1,175,300 365,000 ​ 3.22 ​ 1,175,300 2.65 87,500 5.7 2.65 231,875 87,500 ​ 2.65 ​ 231,875 2.39 136,080 4.3 2.39 325,231 136,080 ​ 2.39 ​ 325,231 2.39 to 10.32 2,613,886 7.4 5.66 14,802,482 1,362,205 4.35 5,926,737 (1) Fully vested options are all exercisable options. On March 29, 2023, the Board of Directors unanimously decided to appoint Ryan Rhodes as the new Chief Executive Officer of the Company, which will become effective on May 1, 2023. Marc Oczachowski will continue to serve as Chairman of the Board of the Company. In this context, the Board decided to accelerate the vesting of all unvested options granted to Mr. Oczachowski under the 2019 option plans such that these options fully vested and became exercisable on March 29, 2023. (Ref. Note 33. Subsequent Events.) (2) The aggregate intrinsic value represents the total pre-tax intrinsic value, based on the Company’s closing stock price of $10.66 at December 31, 2022, which would have been received by the option holders had all in-the-money option holders exercised their options as of that date.
Schedule of Nonvested Share Activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average ​ ​ ​ ​ Grant-Date Fair ​ Options Value (€) Non-vested at January 1, 2020 ​ 455,000 1.58 Granted ​ — — Vested ​ (235,000) 1.58 Forfeited ​ (3,750) 1.54 Non-vested at December 31, 2020 ​ 216,250 1.59 Granted ​ 1,392,428 2.37 Vested ​ (329,571) 2.06 Forfeited ​ (20,000) 1.89 Non-vested at December 31, 2021 ​ 1,259,107 2.32 Granted ​ 571,000 ​ 4.33 Vested (543,426) 2.32 Forfeited (35,000) 2.80 Non-vested at December 31, 2022 1,251,681 3.22 ​
Schedule of Accumulated Other Comprehensive Income (Loss)	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, 2022 ​ ​ Foreign currency ​ Provision for ​ ​ ​ ​ translation ​ retirement indemnities ​ ​ ​ ​ adjustment ​ (net of tax) ​ Total Beginning balance (3,377) (212) (3,589) Other comprehensive income (loss) before reclassifications — — — Reclassified from accumulated other comprehensive loss — — — Net current-period other comprehensive income (loss) (596) 355 (240) Ending balance (3,973) 144 (3,829) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, 2021 ​ ​ Foreign currency ​ Provision for ​ ​ ​ ​ translation ​ retirement indemnities ​ ​ ​ ​ adjustment ​ (net of tax) ​ Total Beginning balance (2,824) (241) (3,064) Other comprehensive income (loss) before reclassifications — — — Reclassified from accumulated other comprehensive loss — — — Net current-period other comprehensive income (loss) (554) 29 (525) Ending balance (3,377) (212) (3,589)

TOTAL SALES (Tables)

TOTAL SALES (Tables)	12 Months Ended
	Dec. 31, 2022
TOTAL SALES
Revenue from External Customers by Geographic Areas	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, Primary geographical markets (€) 2022 2021 2020 Asia 17,936 16,009 15,872 France 10,637 12,251 10,021 United States 15,036 5,524 5,611 Others geographical areas 11,500 10,276 10,146 Total Net Sales 55,108 44,060 41,649 ​
Disaggregation of Revenue	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, Timing of revenue recognition 2022 2021 2020 Products transferred at a point in time 44,173 34,552 32,862 Products and services transferred over time 10,935 9,508 8,787 Total Net Sales 55,108 44,060 41,649

OTHER REVENUES (Tables)

OTHER REVENUES (Tables)	12 Months Ended
	Dec. 31, 2022
OTHER REVENUES
Schedule of Other Revenues	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 2020 Licenses and others — 6 12 Total — 6 12 ​

COSTS OF SALES (Tables)

COSTS OF SALES (Tables)	12 Months Ended
	Dec. 31, 2022
COSTS OF SALES
Schedule of Costs of Sales	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 2020 Direct costs of sales (19,814) (16,199) (14,058) Indirect costs of sales (11,102) (9,443) (9,225) Total costs of sales (30,916) (25,643) (23,283)

RESEARCH AND DEVELOPMENT EXPE_2

RESEARCH AND DEVELOPMENT EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2022
RESEARCH AND DEVELOPMENT EXPENSES
Schedule of Research and Development Expenses	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 2020 Gross research and development expenses (5,751) (4,757) (5,173) Research Tax Credit 581 617 492 Grants 250 739 184 Net Research and development expenses (4,920) (3,402) (4,496) ​

FINANCIAL INCOME, NET (Tables)

FINANCIAL INCOME, NET (Tables)	12 Months Ended
	Dec. 31, 2022
FINANCIAL INCOME, NET
Schedule of Interest Income and Interest Expense	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 2020 Interest income ​ 404 ​ 10 ​ 10 Interest expense (168) (52) (108) Paycheck Protection Program loan forgiveness — 187 — Total 236 145 (98)

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2022
INCOME TAXES
Schedule of Income before Income Tax, Domestic and Foreign	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 2020 France ​ (418) ​ 869 ​ (2,042) Other countries (1,678) 24 854 Total (2,096) 893 (1,188) ​
Schedule of Components of Income Tax (Expense)/Benefit	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 2020 Current income tax expense: ​ ​ ​ France (485) (320) (158) Other countries (251) (436) (312) Sub-total current income tax expense (736) (756) (471) Deferred income tax (expense) benefit: France (8) 8 8 Other countries (93) 556 (53) Sub-total deferred income tax (expense) benefit (101) 563 (45) Total (837) (193) (516) ​
Schedule of Deferred Tax Assets and Liabilities	​ ​ ​ ​ ​ ​ ​ 2022 2021 Net operating loss carry forwards ​ 13,793 ​ 13,611 Elimination of intercompany profit in inventory 480 182 Elimination of intercompany profit in fixed assets 256 278 Provisions for retirement indemnities 658 642 Capital leases treated as operating leases for tax 26 40 Other items 360 487 Total deferred tax assets 15,573 15,239 Total deferred tax liabilities — — Net deferred tax assets 15,573 15,239 Valuation allowance for deferred tax assets (14,744) (14,341) Deferred tax assets (liabilities), net of allowance 829 898 ​
Schedule of Effective Income Tax Rate Reconciliation	​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 2021 2020 Theoretical income tax (expense) benefit at French statutory tax rate ​ 524 ​ (237) ​ 333 Income of foreign subsidiaries taxed at different tax rates (174) (95) 9 Effect of net operating loss carry-forwards and valuation allowances (1) (643) 626 (749) Non-taxable debt fair value variation — — — Permanent differences (99) (258) (159) Effect of cancellation of intra-group positions (366) (130) 152 French business tax included in income tax (CVAE) (99) (85) (156) Other (1) 20 (15) 55 Effective income tax (expense) benefit (837) (193) (516) (1) Certain immaterial amounts in prior years have been reclassified to conform to the current year presentation (deferred income taxes on certain temporary differences impacted by a full valuation allowance reclassified from “other” to “Effect of net operating loss carry-forwards and valuation allowances”).

EARNINGS (LOSS) PER SHARE (Tabl

EARNINGS (LOSS) PER SHARE (Tables)	12 Months Ended
	Dec. 31, 2022
EARNINGS (LOSS) PER SHARE
Schedule of Earnings Per Share, Basic and Diluted	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 2020 Income (loss) available to common shareholders (in Euros) ​ € (2,933,058) ​ € 699,890 ​ € (1,703,668) Weighted average number of shares for the computation of basic EPS ​ 34,392,598 ​ 32,129,047 ​ 29,148,108 Basic EPS (in Euros) ​ € (0.09) ​ € 0.02 ​ € (0.06) Effect of dilutive securities ​ 2,502,171 ​ 293,824 ​ 622,723 Weighted average number of shares for the computation of diluted EPS ​ 34,392,598 ​ 32,422,871 ​ 29,148,108 Diluted EPS income / (loss) (in Euros) ​ € (0.09) ​ € 0.02 ​ € (0.06) ​

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2022
SEGMENT INFORMATION
Schedule of Reconciliation of Operating Profit or Loss from Segments to Consolidated	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 2020 Segment operating income (loss) (4,257) (1,612) 269 Financial income (expense), net 236 145 (98) Foreign Currency exchange (losses) gains, net 1,925 2,360 (1,359) Income tax (expense) benefit (837) (193) (516) Consolidated net income (loss) (2,933) 700 (1,704) ​
Schedule of Segment Reporting Information, by Segment	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ HIFU ESWL DISTRIB Reconciling Total 2022 ​ Division ​ Division ​ Division ​ Items ​ consolidated Sales of goods 9,437 4,880 24,145 ​ — 38,462 Sales of RPPs & leases 4,287 1,058 272 ​ — 5,617 Sales of spare parts and services 1,909 5,630 3,491 ​ — 11,030 Total sales 15,634 11,568 27,907 ​ — 55,108 External other revenues — — — ​ — — Total revenues 15,634 11,568 27,907 ​ — 55,108 Total COS (6,788) (6,732) (17,396) ​ — (30,916) Gross profit 8,846 4,836 10,511 ​ — 24,193 R&D expenses (3,525) (950) (444) ​ — (4,920) Selling and marketing expenses (8,083) (1,887) (6,409) ​ — (16,379) G&A expenses (2,131) (1,077) (1,690) (2,254) (7,152) Total expenses (13,739) (3,914) (8,543) (2,254) (28,450) Operating income (loss) from operations (4,894) 922 1,968 (2,254) (4,257) Total Assets 16,293 ​ 12,997 ​ 26,407 ​ 45,426 101,123 Capital expenditures 1,715 ​ 307 ​ 356 ​ — 2,378 Non-current assets 4,269 ​ 2,149 ​ 4,187 ​ — 10,605 Goodwill 645 ​ 496 ​ 1,271 ​ — 2,412 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ HIFU ESWL DISTRIB Reconciling Total 2021 ​ Division ​ Division ​ Division ​ Items ​ consolidated Sales of goods 4,515 4,236 20,289 — 29,040 Sales of RPPs & leases 3,679 1,022 267 — 4,968 Sales of spare parts and services 1,715 5,758 2,578 — 10,052 Total sales 9,910 11,016 23,134 — 44,060 External other revenues 6 — — — 6 Total revenues 9,915 11,016 23,134 — 44,065 Total COS (5,311) (6,080) (14,252) — (25,643) Gross profit 4,604 4,936 8,882 — 18,422 R&D expenses (2,238) (835) (329) — (3,402) Selling and marketing expenses (3,910) (2,048) (4,774) — (10,732) G&A expenses (1,481) (1,161) (1,355) (1,904) (5,900) Total expenses (7,630) (4,043) (6,458) (1,904) (20,034) Operating income (loss) from operations (3,025) 893 2,424 (1,904) (1,612) Total Assets 13,597 ​ 13,596 ​ 25,344 ​ 24,690 77,226 Capital expenditures 1,234 ​ 141 ​ 261 ​ — 1,636 Non-current assets 3,689 ​ 2,185 ​ 3,971 ​ — 9,845 Goodwill 645 ​ 496 ​ 1,271 ​ — 2,412 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ HIFU ESWL DISTRIB Reconciling Total 2020 ​ Division ​ Division ​ Division ​ Items ​ consolidated Sales of goods 6,000 6,248 15,274 — 27,523 Sales of RPPs & leases 3,594 927 224 — 4,745 Sales of spare parts and services 1,831 5,707 1,844 — 9,382 Total sales 11,425 12,882 17,342 — 41,649 External other revenues 12 — — — 12 Total revenues 11,438 12,882 17,342 — 41,662 Total COS (5,144) (7,232) (10,906) — (23,283) Gross profit 6,293 5,649 6,436 — 18,379 R&D expenses (2,583) (1,555) (358) — (4,496) Selling and marketing expenses (3,151) (2,052) (4,076) 0 (9,279) G&A expenses (1,005) (964) (900) (1,465) (4,335) Total expenses (6,738) (4,572) (5,335) (1,465) (18,110) Operating income (loss) from operations (445) 1,078 1,102 (1,465) 269 Total Assets 16,279 15,567 20,795 2,551 55,193 Capital expenditures 1,144 309 557 — 2,010 Non-current assets 3,706 2,466 3,628 — 9,801 Goodwill 645 496 1,271 — 2,412

VALUATION ACCOUNTS (Tables)

VALUATION ACCOUNTS (Tables)	12 Months Ended
	Dec. 31, 2022
VALUATION ACCOUNTS
Schedule of valuation accounts	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Allowance Allowance ​ ​ ​ ​ for deferred ​ for doubtful ​ Slow-moving ​ Warranty ​ ​ tax assets ​ accounts ​ inventory ​ reserve Balance as of December 31, 2019 14,977 ​ 1,489 ​ 1,084 ​ 371 Charges to costs and expenses 596 ​ 90 ​ 651 ​ 266 Deductions: write-off and others (65) ​ (858) ​ (172) ​ (268) Balance as of December 31, 2020 15,508 ​ 721 ​ 1,563 ​ 369 Charges to costs and expenses 346 ​ 2 ​ 371 ​ 110 Deductions: write-off and others (1,513) ​ 19 ​ (464) ​ (227) Balance as of December 31, 2021 14,341 ​ 742 ​ 1,470 ​ 252 Charges to costs and expenses 1,538 ​ 32 ​ 93 ​ 112 Deductions: write-off and others (1,135) ​ (613) ​ (300) ​ (202) Balance as of December 31, 2022 14,744 ​ 161 ​ 1,262 ​ 162

SUPPLEMENTAL DISCLOSURES OF C_2

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2022
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Schedule of supplemental cash flow disclosures	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 2020 Income taxes paid (refunds received) 410 307 377 Interest paid 168 114 124 Interest received 403 10 10 ​ Non-cash transactions: ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 2020 Financing lease obligations incurred 162 233 192 Operating lease obligations incurred 1,162 674 317 ​ ​ Cash paid for amounts included in the measurement of lease liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 2020 Operating cash flow used in operating leases 900 916 ​ 941 Operating cash flow used in finance leases 12 18 ​ 18 Financing cash flow used in finance leases 350 406 ​ 321

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Short term investments	€ 0
Accounts Receivable, Allowance for Credit Loss, Writeoff	640	€ 0
Gain (loss) derivatives	€ 0
Maximum treasury shares as percentage of total shares issued	10%
Warranty expense	€ 112	110	€ 266
Advertising Expense	929	490	€ 291
Operating lease, right of use	€ 1,784	€ 1,555
Minimum
Warranty term	P1Y
Maximum
Warranty term	two years
Maximum | Sale and leaseback
Useful life	7 years

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and equipment (Details)	12 Months Ended
	Dec. 31, 2022
Leasehold improvements
Property and equipment
Useful life	10 years
Equipment | Minimum
Property and equipment
Useful life	3 years
Equipment | Maximum
Property and equipment
Useful life	10 years
Furniture, fixtures, fittings and other | Minimum
Property and equipment
Useful life	2 years
Furniture, fixtures, fittings and other | Maximum
Property and equipment
Useful life	10 years

SUMMARY OF SIGNIFICANT ACCOUN_6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets (Details)	12 Months Ended
	Dec. 31, 2022
Patents
Intangible assets
Useful life (in years)	5 years
SAP Licenses
Intangible assets
Useful life (in years)	10 years
Other licenses
Intangible assets
Useful life (in years)	5 years
Trade name and trademark
Intangible assets
Useful life (in years)	7 years

CASH EQUIVALENTS - Schedule of

CASH EQUIVALENTS - Schedule of Cash Equivalents and Short Term Investments (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
CASH EQUIVALENTS
Total cash and cash equivalents	€ 63,136	€ 47,183
Short term investments	0
Total cash and cash equivalents	€ 63,136	€ 47,183

TRADE ACCOUNTS AND NOTES RECE_3

TRADE ACCOUNTS AND NOTES RECEIVABLE, NET (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
TRADE ACCOUNTS AND NOTES RECEIVABLE, NET
Trade accounts receivable	€ 12,965	€ 10,992
Notes receivable	617	615
Less: allowance for doubtful accounts	(161)	(742)
Total	13,421	10,864
Less current portion	(13,421)	(10,864)
Bad debt expense:
Bad debt expense	€ 32	€ 2	€ 87

OTHER RECEIVABLES - (Details)

OTHER RECEIVABLES - (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
OTHER RECEIVABLES.
Research and development tax credit receivable from the French State	€ 581	€ 617
Value-added taxes receivable	894	574
Others	46	64
Other receivables	€ 1,522	€ 1,255

INVENTORIES (Details)

INVENTORIES (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
INVENTORIES.
Components, spare parts	€ 7,543	€ 4,955
Work-in-progress	283	250
Finished goods - own manufactured products	1,514	1,166
Finished goods - distribution products	3,702	2,598
Total gross inventories	13,042	8,968
Less: allowance for slow-moving inventory and net realizable value	(1,262)	(1,470)
Total	11,780	7,499
Provision for slow moving inventory:
Inventory Write-down	€ 93	€ 371	€ 651

OTHER ASSETS (Details)

OTHER ASSETS (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
OTHER ASSETS
Prepaid expenses, current portion	€ 660	€ 581
Total	€ 660	€ 581

PROPERTY AND EQUIPMENT, NET - S

PROPERTY AND EQUIPMENT, NET - Schedule of Property and Equipment, net (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Property and equipment
Property and equipment, gross	€ 12,661	€ 11,572
Less: accumulated depreciation and amortization	(8,916)	(8,594)
Total	3,745	2,978
Equipment
Property and equipment
Property and equipment, gross	9,553	8,894
Furniture, fixture, and fittings and other
Property and equipment
Property and equipment, gross	€ 3,108	€ 2,678

PROPERTY AND EQUIPMENT, NET (De

PROPERTY AND EQUIPMENT, NET (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Property and equipment
Depreciation expense	€ 1,194	€ 1,521	€ 1,695
Property and equipment, gross	12,661	11,572
Accumulated amortization	8,916	8,594
Depreciation expense related to financing lease right-of-use assets	303	275	401
Assets leased to customers
Property and equipment
Depreciation expense	37	40	€ 240
Property and equipment, gross	753	423
Accumulated amortization	€ 264	€ 108

PROPERTY AND EQUIPMENT, NET -_2

PROPERTY AND EQUIPMENT, NET - Schedule of Financing leases right-of-use assets (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Property and equipment
Total gross value	€ 1,269	€ 2,007
Less: accumulated depreciation and amortization	813	1,368
Total	€ 455	€ 639
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	us-gaap_PropertyPlantAndEquipmentNet	us-gaap_PropertyPlantAndEquipmentNet
Facilities
Property and equipment
Total gross value	€ 269	€ 290
Equipment
Property and equipment
Total gross value	220	220
Vehicles and IT equipment
Property and equipment
Total gross value	€ 780	€ 1,497

OPERATING LEASE RIGHT-OF-USE _3

OPERATING LEASE RIGHT-OF-USE ASSETS - Components (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Right of use assets:
Operating lease, right of use	€ 1,784	€ 1,555
Facilities
Right of use assets:
Operating lease, right of use	1,536	1,290
Equipment.
Right of use assets:
Operating lease, right of use	57	158
Furniture, fixture, fittings and other
Right of use assets:
Operating lease, right of use	€ 191	€ 107

OPERATING LEASE RIGHT-OF-USE _4

OPERATING LEASE RIGHT-OF-USE ASSETS (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
OPERATING LEASE RIGHT-OF-USE ASSETS.
Reduction to right-of-use assets resulting from reductions to operating lease obligations	€ (910)	€ (917)
Variable lease costs	152	123
Short-term lease costs	€ 74	€ 70

GOODWILL AND INTANGIBLE ASSET_2

GOODWILL AND INTANGIBLE ASSETS (Details) € in Thousands	12 Months Ended
	Dec. 31, 2022 EUR (€) item	Dec. 31, 2021 EUR (€)	Dec. 31, 2020 EUR (€)
Goodwill
Goodwill	€ 2,412	€ 2,412
Reporting units | item	3
Impairment	€ 0
Amortization expense	141	€ 125	€ 113
Urology Devices and Services (ESWL)
Goodwill
Goodwill	496
Distribution Services (DIST)
Goodwill
Goodwill	1,271
High Intensity Focused Ultrasound (HIFU)
Goodwill
Goodwill	€ 645

GOODWILL AND INTANGIBLE ASSET_3

GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Intangible assets
Intangible assets, gross	€ 2,592	€ 2,484
Accumulated amortization	(1,868)	(1,756)
Intangible assets, net	725	728
Licenses
Intangible assets
Intangible assets, gross	1,585	1,448
Accumulated amortization	(863)	(723)
Trade name and trademark
Intangible assets
Intangible assets, gross	370	400
Accumulated amortization	(368)	(397)
Patents
Intangible assets
Intangible assets, gross	412	412
Accumulated amortization	(412)	(412)
Organization costs
Intangible assets
Intangible assets, gross	225	225
Accumulated amortization	€ (225)	€ (225)

GOODWILL AND INTANGIBLE ASSET_4

GOODWILL AND INTANGIBLE ASSETS - Estimated amortization expense (Details) € in Thousands	Dec. 31, 2022 EUR (€)
GOODWILL AND INTANGIBLE ASSETS
2023	€ 143
2024	135
2025	125
2026	122
2027	107
2028 and thereafter	76
Total	€ 706

TRADE ACCOUNTS AND NOTES PAYA_3

TRADE ACCOUNTS AND NOTES PAYABLE (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
TRADE ACCOUNTS AND NOTES PAYABLE
Trade accounts payable	€ 6,640	€ 5,511
Notes payable	7	1
Trade accounts and notes payable	€ 6,647	€ 5,512

DEFERRED REVENUES - Summary of

DEFERRED REVENUES - Summary of Deferred Revenues (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Deferred revenues, total	€ 4,314	€ 3,848
Less long term portion	(264)	(440)
Deferred revenues, current portion	4,050	3,408
Maintenance contracts
Deferred revenues, total	1,803	1,624
RPP
Deferred revenues, total	517	315
Sale of devices
Deferred revenues, total	83	114
Extension of warranty, included in sales contracts
Deferred revenues, total	535	740	€ 782
Treatment probe lease and other
Deferred revenues, total	€ 1,376	€ 1,055

DEFERRED REVENUES - Revenue Rec

DEFERRED REVENUES - Revenue Recognition (Details) € in Thousands	Dec. 31, 2022 EUR (€)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, remaining performance obligation, expected timing of satisfaction, period (Year)	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, remaining performance obligation, expected timing of satisfaction, period (Year)	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, remaining performance obligation, expected timing of satisfaction, period (Year)	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01
Revenue, remaining performance obligation, expected timing of satisfaction, period (Year)	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01
Revenue, remaining performance obligation, expected timing of satisfaction, period (Year)	1 year
Extension of Warranty [Member]
Revenue, remaining performance obligation, amount	€ 535
Extension of Warranty [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, remaining performance obligation, amount	302
Extension of Warranty [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, remaining performance obligation, amount	145
Extension of Warranty [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, remaining performance obligation, amount	84
Extension of Warranty [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01
Revenue, remaining performance obligation, amount	€ 5

DEFERRED REVENUES - Change in D

DEFERRED REVENUES - Change in Deferred Revenue on Extension of Warranty (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Balance	€ 3,848
Balance	4,314	€ 3,848
Extension of Warranty [Member]
Balance	740	782
New extension of warranty	162	256
Recognition of revenue	(367)	(298)
Balance	€ 535	€ 740

OTHER ACCRUED LIABILITIES - Sch

OTHER ACCRUED LIABILITIES - Schedule of other accrued liabilities (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Retirement indemnities	€ 2,153	€ 2,382
Provision for warranty costs	162	252	€ 368
Accruals for payroll and associated taxes	1,848	944
Conditional government advances	463	463
Value added tax payable	531	463
Advances received from customers	861	225
Provision for Asset Retirement Obligation (Japan)	101	109
Others	340	353
Total	6,583	5,289
Less non-current portion	(2,710)	(2,534)
Current portion	3,873	2,755
Korea
Provision for employee termination indemnities	€ 122	€ 97

OTHER ACCRUED LIABILITIES (Deta

OTHER ACCRUED LIABILITIES (Details) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2022
OTHER ACCRUED LIABILITIES.
Conditional Advances, Interest Rate, Percentage		1.44%
Grant received, Reimbursed	€ 0.6
Non-refundable grant	0.4
Proceeds from conditional advances	€ 0.4

OTHER ACCRUED LIABILITIES - Con

OTHER ACCRUED LIABILITIES - Conditional advances (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
OTHER ACCRUED LIABILITIES.
2023	€ 18
2024	93
2025	93
2026	93
2027	86
2028 and thereafter	81
Total	€ 463	€ 463

OTHER ACCRUED LIABILITIES - S_2

OTHER ACCRUED LIABILITIES - Schedule of Changes in warranty costs provision (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
OTHER ACCRUED LIABILITIES.
Beginning of year	€ 252	€ 368
Amount used during the year	(202)	(225)
New warranty expenses	112	110
End of year	162	252
Less current portion	(100)	(206)
Long term portion	€ 62	€ 46

LEASE OBLIGATIONS (Details)

LEASE OBLIGATIONS (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Finance Lease, Liability, Total	€ 548	€ 770
Finance Lease, Interest Expense	€ 12	€ 55	€ 29
Finance Lease, Weighted Average Remaining Lease Term (Year)	1 year 7 days	2 years 1 month 9 days
Finance Lease, Weighted Average Discount Rate, Percent	1.32%	2.93%
Operating Lease, Weighted Average Remaining Lease Term (Year)	2 years 2 months 4 days	2 years 7 months 13 days
Operating Lease, Weighted Average Discount Rate, Percent	2.29%	1.69%
Operating Lease, Expense	€ 912	€ 953	€ 941
Medical Devices [Member]
Finance Lease, Liability, Total	55
Vehicles and Other IT Equipment [Member]
Finance Lease, Liability, Total	€ 494

LEASE OBLIGATIONS - Maturities

LEASE OBLIGATIONS - Maturities of finance leases liabilities (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
LEASE OBLIGATIONS
2023 / 2022	€ 234	€ 358
2024 / 2023	149	215
2025 / 2024	102	124
2026 / 2025	63	75
2027 / 2026	12	46
2028 / 2027 and thereafter	6	7
Total undiscounted minimum lease payments	566	825
Less: amount representing interest	(17)	(55)
Present value of minimum lease payments	548	770
Less: current portion	(224)	(340)
Long-term portion	€ 324	€ 430

LEASE OBLIGATIONS - Maturitie_2

LEASE OBLIGATIONS - Maturities of operating leases liabilities (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
LEASE OBLIGATIONS
2023 / 2022	€ 901	€ 673
2024 / 2023	636	523
2025 / 2024	238	277
2026 / 2025	24	69
2027 / 2026		18
2028 / 2027 and thereafter		2
Total undiscounted minimum lease payments	1,799	1,562
Less: current portion	(901)	(673)
Long-term portion	€ 899	€ 888

SHORT-TERM BORROWINGS (Details)

SHORT-TERM BORROWINGS (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Short-term borrowings	€ 1,846	€ 1,914
Factored Account Receivables [Member]
Short-term borrowings	€ 1,846	€ 1,914

LONG TERM DEBT (Details)

LONG TERM DEBT (Details) € in Thousands	Dec. 31, 2022 EUR (€)
Loans Payable [Member] | Germany | High Intensity Focused Ultrasound (HIFU) Equipment 2 [Member]
Debt Instrument, Collateral Amount	€ 438

LONG TERM DEBT - Schedule of Lo

LONG TERM DEBT - Schedule of Long Term Debt (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Total long term debt	€ 5,188	€ 5,759
Less current portion	(1,601)	(830)
Total long-term portion	3,587	4,930
France
Total long term debt	4,593	4,848
Japan
Total long term debt	558	786
Germany
Total long term debt	28	111
Korea
Total long term debt	€ 8	11
Malaysia
Total long term debt		€ 3

LONG TERM DEBT - Long-term Debt

LONG TERM DEBT - Long-term Debt (Details)	1 Months Ended	12 Months Ended
	Dec. 31, 2020 EUR (€)	Dec. 31, 2022 JPY (¥)	Dec. 31, 2021 JPY (¥)	Dec. 31, 2020 EUR (€)	Dec. 31, 2022 EUR (€)	Dec. 31, 2021 EUR (€)	Dec. 31, 2021 MYR (RM)	Dec. 31, 2021 USD ($)
Japan | EDAP Technomed Co Ltd. [Member] | Loan One [Member]
Debt Instrument, Face Amount | ¥		¥ 80,000,000	¥ 80,000,000
Maturity		Aug. 02, 2026	Aug. 02, 2026
Interest rate		1.98%	1.98%		1.98%	1.98%	1.98%	1.98%
Frequency of principal payments		Monthly installment	Monthly installment
Japan | EDAP Technomed Co Ltd. [Member] | Loan Two [Member]
Debt Instrument, Face Amount | ¥		¥ 50,000,000	¥ 50,000,000
Maturity		Apr. 02, 2025	Apr. 02, 2025
Interest rate		1.80%	1.80%		1.80%	1.80%	1.80%	1.80%
Frequency of principal payments		Monthly installment	Monthly installment
Germany | EDAP TMS GMBH [Member] | High Intensity Focused Ultrasound (HIFU) Equipment 1 [Member] | Loan One [Member]
Debt Instrument, Face Amount					€ 400,000	€ 400,000
Maturity		Apr. 30, 2023	Apr. 30, 2023
Interest rate		2.40%	2.40%		2.40%	2.40%	2.40%	2.40%
Frequency of principal payments		Monthly installment	Monthly installment
France | Loan pledged against countervalue in dollars I [Member] | High Intensity Focused Ultrasound (HIFU) Equipment 1 [Member]
Debt					€ 1,066,081
France | Loan pledged against countervalue in dollars I [Member] | High Intensity Focused Ultrasound (HIFU) Equipment 1 [Member] | Maximum
Debt Instrument, Face Amount					1,530,000
France | EDAP TMS France [Member] | COVID-related loan guaranteed by the French government I [Member]
Debt Instrument, Face Amount	€ 2,000,000			€ 2,000,000
Maturity	Jul. 30, 2026
Interest rate	0.73%			0.73%
Frequency of principal payments	Monthly installment
Debt Instrument, Term at Initiation				1 year
Debt Instrument, Term after Extension				6 years
France | EDAP TMS France [Member] | COVID-related loan guaranteed by the French government II [Member]
Debt Instrument, Face Amount	€ 2,000,000			€ 2,000,000
Maturity				Aug. 04, 2026
Interest rate	0.73%			0.73%
Frequency of principal payments				Monthly installment
Debt Instrument, Term at Initiation				1 year
Debt Instrument, Term after Extension				6 years
France | EDAP TMS France [Member] | COVID-related loan guaranteed by the French government III [Member]
Debt Instrument, Face Amount	€ 2,000,000			€ 2,000,000
Maturity				Jul. 30, 2026
Interest rate	0.73%			0.73%
Frequency of principal payments				Monthly installment
Debt Instrument, Term after Extension				6 years
Debt Instrument, Term				1 year
France | EDAP TMS France [Member] | COVID-related loan guaranteed by the French government IV [Member]
Debt Instrument, Face Amount	€ 2,000,000			€ 2,000,000
Maturity				Aug. 04, 2026
Interest rate	0.73%			0.73%
Frequency of principal payments				Monthly installment
Debt Instrument, Term				1 year
France | EDAP TMS France [Member] | Loan related to acquisition of computer servers [Member]
Debt Instrument, Face Amount	€ 72,222			€ 72,222
Maturity				Jul. 05, 2024
Interest rate	0.45%			0.45%
Frequency of principal payments				Monthly installment
France | EDAP TMS France [Member] | Loan related to ERP SAP project [Member]
Debt Instrument, Face Amount						€ 780,457
Maturity			Apr. 01, 2025
Interest rate			0.99%			0.99%	0.99%	0.99%
Frequency of principal payments			Monthly installment
France | EDAP TMS France [Member] | Loan pledged against countervalue in dollars I [Member] | High Intensity Focused Ultrasound (HIFU) Equipment 1 [Member] | Loan One [Member]
Debt Instrument, Face Amount					€ 1,066,081
Maturity		Jul. 01, 2025
Interest rate		0.99%			0.99%
Frequency of principal payments		Monthly installment
France | EDAP TMS France [Member] | Loan pledged against countervalue in dollars II [Member] | Maximum
Debt Instrument, Face Amount						€ 1,530,000
France | EDAP TMS France [Member] | Loan pledged against countervalue in dollars II [Member] | High Intensity Focused Ultrasound (HIFU) Equipment 1 [Member]
Debt						€ 780,457
Malaysia | EDAP Technomed Sdn Bdh [Member]
Debt Instrument, Face Amount | RM							RM 90,000
Maturity			Jul. 31, 2022
Interest rate			4.64%			4.64%	4.64%	4.64%
Frequency of principal payments			Monthly installment
USA | EDAP Technomed Co Ltd. [Member]
Debt Instrument, Face Amount | $								$ 221,217
Maturity			May 14, 2022
Interest rate			1%			1%	1%	1%
Frequency of principal payments			Monthly installment

LONG TERM DEBT - Schedule Of _2

LONG TERM DEBT - Schedule Of Long-term Debt and Financial Instruments Maturities (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
LONG TERM DEBT
2023	€ 1,601
2024	1,570
2025	1,335
2026	682
Total	€ 5,188	€ 5,759

OTHER LONG-TERM LIABILITIES - O

OTHER LONG-TERM LIABILITIES - Other Long-term Liabilities (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
OTHER LONG-TERM LIABILITIES.
Provision for retirement indemnities (Japan & France), less current portion	€ 1,962	€ 2,281
Provision for employee termination indemnities (Korea) less current portion	122	97
Provision for Asset Retirement Obligation (Japan) less current portion	101	109
Provision for warranty costs, less current portion	62	46
Conditional government advances, less current portion	463
Total	€ 2,710	€ 2,534

OTHER LONG-TERM LIABILITIES - A

OTHER LONG-TERM LIABILITIES - Assumptions (Details)	Dec. 31, 2022 item age	Dec. 31, 2021 age item
Defined Benefit Retirement Indemnity Plans, France [Member]
Discount rate	3.80%	1.05%
Salary increase	3%	2.50%
Retirement age | age	65	65
Average retirement remaining service period | item	24	24
Defined Benefit Retirement Indemnity Plans, Japan [Member]
Discount rate	1.30%	0.60%
Salary increase	2.50%	2.50%
Retirement age | age	60	60
Average retirement remaining service period | item	14	14

OTHER LONG-TERM LIABILITIES - P

OTHER LONG-TERM LIABILITIES - Provision Presentation According to ASC 715 (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Defined Benefit Retirement Indemnity Plans, France [Member]
Non-current liabilities	€ 845	€ 1,080
Current liabilities	89
Total projected benefit obligation	934	1,080
Defined Benefit Retirement Indemnity Plans, Japan [Member]
Non-current liabilities	1,117	1,200
Current liabilities	102	102
Total projected benefit obligation	€ 1,219	€ 1,302

OTHER LONG-TERM LIABILITIES - R

OTHER LONG-TERM LIABILITIES - Reconciliation of Pension Cost Components (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Amortization of Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	us-gaap_GeneralAndAdministrativeExpense, us-gaap_ResearchAndDevelopmentExpense, us-gaap_SellingAndMarketingExpense
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Amortization of Prior Service Cost (Credit), Statement of Income or Comprehensive Income [Extensible Enumeration]	us-gaap_GeneralAndAdministrativeExpense, us-gaap_ResearchAndDevelopmentExpense, us-gaap_SellingAndMarketingExpense
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]	us-gaap_GeneralAndAdministrativeExpense, us-gaap_ResearchAndDevelopmentExpense, us-gaap_SellingAndMarketingExpense
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Settlement and Curtailment Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	us-gaap_GeneralAndAdministrativeExpense, us-gaap_ResearchAndDevelopmentExpense, us-gaap_SellingAndMarketingExpense
Defined Benefit Retirement Indemnity Plans, France [Member]
Projected Benefit obligations at beginning of year	€ 1,080	€ 1,111	€ 969
Service cost	84	90	88
Interest cost	11	6	9
Actuarial (gain) or loss	(241)	(72)	46
Amortization of net prior service cost			1
Benefits paid		(56)
Projected Benefit obligations at end of year	934	1,080	1,111
Unrecognized actuarial (gain) loss	(219)	22	94
Unrecognized prior service cost	14	16	17
Accrued pension cost	934	1,080
Defined Benefit Retirement Indemnity Plans, Japan [Member]
Projected Benefit obligations at beginning of year	1,302	1,310	1,230
Service cost	112	120	123
Interest cost	7	7	7
Amortization of net loss			1
Actuarial (gain) or loss	(30)		(1)
Benefits paid	(75)	(97)	(5)
Exchange rate impact	(95)	(39)	(44)
Projected Benefit obligations at end of year	1,219	1,302	1,310
Unrecognized actuarial (gain) loss	86	126	€ 130
Accrued pension cost	€ 1,219	€ 1,302

OTHER LONG-TERM LIABILITIES (De

OTHER LONG-TERM LIABILITIES (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Defined Benefit Retirement Indemnity Plans, France [Member]
Accumulated Benefit Obligation	€ 701	€ 780
Accumulated other comprehensive income (loss)	205
Defined Benefit Retirement Indemnity Plans, Japan [Member]
Accumulated Benefit Obligation	1,027	€ 1,123
Accumulated other comprehensive income (loss)	€ 86

OTHER LONG-TERM LIABILITIES - E

OTHER LONG-TERM LIABILITIES - Expected Benefit Payments (Details) € in Thousands	Dec. 31, 2022 EUR (€)
Defined Benefit Retirement Indemnity Plans, France [Member]
2023	€ 91
2026	129
2027	85
2028-2032	408
Total	713
Defined Benefit Retirement Indemnity Plans, Japan [Member]
2023	103
2024	75
2025	156
2026	157
2027	72
2028-2032	682
Total	€ 1,246

SHAREHOLDERS' EQUITY (Details)

SHAREHOLDERS' EQUITY (Details)

1 Months Ended

2 Months Ended

5 Months Ended

12 Months Ended

Dec. 31, 2022 EUR (€) € / shares shares

Dec. 15, 2022 EUR (€) € / shares shares

Nov. 08, 2022 EUR (€) € / shares shares

Sep. 28, 2022 shares

Jun. 30, 2022 shares

May 17, 2022 EUR (€) € / shares shares

Mar. 30, 2022 EUR (€) shares

Nov. 17, 2021 EUR (€) € / shares shares

Sep. 28, 2021 EUR (€) shares

Jun. 11, 2021 EUR (€) € / shares shares

Apr. 04, 2019 € / shares shares

Aug. 29, 2018 € / shares shares

Apr. 25, 2017 € / shares shares

Apr. 26, 2016 € / shares shares

Jan. 18, 2013 € / shares shares

Sep. 30, 2022 EUR (€) shares

Apr. 30, 2021 EUR (€) shares

Jul. 31, 2001 EUR (€) shares

Dec. 31, 1998 shares

Dec. 31, 2022 EUR (€) € / shares shares

Dec. 31, 2021 EUR (€) € / shares shares

Dec. 31, 2020 EUR (€) shares

Dec. 31, 2019 EUR (€) shares

Dec. 31, 2018 EUR (€)

Dec. 31, 2017 EUR (€)

Dec. 31, 2016 EUR (€)

Dec. 31, 2013 EUR (€)

Dec. 31, 2022 $ / shares

Sep. 30, 2022 $ / shares

Jun. 30, 2021 shares

Apr. 30, 2021 $ / shares

Jun. 28, 2019 shares

Feb. 18, 2016 shares

Dec. 19, 2012 shares

Common stock, shares issued

37,197,731

37,197,731

33,758,564

Common stock, par value | € / shares

€ 0.13

€ 0.13

€ 0.13

Commons stock, shares outstanding

36,910,925

36,910,925

33,466,136

Issuance costs | €

€ 1,954,000

€ 1,961,000

Statutory Retained Earnings (Statutory Accumulated Deficit) | €

€ 14,329,000

€ 14,329,000

Treasury stock

286,806

286,806

292,428

Treasury Stock, Shares, Acquired (in shares)

180,290

106,516

Treasury Stock, Value, Acquired, Par Value Method | €

€ 697,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)

571,000

1,392,428

Share Price | $ / shares

$ 10.66

The 2012 Plan [Member]

Common Stock, Shares Subscribed but Unissued (in shares)

500,000

The 2016 Plan [Member]

Common Stock, Shares Subscribed but Unissued (in shares)

1,000,000

The 2021 Plan [Member] | Maximum

Common Stock, Shares Subscribed but Unissued (in shares)

2,000,000

Share-based Payment Arrangement, Option [Member]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in EUR per share) | € / shares

€ 9.07

€ 5.56

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)

2,613,886

2,613,886

2,408,508

1,186,900

1,273,900

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)

571,000

1,392,428

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number (in shares)

1,362,205

1,362,205

1,149,401

970,650

Stock issued during period shares stock options exercised

320,622

150,820

23,750

Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | €

€ 2,612,000

€ 2,612,000

Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)

2 years 10 months 24 days

Share-based Payment Arrangement, Option [Member] | The 2012 Plan [Member]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in EUR per share) | € / shares

€ 1.91

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)

10 years

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)

0

0

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)

500,000

Shares Granted, Value, Share-based Payment Arrangement, before Forfeiture | €

€ 660,000

Recognition period of non-cash financial charges

48 months

Share-based Payment Arrangement, Option [Member] | The 2012 Plan [Member] | Minimum

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)

1 year

Share-based Payment Arrangement, Option [Member] | The 2012 Plan [Member] | Maximum

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)

4 years

Share-based Payment Arrangement, Option [Member] | The 2016 Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)

1,000,000

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in EUR per share) | € / shares

€ 3.90

€ 2.65

€ 2.39

€ 3.22

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)

10 years

10 years

10 years

10 years

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)

696,080

696,080

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)

155,000

165,000

260,000

575,000

Shares Granted, Value, Share-based Payment Arrangement, before Forfeiture | €

€ 299,000

€ 219,000

€ 335,000

€ 960,000

Recognition period of non-cash financial charges

48 months

Share-based Payment Arrangement, Expense | €

€ 25,000

€ 65,000

€ 160,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number (in shares)

668,580

668,580

Share-based Payment Arrangement, Option [Member] | The 2016 Plan [Member] | Minimum

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)

1 year

1 year

1 year

1 year

Share-based Payment Arrangement, Option [Member] | The 2016 Plan [Member] | Maximum

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)

4 years

4 years

4 years

4 years

Share-based Payment Arrangement, Option [Member] | The 2019 Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)

358,528

Share-based Compensation Arrangement by Share-based Payment Award, Number of pre-existing shares available for future puchase option

292,428

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in EUR per share) | € / shares

€ 5.59

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)

10 years

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)

1,266,806

1,266,806

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)

1,000,000

Shares Granted, Value, Share-based Payment Arrangement, before Forfeiture | €

€ 681,000

Recognition period of non-cash financial charges

36 months

Share-based Payment Arrangement, Expense | €

€ 1,104,000

1,484,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number (in shares)

633,403

633,403

Share-based Payment Arrangement, Option [Member] | The 2019 Plan [Member] | Minimum

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)

6 months

Share-based Payment Arrangement, Option [Member] | The 2019 Plan [Member] | Maximum

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)

3 years

Share-based Payment Arrangement, Option [Member] | The 2021 Plan [Member]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in EUR per share) | € / shares

€ 9.94

€ 10.32

€ 6.41

€ 5.18

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)

10 years

10 years

10 years

10 years

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)

44,000

44,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)

395,000

32,000

144,000

100,000

61,500

Shares Granted, Value, Share-based Payment Arrangement, before Forfeiture | €

€ 1,858,000

€ 161,000

€ 450,000

€ 259,000

€ 229,000

€ 340,000

Recognition period of non-cash financial charges

36 months

36 months

Share-based Payment Arrangement, Expense | €

€ 442,000

25,000

Share-based Payment Arrangement, Option [Member] | The 2021 Plan [Member] | Minimum

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)

6 months

6 months

6 months

1 year

6 months

1 year

Share-based Payment Arrangement, Option [Member] | The 2021 Plan [Member] | Maximum

Common Stock, Shares Subscribed but Unissued (in shares)

200,000

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)

3 years

3 years

3 years

2 years

3 years

2 years

Share-based Payment Arrangement, Option [Member] | The 2021 Plan [Member] | French resident beneficiaries

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)

57,500

Share-based Payment Arrangement, Option [Member] | The 2021 Plan [Member] | CEO

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)

40,000

Share-based Payment Arrangement, Option [Member] | The Plan 2022

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)

3 years

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)

286,000

286,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)

291,500

Shares Granted, Value, Share-based Payment Arrangement, before Forfeiture | €

€ 2,963,000

Recognition period of non-cash financial charges

36 months

Period between date of grant and start of vesting period

6 months

Share-based Payment Arrangement, Option [Member] | The Plan 2022 | Maximum

Common Stock, Shares Subscribed but Unissued (in shares)

600,000

Options to Subscribe New Shares [Member] | The 2012 Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)

500,000

Options to Subscribe New Shares [Member] | The 2016 Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)

1,000,000

Options to Subscribe New Shares [Member] | The 2019 Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)

1,000,000

Shares Granted, Value, Share-based Payment Arrangement, before Forfeiture | €

€ 2,371,000

Options to Subscribe New Shares [Member] | The 2021 Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)

2,000,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)

651,000

651,000

Common stock

Stock Issued During Period, Shares, New Issues (in shares)

3,444,789

4,300,820

23,750

Common stock | American Depository Shares (ADS) [Member]

Stock Issued During Period, Shares, New Issues (in shares)

3,066,667

4,150,000

Price per share | $ / shares

$ 7.50

$ 6.75

Gross Proceeds From Issuance of Stock | €

€ 23,913,000

€ 23,255,000

Issuance costs | €

€ 1,954,000

€ 1,961,000

SHAREHOLDERS' EQUITY - Stock Op

SHAREHOLDERS' EQUITY - Stock Option Assumptions (Details) - € / shares	1 Months Ended					12 Months Ended
	Dec. 31, 2022	Nov. 30, 2022	May 31, 2022	Nov. 30, 2021	Jun. 30, 2021	Dec. 31, 2022	Dec. 31, 2021
SHAREHOLDERS' EQUITY.
Weighted-average expected life (years) (Year)	5 years 9 months 14 days	5 years 9 months 14 days	5 years 9 months 14 days	5 years 9 months 14 days	5 years 9 months 14 days
Expected volatility rates(1)	45.41%	45.38%	44.96%	45.08%	46.34%
Expected dividend yield	0%	0%	0%	0%	0%
Risk-free interest rate	3.62%	4.32%	3%		0.63%
Risk-free interest rate				1.32%
Weighted-average exercise price (in EUR per share)	€ 9.94	€ 10.32	€ 6.41	€ 5.18	€ 5.59	€ 9.94
Weighted-average fair value of options granted during the year	€ 4.70	€ 5.05	€ 3.13	€ 2.29	€ 2.37	€ 4.33	€ 2.37

SHAREHOLDERS' EQUITY - Disclosu

SHAREHOLDERS' EQUITY - Disclosure of Share-based Compensation Arrangements by Share-based Payment Award (Details) - € / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Non-vested options granted (in shares)	571,000	1,392,428
Share-based Payment Arrangement, Option [Member]
Outstanding - number (in shares)	2,408,508	1,186,900	1,273,900
Outstanding - Weighted average exercise price (in EUR per share)	€ 4.38	€ 2.81	€ 2.78
Non-vested options granted (in shares)	571,000	1,392,428
Granted - Weighted average exercise price (in EUR per share)	€ 9.07	€ 5.56
Exercised - number (in shares)	(320,622)	(150,820)	(23,750)
Exercised - Weighted average exercise price (in EUR per share)	€ 2.14	€ 2.93	€ 2.54
Forfeited - number (in shares)	(45,000)	(20,000)	(21,250)
Forfeited - Weighted average exercise price (in EUR per share)	€ 5.34	€ 4.01	€ 2.55
Expired - number (in shares)			(42,000)
Expired - Weighted average exercise price (in EUR per share)			€ 2
Outstanding - number (in shares)	2,613,886	2,408,508	1,186,900
Outstanding - Weighted average exercise price (in EUR per share)	€ 5.66	€ 4.38	€ 2.81
Exercisable - number (in shares)	1,362,205	1,149,401	970,650
Exercisable - Weighted average exercise price (in EUR per share)	€ 4.35	€ 3.25	€ 2.73
Share purchase options available for grant - number (in shares)	20,000	5,000	292,428
Number of options to subscribe to new shares available for future grant	1,329,000

SHAREHOLDERS' EQUITY - Schedule

SHAREHOLDERS' EQUITY - Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range (Details)	12 Months Ended
	Dec. 31, 2022 EUR (€) € / shares shares
Outstanding options - Number (in shares) | shares	2,613,886
Outstanding options - Weighted average remaining contractual life (Year)	7 years 4 months 24 days
Outstanding options - Weighted average exercise price (in EUR per share)	€ 5.66
Outstanding options - Aggregate intrinsic value | €	€ 14,802,482,000
Exercisable options - Number (in shares) | shares	1,362,205
Exercisable options - Weighted average exercise price (in EUR per share)	€ 4.35
Exercisable options - Aggregate intrinsic value | €	€ 5,926,737,000
Exercise price, Lower range (in EUR per share)	€ 2.39
Exercise price, Upper range (in EUR per share)	€ 10.32
Range 1 [Member]
Outstanding options - Number (in shares) | shares	32,000
Outstanding options - Weighted average remaining contractual life (Year)	9 years 9 months 18 days
Outstanding options - Weighted average exercise price (in EUR per share)	€ 10.32
Outstanding options - Aggregate intrinsic value | €	€ 330,240,000
Exercise price, Lower range (in EUR per share)	€ 10.32
Range 2 [Member]
Outstanding options - Number (in shares) | shares	395,000
Outstanding options - Weighted average remaining contractual life (Year)	10 years
Outstanding options - Weighted average exercise price (in EUR per share)	€ 9.94
Outstanding options - Aggregate intrinsic value | €	€ 3,926,300,000
Exercise price, Lower range (in EUR per share)	€ 9.94
Range 3 [Member]
Outstanding options - Number (in shares) | shares	124,000
Outstanding options - Weighted average remaining contractual life (Year)	9 years 3 months 18 days
Outstanding options - Weighted average exercise price (in EUR per share)	€ 6.41
Outstanding options - Aggregate intrinsic value | €	€ 794,840,000
Exercisable options - Number (in shares) | shares	24,111
Exercisable options - Weighted average exercise price (in EUR per share)	€ 6.41
Exercisable options - Aggregate intrinsic value | €	€ 154,552,000
Exercise price, Lower range (in EUR per share)	€ 6.41
Range 4 [member]
Outstanding options - Number (in shares) | shares	1,266,806
Outstanding options - Weighted average remaining contractual life (Year)	8 years 4 months 24 days
Outstanding options - Weighted average exercise price (in EUR per share)	€ 5.59
Outstanding options - Aggregate intrinsic value | €	€ 7,081,446,000
Exercisable options - Number (in shares) | shares	633,403
Exercisable options - Weighted average exercise price (in EUR per share)	€ 5.59
Exercisable options - Aggregate intrinsic value | €	€ 3,540,723,000
Exercise price, Lower range (in EUR per share)	€ 5.59
Range 5 [Member]
Outstanding options - Number (in shares) | shares	100,000
Outstanding options - Weighted average remaining contractual life (Year)	8 years 9 months 18 days
Outstanding options - Weighted average exercise price (in EUR per share)	€ 5.18
Outstanding options - Aggregate intrinsic value | €	€ 518,000,000
Exercisable options - Number (in shares) | shares	36,111
Exercisable options - Weighted average exercise price (in EUR per share)	€ 5.18
Exercisable options - Aggregate intrinsic value | €	€ 187,055.56
Exercise price, Lower range (in EUR per share)	€ 5.18
Range 6 [Member]
Outstanding options - Number (in shares) | shares	107,500
Outstanding options - Weighted average remaining contractual life (Year)	6 years 9 months 18 days
Outstanding options - Weighted average exercise price (in EUR per share)	€ 3.90
Outstanding options - Aggregate intrinsic value | €	€ 419,250,000
Exercisable options - Number (in shares) | shares	80,000
Exercisable options - Weighted average exercise price (in EUR per share)	€ 3.90
Exercisable options - Aggregate intrinsic value | €	€ 312,000,000
Exercise price, Lower range (in EUR per share)	€ 3.90
Range 7 [Member]
Outstanding options - Number (in shares) | shares	365,000
Outstanding options - Weighted average remaining contractual life (Year)	3 years 3 months 18 days
Outstanding options - Weighted average exercise price (in EUR per share)	€ 3.22
Outstanding options - Aggregate intrinsic value | €	€ 1,175,300,000
Exercisable options - Number (in shares) | shares	365,000
Exercisable options - Weighted average exercise price (in EUR per share)	€ 3.22
Exercisable options - Aggregate intrinsic value | €	€ 1,175,300,000
Exercise price, Lower range (in EUR per share)	€ 3.22
Range 8 [Member]
Outstanding options - Number (in shares) | shares	87,500
Outstanding options - Weighted average remaining contractual life (Year)	5 years 8 months 12 days
Outstanding options - Weighted average exercise price (in EUR per share)	€ 2.65
Outstanding options - Aggregate intrinsic value | €	€ 231,875,000
Exercisable options - Number (in shares) | shares	87,500
Exercisable options - Weighted average exercise price (in EUR per share)	€ 2.65
Exercisable options - Aggregate intrinsic value | €	€ 231,875,000
Exercise price, Lower range (in EUR per share)	€ 2.65
Range 9 [Member]
Outstanding options - Number (in shares) | shares	136,080
Outstanding options - Weighted average remaining contractual life (Year)	4 years 3 months 18 days
Outstanding options - Weighted average exercise price (in EUR per share)	€ 2.39
Outstanding options - Aggregate intrinsic value | €	€ 325,231,000
Exercisable options - Number (in shares) | shares	136,080
Exercisable options - Weighted average exercise price (in EUR per share)	€ 2.39
Exercisable options - Aggregate intrinsic value | €	€ 325,231,000
Exercise price, Lower range (in EUR per share)	€ 2.39

SHAREHOLDERS' EQUITY - Non-vest

SHAREHOLDERS' EQUITY - Non-vested Options Activity (Details) - € / shares	1 Months Ended					12 Months Ended
	Dec. 31, 2022	Nov. 30, 2022	May 31, 2022	Nov. 30, 2021	Jun. 30, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
SHAREHOLDERS' EQUITY.
Non-vested options outstanding (in shares)						1,259,107	216,250	455,000
Non-vested options outstanding, weighted average grant-date fair value (in EUR per share)						€ 2.32	€ 1.59	€ 1.58
Non-vested options granted (in shares)						571,000	1,392,428
Non-vested options granted, weighted average grant-date fair value (in EUR per share)	€ 4.70	€ 5.05	€ 3.13	€ 2.29	€ 2.37	€ 4.33	€ 2.37
Non-vested options vested (in shares)						(543,426)	(329,571)	(235,000)
Non-vested options vested, weighted average grant-date fair value (in EUR per share)						€ 2.32	€ 2.06	€ 1.58
Non-vested options forfeited (in shares)						(35,000)	(20,000)	(3,750)
Non-vested options forfeited, weighted average grant-date fair value (in EUR per share)						€ 2.80	€ 1.89	€ 1.54
Non-vested options outstanding (in shares)	1,251,681					1,251,681	1,259,107	216,250
Non-vested options outstanding, weighted average grant-date fair value (in EUR per share)	€ 3.22					€ 3.22	€ 2.32	€ 1.59

SHAREHOLDERS' EQUITY - Componen

SHAREHOLDERS' EQUITY - Components of Accumulated Other Comprehensive Income (Loss) Net of Tax (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Balance	€ 50,054	€ 26,248
Balance	71,632	50,054
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Balance	(3,377)	(2,824)
Net current-period other comprehensive income (loss)	(596)	(554)
Balance	(3,973)	(3,377)
Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]
Balance	(212)	(241)
Net current-period other comprehensive income (loss)	355	29
Balance	144	(212)
Other comprehensive income (loss)
Balance	(3,589)	(3,064)
Net current-period other comprehensive income (loss)	(240)	(525)
Balance	€ (3,829)	€ (3,589)

TOTAL SALES - Sales by Geograph

TOTAL SALES - Sales by Geographical Area (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenues	€ 55,108	€ 44,060	€ 41,649
Asia
Revenues	17,936	16,009	15,872
France
Revenues	10,637	12,251	10,021
USA
Revenues	15,036	5,524	5,611
Other geographical Areas
Revenues	€ 11,500	€ 10,276	€ 10,146

TOTAL SALES - Timing of Revenue

TOTAL SALES - Timing of Revenue Recognition (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenues	€ 55,108	€ 44,060	€ 41,649
Products transferred at a point in time
Revenues	44,173	34,552	32,862
Products and services transferred over time
Revenues	€ 10,935	€ 9,508	€ 8,787

OTHER REVENUES - Other Revenues

OTHER REVENUES - Other Revenues (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Other revenues:
Revenues	€ 55,108	€ 44,060	€ 41,649
Other revenues
Other revenues:
Revenues		6	12
Licenses and others.
Other revenues:
Revenues		€ 6	€ 12

COSTS OF SALES - Schedule of Co

COSTS OF SALES - Schedule of Costs of Sales (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
COSTS OF SALES
Direct costs of sales	€ (19,814)	€ (16,199)	€ (14,058)
Indirect costs of sales	(11,102)	(9,443)	(9,225)
Total cost of sales	€ (30,916)	€ (25,643)	€ (23,283)

RESEARCH AND DEVELOPMENT EXPE_3

RESEARCH AND DEVELOPMENT EXPENSES - Research and Development Expenses (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
RESEARCH AND DEVELOPMENT EXPENSES
Gross research and development expenses	€ (5,751)	€ (4,757)	€ (5,173)
Research Tax Credit	581	617	492
Grants	250	739	184
Net Research and development expenses	€ (4,920)	€ (3,402)	€ (4,496)

FINANCIAL INCOME, NET - Schedul

FINANCIAL INCOME, NET - Schedule of Financial Income (Expense) (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
FINANCIAL INCOME, NET
Interest income	€ 404	€ 10	€ 10
Interest expense	(168)	(52)	(108)
US Paycheck protection program loan forgiveness		187
Total	€ 236	€ 145	€ (98)

INCOME TAXES (Details)

INCOME TAXES (Details) € in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022 EUR (€)	Dec. 31, 2019	Dec. 31, 2018 USD ($)	Dec. 31, 2017
Operating Loss Carryforwards, Total	€ 59,632
Deferred Tax Assets, Operating Loss Carryforwards, Foreign	13,793
Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration	€ 58,856
U.S Subsidiary Taxable Net Income Subject to Lower Taxes with New Tax Law, Minimum | $			$ 100
Effective Income Tax Rate Reconciliation, at French Corporate Income Tax Rate, Percent	25%	28%
EDAP TMS S.A. [Member]
Operating Loss Carryforwards, Total	€ 29,791
EDAP Technomed Inc. [Member]
Operating Loss Carryforwards, Total	29,022
Edap Technomed Co Ltd Japan [Member]
Operating Loss Carryforwards, Total	776
EDAP TMS GMBH [Member]
Operating Loss Carryforwards, Total	€ 43
Foreign Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent			21%
Foreign Tax Authority [Member] | Minimum | Internal Revenue Service (IRS) [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent				15%
Foreign Tax Authority [Member] | Maximum | Internal Revenue Service (IRS) [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent				39%

INCOME TAXES - Income (Loss) Be

INCOME TAXES - Income (Loss) Before Income Taxes (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income (loss)	€ (2,096)	€ 893	€ (1,188)
France
Income (loss)	(418)	869	(2,042)
Other countries
Income (loss)	€ (1,678)	€ 24	€ 854

INCOME TAXES - Income Tax Benef

INCOME TAXES - Income Tax Benefit (Expense) (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Current income tax expense	€ (736)	€ (756)	€ (471)
Deferred income tax (expense) benefit	(101)	563	(45)
Total	(837)	(193)	(516)
France
Current income tax expense	(485)	(320)	(158)
Deferred income tax (expense) benefit	(8)	8	8
Other countries
Current income tax expense	(251)	(436)	(312)
Deferred income tax (expense) benefit	€ (93)	€ 556	€ (53)

INCOME TAXES - Deferred Tax Ass

INCOME TAXES - Deferred Tax Assets and Liabilities (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
INCOME TAXES
Net operating loss carry forwards	€ 13,793	€ 13,611
Elimination of intercompany profit in inventory	480	182
Elimination of intercompany profit in fixed assets	256	278
Provisions for retirement indemnities	658	642
Capital leases treated as operating leases for tax, asset	26
Capital leases treated as operating leases for tax, liability		40
Other items	360	487
Total deferred tax assets	15,573	15,239
Net deferred tax assets	15,573	15,239
Valuation allowance for deferred tax assets	(14,744)	(14,341)
Deferred tax assets (liabilities), net of allowance	€ 829	€ 898

INCOME TAXES - Effective Tax Ra

INCOME TAXES - Effective Tax Rate Reconciliation (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
INCOME TAXES
Theoretical income tax (expense) benefit at French statutory tax rate	€ 524	€ (237)	€ 333
Income of foreign subsidiaries taxed at different tax rates	(174)	(95)	9
Effect of net operating loss carry-forwards and valuation allowances	(643)	626	(749)
Permanent differences	(99)	(258)	(159)
Effect of cancellation of intra-group positions	(366)	(130)	152
French business tax included in income tax (CVAE)	(99)	(85)	(156)
Other	20	(15)	55
Effective income tax (expense) benefit	€ (837)	€ (193)	€ (516)

EARNINGS (LOSS) PER SHARE - Sch

EARNINGS (LOSS) PER SHARE - Schedule of Earnings Per Share, Basic and Diluted (Details) - EUR (€)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
EARNINGS (LOSS) PER SHARE
Net income (loss)	€ (2,933,058)	€ 699,890	€ (1,703,668)
Weighted average number of shares for the computation of basic EPS	34,392,598	32,129,047	29,148,108
Basic EPS (in Euros)	€ (0.09)	€ 0.02	€ (0.06)
Effect of dilutive securities (in shares)	2,502,171	293,824	622,723
Weighted average number of shares for the computation of diluted EPS	34,392,598	32,422,871	29,148,108
Diluted EPS income / (loss) (in Euros)	€ (0.09)	€ 0.02	€ (0.06)

CONCENTRATION OF CREDIT RISK (D

CONCENTRATION OF CREDIT RISK (Details) - EUR (€) € in Millions	Dec. 31, 2022	Dec. 31, 2021
CONCENTRATION OF CREDIT RISK
Allowance for doubtful accounts receivable	€ 0.2	€ 0.7

SEGMENT INFORMATION (Details)

SEGMENT INFORMATION (Details)	12 Months Ended
	Dec. 31, 2022 segment
SEGMENT INFORMATION
Reportable segments	3

SEGMENT INFORMATION - Reconcili

SEGMENT INFORMATION - Reconciliation of Operating Profit (Loss) From Segments to Consolidated (Details) - EUR (€)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
SEGMENT INFORMATION
Segment operating income (loss)	€ (4,257,000)	€ (1,612,000)	€ 269,000
Financial income (expense), net	236,000	145,000	(98,000)
Foreign Currency exchange (losses) gains, net	1,925,000	2,360,000	(1,359,000)
Income tax (expense) benefit	(837,000)	(193,000)	(516,000)
Net income (loss)	€ (2,933,058)	€ 699,890	€ (1,703,668)

SEGMENT INFORMATION - Schedule

SEGMENT INFORMATION - Schedule of Segment Reporting Information By Segment (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenues	€ 55,108	€ 44,065	€ 41,662
Cost of sales	(30,916)	(25,643)	(23,283)
Gross profit	24,193	18,422	18,379
R&D expenses	(4,920)	(3,402)	(4,496)
Selling and marketing expenses	(16,379)	(10,732)	(9,279)
G&A expenses	(7,152)	(5,900)	(4,335)
Segment operating income (loss)	(4,257)	(1,612)	269
Total Assets	101,123	77,226
Goodwill	2,412	2,412
Product
Revenues	55,108	44,060	41,649
RPP's and leases
Revenues	5,617	4,968	4,745
Cost of sales	(3,387)	(3,108)	(2,601)
Spare parts and services
Revenues	11,030	10,052	9,382
Cost of sales	(7,000)	(6,354)	(5,732)
FDA [Member]
Revenues	55,108	44,065	41,662
Cost of sales	(30,916)	(25,643)	(23,283)
Gross profit	24,193	18,422	18,379
R&D expenses	(4,920)	(3,402)	(4,496)
Selling and marketing expenses	(16,379)	(10,732)	(9,279)
G&A expenses	(7,152)	(5,900)	(4,335)
Total expenses	(28,450)	(20,034)	(18,110)
Segment operating income (loss)	(4,257)	(1,612)	269
Total Assets	101,123	77,226	55,193
Capital expenditures	2,378	1,636	2,010
Non-current assets	10,605	9,845	9,801
Goodwill	2,412	2,412	2,412
FDA [Member] | Product
Revenues	38,462	29,040	27,523
FDA [Member] | RPP's and leases
Revenues	5,617	4,968	4,745
FDA [Member] | Spare parts and services
Revenues	11,030	10,052	9,382
FDA [Member] | Product and Services, Excluding Other
Revenues	55,108	44,060	41,649
FDA [Member] | Other revenues.
Revenues		6	12
Operating Segments | High Intensity Focused Ultrasound (HIFU)
Revenues	15,634	9,915	11,438
Cost of sales	(6,788)	(5,311)	(5,144)
Gross profit	8,846	4,604	6,293
R&D expenses	(3,525)	(2,238)	(2,583)
Selling and marketing expenses	(8,083)	(3,910)	(3,151)
G&A expenses	(2,131)	(1,481)	(1,005)
Total expenses	(13,739)	(7,630)	(6,738)
Segment operating income (loss)	(4,894)	(3,025)	(445)
Total Assets	16,293	13,597	16,279
Capital expenditures	1,715	1,234	1,144
Non-current assets	4,269	3,689	3,706
Goodwill	645	645	645
Operating Segments | High Intensity Focused Ultrasound (HIFU) | Product
Revenues	9,437	4,515	6,000
Operating Segments | High Intensity Focused Ultrasound (HIFU) | RPP's and leases
Revenues	4,287	3,679	3,594
Operating Segments | High Intensity Focused Ultrasound (HIFU) | Spare parts and services
Revenues	1,909	1,715	1,831
Operating Segments | High Intensity Focused Ultrasound (HIFU) | Product and Services, Excluding Other
Revenues	15,634	9,910	11,425
Operating Segments | High Intensity Focused Ultrasound (HIFU) | Other revenues.
Revenues		6	12
Operating Segments | Urology Devices and Services (ESWL)
Revenues	11,568	11,016	12,882
Cost of sales	(6,732)	(6,080)	(7,232)
Gross profit	4,836	4,936	5,649
R&D expenses	(950)	(835)	(1,555)
Selling and marketing expenses	(1,887)	(2,048)	(2,052)
G&A expenses	(1,077)	(1,161)	(964)
Total expenses	(3,914)	(4,043)	(4,572)
Segment operating income (loss)	922	893	1,078
Total Assets	12,997	13,596	15,567
Capital expenditures	307	141	309
Non-current assets	2,149	2,185	2,466
Goodwill	496	496	496
Operating Segments | Urology Devices and Services (ESWL) | Product
Revenues	4,880	4,236	6,248
Operating Segments | Urology Devices and Services (ESWL) | RPP's and leases
Revenues	1,058	1,022	927
Operating Segments | Urology Devices and Services (ESWL) | Spare parts and services
Revenues	5,630	5,758	5,707
Operating Segments | Urology Devices and Services (ESWL) | Product and Services, Excluding Other
Revenues	11,568	11,016	12,882
Operating Segments | Distribution (DISTRIB) Division [Member]
Revenues	27,907	23,134	17,342
Cost of sales	(17,396)	(14,252)	(10,906)
Gross profit	10,511	8,882	6,436
R&D expenses	(444)	(329)	(358)
Selling and marketing expenses	(6,409)	(4,774)	(4,076)
G&A expenses	(1,690)	(1,355)	(900)
Total expenses	(8,543)	(6,458)	(5,335)
Segment operating income (loss)	1,968	2,424	1,102
Total Assets	26,407	25,344	20,795
Capital expenditures	356	261	557
Non-current assets	4,187	3,971	3,628
Goodwill	1,271	1,271	1,271
Operating Segments | Distribution (DISTRIB) Division [Member] | Product
Revenues	24,145	20,289	15,274
Operating Segments | Distribution (DISTRIB) Division [Member] | RPP's and leases
Revenues	272	267	224
Operating Segments | Distribution (DISTRIB) Division [Member] | Spare parts and services
Revenues	3,491	2,578	1,844
Operating Segments | Distribution (DISTRIB) Division [Member] | Product and Services, Excluding Other
Revenues	27,907	23,134	17,342
Reconciling Items | EDAP Technomed Co Ltd. [Member]
Selling and marketing expenses			0
G&A expenses	(2,254)	(1,904)	(1,465)
Total expenses	(2,254)	(1,904)	(1,465)
Segment operating income (loss)	(2,254)	(1,904)	(1,465)
Total Assets	€ 45,426	€ 24,690	€ 2,551

VALUATION ACCOUNTS (Details)

VALUATION ACCOUNTS (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Allowance for deferred tax assets
Balance	€ 14,341	€ 15,508	€ 14,977
Charges to costs and expenses	1,538	346	596
Deductions: write-off and others	(1,135)	(1,513)	(65)
Balance	14,744	14,341	15,508
Allowance for doubtful accounts
Balance	742	721	1,489
Charges to costs and expenses	32	2	90
Deductions: write-off and others	(613)	19	(858)
Balance	161	742	721
Slow-moving inventory
Balance	1,470	1,563	1,084
Charges to costs and expenses	93	371	651
Deductions: write-off and others	(300)	(464)	(172)
Balance	1,262	1,470	1,563
Warranty reserve
Balance	252	369	371
Charges to costs and expenses	112	110	266
Deductions: write-off and others	(202)	(227)	(268)
Balance	€ 162	€ 252	€ 369

SUPPLEMENTAL DISCLOSURES OF C_3

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Income taxes paid (refunds received)	€ 410	€ 307	€ 377
Interest paid	168	114	124
Interest received	403	10	10
Financing lease obligations incurred	162	233	192
Operating lease obligations incurred	1,162	674	317
Operating cash flow used in operating leases	900	916	941
Operating cash flow used in finance leases	12	18	18
Financing cash flow used in finance leases	€ 350	€ 406	€ 321

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) € in Thousands	Dec. 31, 2022 EUR (€)	Dec. 31, 2021 EUR (€)	Apr. 27, 2021 MYR (RM)	Apr. 22, 2020 JPY (¥)	Aug. 19, 2019 JPY (¥)
Related Party Transaction [Line Items]
Fixed deposit | €	€ 656	€ 634
EDAP Technomed Co Ltd. [Member] | Japan | Loans Payable [Member]
Related Party Transaction [Line Items]
Loan amount | ¥				¥ 50,000,000	¥ 80,000,000
EDAP Technomed Sdn Bdh [Member] | Malaysia | Performance Guarantee
Related Party Transaction [Line Items]
Contractual obligation			RM 8,000
Fixed deposit			RM 8,000